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"All who have studied in any detail the cases which have been grouped 
together under the name of Raynaud's disease will admit that the time 
has arrived when they ought to be classified. They are not all alike 
nor do they all tend to the same result. It would be well indeed if we 
could cease to use the term Raynaud's disease and speak rather of 
Raynaud's phenomenon. The latter expression is capable of having 
assigned to it a clear and definite meaning; the former is not. The 
phenomena in question are those of acroteric asphyxia and are liable 
to variation at different times being in many cases distinctly paro-
xysmal and are to be explained by reference to the influence of the 
nervous system upon the blood vessels Many of the cases that 
have been quoted as examples of Raynaud's disease are, however, com-
plicated or even primarily induced by organic disease of the skin 
(scleroderma), the blood vessels or the heart." 
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CHAPTER 1. 
OUTLINE OF THE STUDY. 
In his thesis entitled "Adrenergic receptor agonists and antagonists 
in Raynaud's syndrome", Cleophas (1982) emphasised the important role 
of the sympathetic nervous system in the pathophysiology and there-
fore in the therapy of digital vasospasms. 
His major results were the following: He developed a standardised 
finger cooling test with a good reproducibility to serve as a model 
for a Raynaud's attack. By this test normal subjects and patients with 
Raynaud's phenomenon could be distinguished to some extent and it 
proved to be an appropriate test to objectify the therapeutic efficacy 
of vasoactive drugs. Furthermore, he showed that beta-adrenoceptor 
stimulation and beta-adrenoceptor blockade only had a minor influence 
on skin temperature in Raynaud patients. Finally, he found that non-
selective alpha-adrenoceptor blockade by phenoxybenzamine improved 
skin temperature in patients with primary and with secondary Raynaud's 
phenomenon. 
The investigations described in this thesis were based on the results 
of these studies. In brief we tried to find answers to the following 
questions: 
1. What is the diagnostic value of various clinical, immunological and 
noninvasive vascular tests to identify the several subtypes of 
Raynaud's phenomenon'' 
2. Is there evidence for an increased sympathetic activity or an en-
hanced vascular reactivity to sympathetic stimulation in patients 
with primary Raynaud's phenomenon7 
3. Are different types of vasodilating agents benificial in Raynaud's 
phenomenon7 Which agent can be selected as the therapy of choice7 
Are there differences in the reactions to therapy between patients 
with the primary and the secondary type7 
In the following chapter of part I, a review is given of the current 
theoretical concepts dealing with Raynaud's phenomenon. 
In part II, the differential diagnostic value of simple clinical signs 
and symptoms and of antinuclear antibody determination by several im-
munological methods in patients presenting with Raynaud's phenomenon 
is evaluated. 
2 
Part III starts with a literature review stressing the role of the 
sympathetic nervous system in the pathophysiology and therapy of 
Raynaud's phenomenon. Subsequently, the effects of several tests that 
stimulate the sympathetic nervous system on vascular reactivity are 
studied in normal control subjects and in patients with primary 
Raynaud's phenomenon. 
In the following chapters two new techniques are evaluated that 
measure skin perfusion: laser Doppler velocimetry for determination of 
the total skin blood flow and transcutaneous measured oxygen tension 
as a possible measure of capillary nutritive skin perfusion. Through 
laser Doppler we evaluated the vasodilating properties of heating and 
of ischaemia. We questioned if skin perfusion in primary Raynaud's 
phenomenon is able to increase to the same extent as in normal 
subjects during suppression of the sympathetic nervous system by local 
heating up to 40 °C. Furthermore we studied whether the impairment in 
post occlusion hyperaemia is related to the degree of vessel wall 
disease. By conducting transcutaneous oxygen tension measurements we 
tried to identify patients with a disturbed nutritive capillary blood 
flow. 
In part IV, the therapeutic effect of the selective alpha-1 adrenocep-
tor blocker prazosin is studied in a controlled trial in patients with 
Raynaud's phenomenon and its optimal dose is determined. Furthermore, 
the therapeutic action of dihydropyndine derivatives out of the cal-
cium entry blocking agents group is evaluated. 
In the concluding chapter we summarise our findings and propose 
questions for future studies. 
CHAPTER 2. 
RAYNAID'S PHENOMENON. A CLINICAL REVIEW. 
Introduction 
Complaints of aerai discoloration on exposure to cold are far from 
rare. In 1Θ62 Maurice Raynaud first described this condition which now 
bears his name. Raynaud's phenomenon (RP) 13 defined as an episodic 
attack of at least a bi- but mostly triphasic well demarcated disco­
loration that mostly occurs in the digits of the hands and sometimes 
the feet. Although rarely, the nose, ears or tongue may also be in­
volved. The most common sequence is initial pallor, followed by cyano­
sis while rubor is seen when the attack finally subsides. During the 
color changes the fingers are cold and often the sensory acuity is 
diminished. In the hyperaemic phase paresthaesias occurs and at the 
end of an attack slight swelling of the fingers involved is sometimes 
noticed. Usually the episodes are precipitated by cold and less often 
by emotion. Table 1 shows some of the attack characteristics as 
analysed by a questionnaire in 223 Raynaud's patients. RP should be 
distinguished from acrocyanosis, livedo reticularis, erythromelalgia 
and pernio. 
RP symptoms range from mild painless pallor of a single digit to 
severe, almost constant painful ischaemia and finally even fingertip 
ulceration. The more benign symptoms are most frequently seen in so-
called primary RP (PRP) that may affect up to 15А of otherwise healthy 
adolescents'! and in whom no known associated disease is present. Most 
of these cases do not come to the attention of a physician and the 
majority of the cases remains undetected. True RP has to be distin­
guished from the normal physiologic vasoconstriction on exposure to 
cold that often causes cold hands, or after strong stimulation, may 
cause monophasic pallor of the fingers being rapidly reversible on 
warming. The criteria most commonly used to diagnose PRP were ori­
ginally proposed by Allen and Brown? with emphasis on the bilateral 
and symmetrical occurrence of the complaints, absence of trophic skin 
changes, normal pulses of the palpable arteries and still absence of 
any causal disease when the symptoms are already present for at least 
2 years. 
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Table 1 Characteristics of a Raynaud attack as analysed in 223 
Raynaud patients. 
number percentage 
Discoloration white 
blue 
red 
tn-phasic 
bi-phasic 
211 
189 
179 
133 
90 
(94.6) 
(84.7) 
(80.3) 
(59.6) 
(40.3) 
Additional symptoms numbness 
tingling 
pain 
pulsations 
swelling 
1B4 
152 
82 
57 
54 
(82.5) 
(68.2) 
(36.8) 
(25.6) 
(24.2) 
Localisation fingers 
toes 
nose 
ears 
tongue 
bilateral 
symmetric 
203 
126 
17 
12 
2 
155 
136 
(91.0) 
(56.5) 
(7.6) 
(5.4) 
(0.9) 
(69.5) 
(61.0) 
Precipitating events cold 
emotion 
unknown 
smoking 
210 
92 
13 
3 
(94.2) 
(41.2) 
(5.8) 
(1.3) 
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If RP accompanies an underlying disease, the patient is designated as 
having secondary RP (SRP). The differential diagnosis between primary 
and secondary RP may be difficult, especially near the onset of com-
plaints. For example, RP may be the only presenting symptom of a dis-
ease, which will later on develop to a fullblown connective tissue 
disease?t^. Although the criteria proposed by Allen and Brown are 
still clinically useful, today we recognise that a more extensive 
diagnostic evaluation is necessary to exclude or demonstrate an asso-
ciated disease (see table 2) and that the two-year limit is certainly 
arbitrary. Especially when signs or symptoms of an underlying disease 
are present, more specialised investigations are needed. Table 3 shows 
a complete enumeration of the possible serologic, radiologic, histo-
logic and other procedures to reach a definite diagnosis. By using 
this scheme, 301 patients presenting with the RP in the period 1976-
1987 could be classified and are presented in table 4. 
Pathophysiology 
The whiteness of the skin is caused by a sudden cessation of cutaneous 
blood flow due to arterial vasospasm. The subsequent cyanosis is con-
sidered to be the consequence of the decrease in oxygen supply caused 
by the reduced blood flow and stasis in skin capillaries and veins. 
During the final hyperaemic phase, vasodilation occurs with rapid re-
filling by arterial blood. 
The site of the circulatory arrest is still unknown. There are 
studies5,6,7 indicating that functional vasospasm occurs in PRP within 
the arteriovenous shunt system of the skin which serves heat-ex-
change. In contrast, in most cases of SRP a physiologic vasocon-
striction in small arterioles, shunts, capillaries and to some extent 
veins in the presence of a diffuse vessel wall thickening may tempora-
ry cause a total occlusion of vessels. However, this concept still 
lacks sufficient confirmation. 
The pathophysiology of RP is poorly understood. In table 5 some aetio-
logical factors are listed. The first three are supposed to play a 
pathogenetic role in the PRP and the final three in the SRP. Whether 
the sympathetic nervous system is overactive, as originally suggested 
by Maurice RaynaudB, or whether a local vascular fault exists in the 
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Table 2 Diagnostic evaluation protocol used in patients presenting 
with RP. 
History: age at onset 
attack characteristics: precipitating events (cold, emotion, smoking) 
color changes, reactive hyperaemia present 
associated symptoms: pain, numbness, par-
esthaesia, swelling 
localisation: bilateral, symmetric, thumb in-
volved, face involved (ear-
lobes, nose, tongue) 
attack rate, duration (summer, winter) 
pain, progression 
true attacks or more permanent complaints 
hormonal influences (menstrual cycle, oral 
contraceptives, pregnan-
cy, menopause). 
associated disease (migraine, variant angina, hypertension, vascular 
'occlusive disease, connective tissue disease) 
family history (vasospastic disease, connective tissue disease) 
drugs (ergot alkaloids, beta-adrenoceptor blockers, bleomycin) occu-
pation, exposure to trauma (cold, vibrating tools, typists, pianists) 
smoking 
positional symptoms in the arms, hands 
skin lesions, healing tendency after trauma 
symptoms associated with connective tissue disease: 
arthralgia, arthritis, proximal muscle weakness 
dry eyes, dry mouth, skin rash, fever 
heart burn, dyspnoe on exertion 
Physical exaaination: 
sex 
weight, length, blood pressure, heart rate (lying, standing) 
teleangiectasias (lips, fingers) 
ulcerations mouth 
enlarged parotid gland 
inspection digits: permanent color changes, swelling, skin-thickening-
hardening, skin lesions, nails, pitting scars, sub-
cutaneous calcifications, flexion contractures 
peripheral pulses, bruits 
Allen's test 
neurologic examination 
various maneuvers to demonstrate thoracic outlet 
splenomegaly, pleuritis, pericarditis 
Laboratory: 
sedimentation rate 
complete blood count 
creatinine 
cryoglobulins 
antinuclear antibody 
urinanalysis (proteinuria, casts) 
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Table 3 Detailed diagnostic work-up protocol, performed in patients 
presenting with RP in whom associated disease is suspected. 
Laboratory: creatine Phosphokinase 
cholesterol 
cold agglutinins 
immunoglobulin-electrophoresis 
iimunologic: Rose, Latex, anti-PNF 
immune complexes, complement 
ΑΝΑ-testing by immunofluorescense and ιιπηυηο-
blotting 
anti-ds DNA 
anti-ENA by counter immuno-electrophoresis 
thrombocyte functions: thromboglobulin, platelet factor IV 
haemorheologic testing: viscosity, red cell deformability/ 
aggregation 
Chest X-ray 
Lungfunction test (CO-transfer, compliance) 
Oesophageal motility studies 
Schirmer test 
Nailfold capillaroscopy (static, dynamic) 
Arteriography (only if surgery is considered or if extensive athero­
sclerosis is suspected) 
Skin or muscle biopsy (immunofluorescence) 
Electromyography 
Quantitive assessment of digital blood flow and tests on vascular 
reactivity: baseline blood flow 
cooling test 
heating test 
reactive hyperaemia test 
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Table 4 Classification of Raynaud's phenomenon in 301 patients pre-
senting in the period 1976-1987. 
Diagnosis Number (.%) 
Primary Raynaud's phenomenon 160(53.1) 
Secondary Raynaud's phenomenon 141(46.9) 
1. Connective tissue disease 
Progressive systemic sclerosis 
CREST-syndrome 
Systemic lupus erythematosus 
Mixed connective tissue disease 
Rheumatoid arthritis 
Sjögrens syndrome 
Poly-dermatomyositis 
Undifferentiated connective tissue disease 
Overlap syndromes 
2. Vasculitis 
Polyarteritis nodosa 
Thromboangiitis obliterans 
Necrotizing vasculitis 
Wegeners granulomatosis 
No definite classification 
3. Drug-induced 
G-adrenoceptor blocking drugs 
Ergot-den vati ves 
Bleomycine 
4. Hyperviscosity 
Monoclonal gammopathy 
Cryoglobulinaemia 
Polycythaemia 
5. Vascular occlusive disease 
6. Thoracic outlet syndromes 
7. Related to occupation 
81(26.9) 
9(3.0) 
20(6.6) 
9(3.0) 
12(4.0) 
6(2.0) 
4(1.3) 
23 
12 
11 
8 
7 
7 
3 
7 
3 
2 
2 
2 
1 
2 
16 
2 
2 
4 
3 
2 
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digital vessels, leading to a hypersensitive reaction pattern towards 
all kinds of stimuli as later assorted by Sir Thomas Lewis9, is still 
debated. 
The vasomotor tone within skin vessels, particularly shunt vessels, is 
reflexly influenced by the sympathetic nervous system and directly by 
local circulating mediators causing either vasoconstriction or vaso­
dilation (see table 6). All mechanisms listed in this table have been 
suggested to play a pathophysiologic role. An altered release or 
breakdown of vasoactive substances may cause either an increase in 
vasoconstriction''^ ,'''' or a decrease in vasodilation^, 15,16 or an 
imbalance between both. Besides an altered sensitivity of the vascular 
smooth muscle wall for these factors17,18 may lead to excessive vaso­
constriction or delayed vasodilation. In addition immune complex 
vasculitis1', increased thrombocyte aggregation20 or an increased 
blood viscosity21 may play a pathogenetic role. These factors are 
normal in PRP. The disturbances in thrombocyte function and viscosity 
are supposed to be a longterm complication of the already damaged 
vessel wall in SRP, especially in patients with connective tissue 
disease22I23. 
Smoking may play an important additional role, although it is unknown 
whether the intense and long-lasting vasoconstriction that is elicited 
by smoking24 or the induced vessel wall changes are responsible25. 
Pathophysiologic studies dealing with RP are all hampered by the fact 
that there is no animal model for experimental investigations. 
Measurements of blood flow by a variety of techniques (see table 7) 
have been performed under standardised conditions in patients with RP, 
but more problems are caused than solved by them (see table Θ). 
At room temperature, blood flow is decreased in RP in comparison to 
normal volunteers26. After provocation (cold-challenge, stress-test) 
the decrease in blood flow is more pronounced in RP-patients and 
remains lower than in normáis^. However, there exists a considerable 
overlap between groups26>27 with the best discrimination occurring 
during the recovery period2e. 
The major decrease in skin blood flow in PRP-patients seems to be lo-
cated within the arteriovenous shunt 3ystem29|30 whereas both the 
shunt and the capillary nutritive flow seem to be affected in SRP-
patients'1,^2 probably due to the more generalised vessel wall alter-
ations as a consequence of vasculitis, connective tissue disease or 
atherosclerosis. Some of these proposed pathophysiologic differences 
between PRP and SRP are summarised in table 9. 
10 
Table 5 Possible mechanisms in the pathophysiology of RP. 
1. Increased sympathetic nervous system outflow or an altered sympa-
thetic-parasympathetic balance 
2. Generalized or specific hyperreactivity of the vascular smooth 
muscle wall 
3. Decreased ability for vasodilation 
4. Immunologically mediated vasculitis 
5. Thrombosis 
6. Haemorheologic factors (viscosity, erythrocyte deformability) 
Table 6 Local mediators influencing vasomotor tone which may play a 
role in the pathophysiology of vasospasms, and their anta­
gonists or agonists used in therapeutic studies. 
mediators causing vasoconstriction therapeutic agents 
noradrenaline prazosin 
serotonine ketanserin 
thromboxane A2 dazoxiben 
angiotensin II Captopril 
calcium nifedipine 
mediators causing vasodilation 
adrenaline terbutaline 
prostaglandins prostacyclin 
histamine 
bradykinine 
endothelium derived relaxing factor 
Table 7 Techniques used to measure peripheral blood flow in patients 
with Raynaud's phenomenon. 
1. Temperature measurements, infrared-thermography 
2* Plethysmography: venous occlusion plethysmography, 
photoelectric plethysmography 
3. Radio-isotope techniques O'^Xenon wash-out curves) 
4* Doppler-techmques: ultrasound 
laserlight 
5. Dynamic capillary microscopy 
6. Angiography 
•Measurements of finger systolic blood pressure are possible using a 
proximal occluding cuff around the fingerbase and в distal sensor of 
pulsations registrated by plethysmography or by Doppler-techmques. 
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Table В Problems in the evaluation of ischaemia of the hand. 
A. Physiological problems: 
1. Large inter- and intra-individual variability in skin blood flow 
2. Overlap between normals, subjects with complaints of cold hands, 
subjects with occasionally a white monophasic discoloration and 
Raynaud patients 
3. Difficulties in provoking a Raynaud's attack in laboratory condi­
tions 
4. Many types of ischaemia of the hand with possible differences in 
pathophysiology 
B. Methodological problems: 
5. Inadequate differentiation between muscle-, skin-nutritive (capil­
laries), skin-thermoregulatory (shunts) and venous blood flow 
6. Many different measurement techniques and provocation tests without 
a "golden standard". 
Table 9 Pathophysiologic differences between patients with primary 
and with secondary Raynaud's phenomenon. 
Primary Raynaud's 
phenomenon 
Secondary Raynaud's 
phenomenon 
Defect 
Vascular event 
Anatomic localisation 
Primary defect 
functional 
pathologic vasospasm 
in an anatomically 
normal blood vessel 
shunt vessels 
vascular hyper­
reactivity 
Pathogenetic role of: 
sympathetic nervous system +++ 
local vasoactive substances + 
viscosity, thrombosis 
vessel wall alterations 
structural 
physiologic vasocon­
striction in a narrow­
ed vessel 
shunt vessels 
capillaries 
vessel wall disease 
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Treatnent 
In patients with a RP, multiple treatment modalities^ are used (table 
10), most of them being based on presumed theoretical efficacy or on 
uncontrolled studieB34,35. However, the clinical response is fre-
quently disappointing, especially in patients with severe underlying 
disease. 
Sympathectomy was once popular^ but is now infrequently performed, 
primarily because of the variable response, the side effects^T, and 
the high relapse rate38. particularly in SRP patients and in patients 
who have been treated by cervical sympathectomy}?,^ the results 
are disappointing. Perhaps the availability of superselective digital 
sympathectomy may provide a new approach for patients, refractory to 
other measures^l. 
Most vasoactive drugs provide some symptomatic relief, although their 
use is limited by side-effects caused by the systemic vasodilation. 
Most of the studies are anecdotal, performed in small groups over a 
short time, uncontrolled, with all types of Raynaud's phenomenon 
grouped together. Since there is a high placebo response*^, controlled 
trials are needed. Only nifedipine, a calcium influx blocking agent, 
has been proven to be valuable in a sufficient number of controlled 
studies^'. However, it is only effective in a part of the treated 
patients, whereas in most responderá it does not completely eliminate 
the attacks and often objective improvement of digital circulation 
cannot be found**. Therapy with vasoactive drugs should only be em-
ployed in patients with severe complaints during periods of exacerba-
tion, whereas the partial relief of symptoms should be outweighed 
against side effects. 
The majority of patients are better served by a careful explanation of 
their symptoms, a pair of warm gloves and the cessation of smoking 
than by the inconvenience of pharmacological or surgical treatment. 
In conclusion, we must admit that 126 years after Maurice Raynaud's 
first description of the symptom complex, most of the problems that he 
already pointed out have not yet been resolved: we still do not under-
stand the pathophysiology, we still have major problems in differen-
tiating the several subtypes, we still do not have an adequate method 
of measuring vasospasm available and finally, therapy is still in its 
symptomatic stage. 
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Table 10 Palliative treatment modalities for Raynaud's phenomenon. 
1. Simple explanation and reassurance in cases of primary Raynaud's 
phenomenon 
2. Appropriate management of the underlying disorder: non steroidal 
anti-inflammatory drugs, iimunosuppressive drugs, plasmapheresis 
3. Avoidance of precipitating or aggravating stimuli: cold, emotion, 
smoking, beta-adrenoceptor blocking drugs, ergotamine-denvatives, 
bleomycine, estrogens 
4. Drug therapy: 
a. Vasodilators:-aspecific action: nitrates, hydralazine 
-sympathicolytic agents; reserpine, prazosin 
-calcium entry blockers: nifedipine 
-serotonin blocking agents: ketansenn 
-angiotensin converting enzyme inhibitors: Capto-
pril 
-prostacyclin analogues: iloprost 
-thromboxane synthetase inhibitors: dazoxiben 
b. Thrombocyte aggregation inhibitors or haemorheologic agents: 
-acetylsalicylate 
-buflomedil 
-pentoxifylline 
-dextrane 
-stanozolol 
5. Psychological: biofeedback 
autogenic training 
6. Physiotherapy: electromodulation according to Trabert 
7. Surgery: stellate ganglion blockade 
sympathectomy 
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CHAPTER 3. 
THE DIAGNOSTIC VALUE OF CLINICAL SIGNS AND SYMPTOMS IN PATIENTS WITH 
RAYNAUD'S PHENOfCNON. A CROSS-SECTIONAL STUDY. 
Introduction 
In dealing with disorders of the peripheral circulation in the upper 
extremity, it is obvious that a proper diagnosis and a rational patho­
physiologic explanation are important. 
On presentation patients with Raynaud's phenomenon (RP) may pose a 
problem in differential diagnosis. The major question is whether the 
complaints are due to idiopathic (benign), so-called primary RP 
(PRP) or whether these are caused by an underlying disease, mostly in­
volving the vessel wall, such as the connective tissue diseases (CTD), 
the vasculitis syndromes or vascular occlusive disease (VOD) due to 
atherosclerosis. PRP іэ common in otherwise healthy females (1) where­
as secondary RP (SRP) is relatively rare in the community. However, 
severe cases, which are more prevalent in SRP, are more often referred 
to hospitals (2). This is the main reason why nearly 40% of patients 
presenting with RP at our out-patient clinic do have an associated 
disease (3). 
Clinical data, studies on vascular reactivity (4), finger systolic 
blood pressure measurements (5), biochemical and immunological tests 
(6), angiography or biopsies are mostly used to differentiate PRP from 
SRP. Pnollet et al (7) emphasised the importance of a proper history 
taking and physical examination by showing that the combination of 
clinical examination, screening for antinuclear antibodies and capil-
laroscopy correctly identified 975» of secondary cases. To investigate 
the value of data obtained by history taking and physical examination 
in the differential diagnosis between PRP and SRP and the patho­
physiological understanding of digital vasospasms, we performed a 
cross-sectional study of the clinical manifestations of RP. For this 
purpose we prospectively classified patients by a check-list dealing 
with signs and symptoms that are supposed to be more or less charac­
teristic for certain diseases which may be associated with RP. 
Besides, this check-list was used to analyse some of the pathophysio-
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logic mechanisms in pure vasospastic PRP, such as the relationship 
with other vasospastic disorders, the influence of hormonal factors 
and a possibly altered sympathetic reactivity. As these factors may 
not influence RP due to vessel wall disease, they should be absent in 
SRP and thus contribute to solve the differential diagnostic problem. 
Patients 
In a cross-sectional study, during the period January 1986 until 
November 19Θ7 we evaluated 225 patients who were examined because of a 
history of a bi- or a tn-phasic discoloration of fingers or toes, in­
duced by cold and/or emotion. A checklist was filled in, dealing with 
signs and symptoms thought to be specific for PRP or certain types of 
SRP. The patients were divided into 5 groups: 
J_. 98 patients with PRP who fulfilled the criteria of Allen and 
Brown (8), later modified by Allen, Barker and Mines (9): episodical, 
bilateral and symmetric complaints of bi- or triphasic discoloration 
of fingers and toes, induced by cold or emotion. The patients should 
have normal peripheral pulses and at the most, minor skin lesions 
should be allowed to occur. The symptoms should be present for more 
than 2 years without signs of an underlying disease, as demonstrated 
by an extensive work-up protocol which has been presented in the pre­
ceding chapter. 
2^ . 26 patients with questionable PRP who had one (n=9) or more 
(n=17) symptoms of a connective tissue disease (CTD), but could not be 
classified according to criteria of the American Rheumatism Associa­
tion (ARA). 
2· 54 patients with SRP due to CTD who fulfilled the ARA or other 
appropriate criteria for associated CTD, being: scleroderma (10) (SCL; 
n=19), the CREST-syndrome (calcinosis, Raynaud's phenomenon, esopha­
geal motility disturbances, sclerodactyly, teleangiectasia) (n=10), 
systemic lupus erythematosus (11) (SLE; n=6), mixed connective tissue 
disease (12) (MCTD; n=8), rheumatoid arthritis (13) (RA; n=6), 
Sjögrens syndrome (14) (SS; n=4), dermatomyositis (15) (DM; n=1). 
4^ 24 patients with SRP due to vascular occlusive disease (VOD) in 
whom arteriography or digital subtraction angiography revealed severe 
obstructive vascular disease of digital arteries. 
2· A restgroup with SRP due to the thoracic outlet syndrome (n=5), 
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neurologic disease (пгЗ), medications known to provoke RP like ß-adre-
noceptor blocking agents, ergot containing compounds or bleomycin 
(n=7), vasculitis such as Periarteriitis nodosa, Wegener's granulo-
matosis and Burger's disease (n=5) or haematologic malignancies with 
cryoglobulinaemia or hyperviscosity (n=3). 
Excluded from analysis were groups 2 and 5 (n=49). 
The same questionnaire was used in 50 controls, matched for age and 
sex in comparison to the PRP-group, drawn from a population of 
patients attending the outpatient clinic because of kidney stone dis-
ease (n=12), bone diseases like osteoporosis, Paget's disease, osteo-
malacia, and hyper- or hypoparathyroidism (n=32), and unexplained ab-
dominal pain (n=6). 
Methods 
On evaluation, a checklist was filled in by the physician including 
the following items: 
1. Sex 
2. Age on presentation and age at the date of evaluation 
3. Attack characteristics : 
a. provocative factors: cold, emotion, smoking 
b. localisation of discoloration: hands, feet, face (ears, nose, 
tongue); 
bilateral, symmetric 
thumb involved 
c. discoloration: reactive hyperaemia (rubor in the recovery phase 
of an attack) 
bi- or triphasic 
d. associated symptoms: pain (-score; 10 points scale) 
excessive sweating 
e. episodic or more permanent complaints 
f. progression 
4. Family history: RP without known underlying disease 
migraine 
connective tissue disease 
5. Associated disease: 
Migraine; common migraine was supposed to be present if attacks 
occurred of pulsatile hemicrama with nausea or vomiting and with 
photo- or phonophobia. If these attacks were preceded by an aura, 
classic migraine was assumed and if transient neurologic symptoms 
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were noticed, we designated the attacks as complicated migraine. 
Variant angina (VA) was suspected if periodical anginal pain at 
rest had been experienced together with either transient ECG-
changea compatible with ischaemia or with a prompt reaction of the 
pain to sublingual nitroglycerin in patients beneath 60 years of 
age, without cardiovascular risk factors or signs of VOD else-
where. If coronary angiography was performed and found normal in 
these patients, VA was considered to be proven. 
Acrocyanosis: a constant cyanotic discoloration and coldness of 
the whole hands and feet, aggravated by cold. 
Livedo reticularis: intense, persistent reddish-blue mottling of 
the skin of the lower extremities and sometimes the upper extremi-
ties or the trunk, which ia more pronounced during cold exposure. 
Orthostatic hypotension was defined as a reduction in systolic 
blood pressure of more than 20 mm Hg after standing upright for one 
minute. 
Hyperventilation was suspected if there were complaints of paro-
xysmal dyspnoe with paraesthesias, dizziness and thoracic pain. It 
was considered to be proven if the patients recognised their com-
plaints during a provocation test and if they were unable to nor-
malise their increased ventilation rate afterwards. 
Mitral valve prolaps was suspected if a mid systolic click was 
heard during cardiac auscultation. In case of a positive echocar-
diography, it was considered as proven. 
Psychosocial problems were supposed to have been present in case 
of psychiatric or psychologic consultation in the past. 
Claudication of the hands or legs. 
Cardiovascular disease: a history of classical angina or myocar-
dial infarction. 
Cerebrovascular disease: a history of transient ischaemic 
attacks or stroke. 
6. Hormonal influences on the Raynaud attacks: 
menstrual cycle: recurrent cyclic worsening or improvement of 
complaints in females with a regular cycle 
(24-32 days). 
oral contraceptives: deterioration of complaints during the use 
of oral contraceptive drugs. 
pregnancy: improvement of complaints during pregnancy. 
menopause: improvement of complaints after menopause. 
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7. Associated cardiovascular risk factors: 
smoking, the daily number of cigarettes smoked and the number of 
years of smoking. 
hypertension: supine blood pressure >160/95 (16). 
hypercholesterolaemia: cholesterol >7.4 rmral/L; being the 905» 
upper limit of all cholesterol determinations performed at the 
Lipid Research Laboratory of the Department of Medicine (17). 
overweight (18). 
diabetes mellitus: fasting glucose >7.7 mmol/L (19). 
Θ. Physical examination: 
length in cm; weight in kg; from these the Quetelet Index (QI) 
was determined by the formula: QI=weight : length2 (kg/m2). 
blood pressure in mmHg and heart rate in bpm: supine and after 
one minute of standing upright. 
visible color changes of hands/feet. 
trophic skin lesions. 
palpable pulses. 
Allen's test: to evaluate the patency of the radial and ulnar 
artery. The test was performed as described by Fairbairn (20) 
by compression of the contralateral artery and observation of 
the color changes during repeated (10 times) closing and open­
ing of the hand. Then the reactive hyperaemia was determined 
after compression of both arteries and decompression of each. 
capillary refill in seconds. 
For most of the anamnestic items: yes, no or unknown could be filled 
in. 
Results and Discussion 
Patients characteristics 
Table 1 shows some characteristics of the groups studied. Of all 176 
patients with RP analysed in this study, 56й had PRP, 31% an under­
lying CTD and 14JS VOD. Females predominate in the group of normal sub­
jects (BOS), the PRP-patients ( 2Й) and the patients with CTD ( 1Й) 
whereas in the group with VOD no sex preference was seen. As expected, 
the groups of patients with VOD and to a lesser degree the group with 
CTD were older and the age at onset was higher than in the PRP 
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patients. There was a long period between the age at onset and the age 
at evaluation in all three groups; 13 years in the PRP patients and 7 
years in the patients with CTD or VOO. 
Attack characteristics 
In Table 2 some characteristics of the digital vasospastic attacks are 
shown. Cold is a very important provocative factor, noticed by almost 
all the RP-patients (97Я). As already stated by Gifford (21,22) emo­
tional reactions play an important role in precipitating the attacks, 
which we also Found in our PRP-patients, especially in females (59%), 
whereas in VQD-patients emotional stress is seldom (13%) able to in­
duce discolorations. Our findings are not as definite as those of 
Spiteli (23) who did not encounter any case of VOD in whom psychologic 
events precipitated the vasospasms. Although smoking causes intense 
vasoconstriction in finger skin vessels (24) and is supposed to play a 
role in the provocation of an attack, only 5% of the 76 smoking RP-
patients reported a Raynaud's attack to occur during smoking. 
The final reddening at the end of a Raynaud's attack is thought to 
be present only in pure vasospasms. No reactive hyperaemia is supposed 
to occur (25,26) in the presence of advanced obliterative arterial 
vessel wall lesions, which is in accordance with the impaired reactive 
hyperaemia that can be seen after temporary occlusion of the finger in 
SRP-patienta (27). As can be seen in Table 2, reactive hyperaemia has 
differential diagnostic power although there are PRP-patients without 
(13й) and VOD-patients with (13£) rubor. Birnstingl (28) also found a 
low prevalence (17S) of reactive hyperaemia in SRP-patients with VOD. 
Bollinger and Putti (29) assert that the thumb із classically not in­
volved in PRP. Conversely, Dabich et al (30) noted less frequent 
vessel wall disease in the digital artery of the thumb of scleroderma 
patients, a finding in keeping with the clinical observation of lesser 
cold sensitivity of the thumbs in scleroderma according to Coffman and 
Davis (31). Although we found that the thumb was least involved of all 
fingers, this was true in all 3 groups, perhaps because of the differ­
ent vasculansation pattern in comparison to the other fingers. 
As already stated by Allen and Brown (B), the presence of pain during, 
but especially between attacks militates against the diagnosis of 
PRP. Patients with VOD, like patients with CTD had more persistent 
complaints (33% and 56%, respectively) and the symptoms were more 
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Table 1 Total nutrber af patients evaluated in each diagnostic group 
with the sex-ratio, the age at evaluation and the ace at onset. 
МіяЬог 
Геяв1е:іів1е 
Age* at e v a l u a t i o n ; 
nean + SO 
range 
Age» at onset; 
nean • SO 
range 
CONTROL 
SUBJCCTS 
50 
«OHO 
39.2+12.0 
19-73 
RAVNAUD'S PHENOCNON 
Primary 
98 
80:18 
3 6 . Í * ! 1 . 4 
12-64 
22.9+8.6 
11-55 
Secondary 
Connective 
t iaaue disease 
54 
44:10 
51.3+16.3 
22-79 
44 .3+15.8 
16-78 
Vaacular 
occlusive 
disease 
24 
11:13 
62 .0+10.4 
46-85 
54.8+12.7 
20-84 
•Age in years 
Table 2 Provocative factora and attack cheractenstica uaed in the d i f -
ferent ia l diegnoais of Raynaud'a phenomenon. Absolute runbers 
and percentage («) . 
Provocative Factors: 
cold 
stress 
snoking 
Attack c h a r a c t e r i s t i c s : 
reac t ive hyperaetnia 
thunb involved 
pain 
L o c a l i s a t i o n of the a t tacks : 
hands 
feet 
face · 
a y m e t n c 
b i l a t e r a l 
Between a t tacks also p e r s i s -
tent conpls ints 
Psin between a t tacks 
Progression 
Cold e x t r e m i t i e s 
i n childhood 
Primary 
94 (96) 
49 (50) 
1 (1) 
85 (87) 
10 (10 ) 
10 (10) 
98 (100) 
48 (49) 
34 (35) 
86 (88) 
97 (99) 
19 (19) 
6 ( 6 ) 
29 (29) 
46 (47) 
RAYNAUD'S PHENOMENON 
Secondary 
Connective 
t issue dlseass 
53 (98) 
13 (24) 
0 
16 (30) 
20 ( 3 7 ) 
30 (55) 
54 (100) 
35 (65 ) 
6 (11) 
26 ( 4 8 ) 
40 (74) 
30 (56) 
21 (39) 
35 (64) 
18 (33 ) 
Vascular occlusive 
disease 
24 (100) 
3 (13 ) 
3 (13) 
3 (13) 
8 (33 ) 
7 (29) 
24 (100) 
24 (100) 
1 (4) 
11 (46 ) 
15 (63) 
8 (33) 
3 (13 ) 
12 (50) 
2 ( 8 ) 
•tongue, earlobes and/or nose 
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often progressive (50Χ and 6U%, respectively) in comparison to PRP-
patients. 
Although the hands were involved in all Raynaud patients, in VOD-
patients the complaints were always also located in the feet. Often 
(71й) the feet problems were more severe than tne complaints of their 
hands, whereas the face was usually (96Я) free. Coffman and Davies 
(31) describe a 40!· incidence of feet involved in PRP with exceptional 
color changes in the earlobes, the tip of the nose and the tongue. A 
100!» involvement of the feet which was often more severe (71Й) than in 
the hands was found by Birnstingl (2B) in a study of 26 Raynaud's 
patients with atherosclerosis of the finger arteries. All these 
studies show that VOD is more prominent in the lower extremities, 
whereas true vasospastic disease closely follows the anatomical dis­
tribution of arteriovenous shunts in the skin (32), which have a high 
density in the fingers and a lower density in the toes, nose and ear-
lobes. Birnstingl (28) also found asymmetric complaints more often 
(58Й) in V0O, which is in accordance with our findings in patients 
with V0O (54Й) and СТО (52Й). 
Although the discoloration in PRP was not always strictly symmetric 
(12%) or bilateral (1%), as it should be according to the criteria of 
Allen and Brown (8), these investigators already recognised that their 
criteria are not always totally fulfilled in all PRP-patients. From 
the patients in the PRP-group, 12% reported cold extremities in their 
childhood, whereas in the СТО- and in the VOD-group this number 
approximated to 785» and 20% respectively, similar to the data of Holti 
(25). 
Psychosomatic conditions related to RP and syndromes in which the 
sympathetic nervous system could be involved 
Table 3 shows some psychosomatic diseases that may be related to RP 
and complaints that could be due to sympathetic hyperactivity. 
Some authors claim that psychiatric disturbances, especially anorexia 
nervosa (33), or "the typical case of Raynaud's disease in under­
weight, asthenic women" (31) have a higher incidence in PRP (29,34, 
35). This even seduced Gifford (22), who has probably analysed the 
largest RP population, to state that "women with Raynaud's disease 
characteristically exhibit emotional instability and are prone to 
deluge the physician with a multitude of neurotic complaints". 
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Table 3 Psychoamatic diseases related to RP and complainte related to RP 
in which alterations οΓ the sympathetic nervous system could play 
a rale. Absolute numbers end percentage (5). 
Paychoeoctal ргоЫеяэ 
Anorexia nervosa 
Generalised ccmplaintff*-
Hyperventilation 
.euapected 
.proven 
Increaaed sweating 
Mitral valve prolapa 
.Midayatolic click 
.proven* 
Flushing 
Orthoatatlc hypotension 
CONTROL 
5U8XCTS 
5 (10) 
0 
a (16) 
5 (10) 
0 
7 (14) 
2 (4) 
0 
6 (6) 
2 (4) 
Primary 
45 (46) 
12 (12) 
47 (48) 
39 (40) 
36 (37) 
40 (41) 
14 (14) 
6 (6) 
21 (21) 
14 (14) 
RAVNAUD'S PHENOMENON 
Secondary 
Connective 
tissue diseaae 
10 da) 
1 (2) 
15 (2β) 
12 (22) 
10 (19) 
10 (IB) 
3 (6) 
2 (4) 
6 (11) 
5 (9) 
Vaacular 
occlusive 
disease 
2 (8) 
0 
4 (17) 
6 (25) 
4 (17) 
4 (17) 
1 (4) 
1 (4) 
6 (25) 
2 (8) 
" coaplainta concerning «ore than 3 organ aystena 
* by echocardiography 
Table 4 Positive family history in Raynaud's phenomenon. 
Absolute numbers and percentage (S). 
Pnnary Raynaud's 
phenonenon 
Migraine 
Connective tissue 
disease 
Cardiovasculsr 
diseeaes" 
CONTROL 
SUBJECTS 
4 (8) 
6 (12) 
2 (4) 
27 (54) 
Pnnary 
50 (51) 
41 (42) 
3 (3) 
34 (35) 
RAYNAUD'S PHENOWNON 
Secondary 
Connective 
tiaaue diseaae 
11 (20) 
β (15) 
5 (9) 
26 (48) 
Vascular 
occlusive 
disesse 
5 (21) 
4 (17) 
0 
21 ( M ) 
" Claudication, classical angina, nyocardial infarction, cerebrovascular 
disease. 
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However, real data that support these assumptions have never been 
shown. In our PRP-patients, the incidence of psychiatric or psycho­
logic consultation in past or present was high (А6Й) and in these 
patients anorexia nervosa (27%), depression (18%) and neurosis (18%) 
were mentioned most frequently. The incidences of aspecific complaints 
(48%) and hyperventilation (37%) were also high, as already noticed in 
literature (29, 36). Especially in the German literature, the term 
"vasomotor instability", defined as complaints of flushing and ortho­
static hypotension (29), is used in relationship to PRP. Flushing was 
already described by Maurice Raynaud (37) whereas Blain (34) found a 
low blood pressure in patients with PRP. In this study, many women 
(21%) complained of increased flushing which was relatively rare in 
men (4%). Flushing was a prominent feature in the PRP- (21%) and in 
the VOO- (25%) group, although the high prevalence in the latter could 
have been due to the menopausal phase of all females in this group. 
In their excellent reviews, Blain (34), Gifford (38) and later Coffman 
and Davies (31) state that during a vasospastic attack sweating of the 
affected parts is encountered in nearly half of the PRP-patients, 
whereas between the attacks the extremities generally tend to perspire 
excessively. From our patients, 31% complained of increased perspira­
tion of the hands during or between attacks and these patients mostly 
(74%) belonged to the PRP group, which may indicate that besides an 
increased vasomotor tone also an increased sudomotor tone could also 
be present.This may support the theory of an increased sympathetic 
nervous system reactivity in PRP, because emotions increase both the 
sympathetic vasomotor- and sudomotor-outflow to the extremities (39). 
Although a mitral valve prolaps, a condition assumed to be due to an 
increased sympathetic nervous system activity (40), was more often 
found in PRP patients, this might in part be due to the high propor­
tion of young females in this group in which the prevalence of mitral 
valve prolaps is high (41). The supposed increased activity of the 
sympathetic nervous system is not consistent with the slightly in­
creased incidence of orthostatic hypotension in PRP-patients (20%), 
because the maintenance of blood pressure on standing is one of the 
most firmly established sympathetic reflexes (42). 
27 
The family history in RP-patients 
Table U shows the analysis of the family history in all patients and 
controls. Holti (25) and Wouda (26) think PRP probable if RP occurs in 
"close relatives who are, and have remained, in good health" or speak 
of "benign, often familial" PRP. Our data show that PRP, and an asso­
ciated vasospastic disorder like migraine, indeed have a high preva­
lence in family members of PRP-patients, although the prevalence of RP 
and migraine in the normal population is so high (1,43) that this 
issue gives no more than an indication. Catalano et al (44) found a 
positive family history in 2850 of 58 PRP patients and Hooper and 
Nikaein (45) even found an argunent for a genetic basis for the 
familial occurrence of PRP. As could be expected, familial cardio­
vascular disease was more prevalent in patients with VOD, whereas 
there were so many uncertainties in the familial history regarding CTD 
that no conclusions should be drawn from these data. 
Related vasospastic syndromes in RP 
Table 5 shows that the prevalence of related vasospastic manifesta­
tions was higher in RP-patients than in the control group. The combi­
nation of variant angina with migraine and RP has already been de­
scribed in several controlled (46,47) and uncontrolled (21,34,44,48, 
49) studies. Also essential (50) and pulmonary (51,52,53) hyperten­
sion, both considered to be diseases with an increased vascular re­
sistance, are described in association with PRP. Although we did not 
actively screen our RP patients for pulmonary hypertension, no clini­
cally evident cases were present in the PRP- and VOD-group, whereas in 
4 scleroderma patients with advanced pulmonary fibrosis, signs of 
right cardiac failure were seen. Perhaps some of the cases reported in 
the literature could be due to an underlying disease. Whether the 
association of these syndromes is coincidental remains unclear. As RP 
may affect about 2Ό% of otherwise healthy young females (1) and over 
ЗОй of random patients from a hospital population (54), it is not sur­
prising that, purely by chance, RP is often found in association with 
hypertension and migraine. Since the prevalence of both is about 10% 
in the general population (43,55), the incidence of hypertension can­
not be considered to be increased in our PRP-group. The incidences of 
acrocyanosis, migraine and perhaps variant angina are clearly more 
prominent in our PRP-population, although we must admit that our 
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diagnostic protocol regarding variant angina is somewhat week because 
ergonovine testing is not routinely applied in our clinic. The com-
bination of RP, migraine and variant angina was seen in 8 patients, 
all having PRP. This combined occurrence, the similarities in provo-
cative events like cold and emotion, the similarities in vascular 
reactions with vasospasm followed by reactive vasodilation and the 
similar reaction to the same types of therapy suggest a common patho-
genetic mechanism (56) that is expressed in more than one arterial bed 
(57,5B). A single pathogenetic mechanism that is commonly found of im-
portance in these types of vasospastic disease is a hyperreactivity of 
the sympathetic nervous system (59, 60,61). This could have implica-
tions for future investigations, because pathophysiologic research in 
one vasospastic syndrome may learn something about the others. Despite 
all similarities, in none of the patients with a combined vasospastic 
syndrome the Raynaud, migraneous or anginal attacks occurred simul-
taneously. The incidence of livedo reticularis, another peripheral 
vasospastic disease, was found high in our CTD-patients which has also 
been reported in the literature (62). 
Hormonal influences in RP 
Hormonal influences may play an important modulating or even pathoge-
netic role in peripheral vasoconstriction or vasospasms. 
Normal healthy women in their menstrual phase of life, have a lower 
peripheral skin circulation than men (29) whereas skin blood flow is 
equal in both sexes prior to the menarche and after menopause 
(29,63). Healthy females have a fluctuating finger skin perfusion 
during one menstrual cycle (64,65,66) with a lower flow during the 
period with high estrogen levels (67). 
Complaints of RP more often occur in women, with a sex ratio between 6 
and 9 to 1 in most reports (8,23,25,68). In most female patients the 
RP starts before the age of 30 (8,23,25,31) and some investigators 
even found a close relationship between the initial complaints and the 
age of menarche (6,31) with an improvement after menopause (21,25,31) 
or during pregnancy (21). Although anecdotal, oral contraceptives have 
been accused of causing or worsening RP (69,70), which has led to the 
discouraging of oral contraceptives for Raynaud patients in review 
articles (54). An explanation for these observations is perhaps found 
in experimental investigations that show evidence that estrogens in-
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Table Ь Associated vasospastic syndromes in Raynaud's phenomenon. Abaolute numbers and percentage ( 5 ) . 
Migraine 
. С О М Ю П 
. c l a e a i c 
.complicated 
V a r i a n t angina 
.auapected 
.proven 
Acrocyanoeia 
Livedo r e t i c u l a r i s 
CONTROL 
SUBJECTS 
6 ( 1 2 ) 
5 
1 
0 
0 
0 
0 
1 ( 2 ) 
Primary 
41 ( 4 2 ) 
21 
12 
В 
10 ( 1 0 ) 
5 ( 5 ) 
12 ( 1 2 ) 
2 ( 2 ) 
RAYNAUD'S PHENOCNON 
Secondary 
Connective 
t i s s u e disease 
11 ( 2 0 ) 
a 
3 
0 
3 ( 6 ) 
0 
0 
7 ( 1 3 ) 
Vasculsr 
occlusive 
disease 
3 (13) 
3 
0 
0 
я 
X 
3 ( 1 3 ) 
4 ( 1 7 ) 
1
 Lfriknown, because classical angina and variant angina cannot be d i f f e r ­
entiated properly by the methods used. 
Table 6 Hormonal influencée on Raynaud's phenomenon. Only female patients e l i g ib le to theae 
hormonal itene неге included. Absolute numbers and percentage (%). 
C y c l i c i n f l u e n c e of menstrual c y c l e 
D e t e n o r s L i o n during o r a l c o n t r a c e p t i v e s 
Improvement during pregnancy 
Improvement a f t e r menopause 
RAYNAUD 
Primary 
4 3 / 6 0 ( 7 2 ) 
11/64 ( 1 7 ) 
30/43 ( 7 0 ) 
4 / 7 ( 5 7 ) 
S PHENOMENON 
Connective t i s s u e 
disssse 
11/25 ( 4 4 ) 
3/30 ( 1 0 ) 
6/29 ( 2 1 ) 
1/21 ( 5 ) 
Table 7 Aaaociated cardiovascular r i s k factora and diseases. Absolute numbers and percentage (S). 
Smoking 
Hypertension 
Hypercholesterolasmia 
O v e r m l g h t 
Diabetes m e l l i t u s 
C l a u d i c a t i o n : legs 
hands 
C l a s s i c e l engins 
Myocardial i n f a r c t i o n 
Cerebrovascular 
disease 
CONTROL 
SLBJECTS 
19 ( 3 8 ) 
4 ( 8 ) 
2 ( 4 ) 
14 ( 2 8 ) 
0 
2 ( 4 ) 
0 
2 ( 4 ) 
0 
1 ( 2 ) 
Pnmsry 
35 (36) 
11 ( 1 1 ) 
1 ( 1 ) 
13 ( 1 3 ) 
0 
1 ( 1 ) 
0 
1 ( 1 ) 
0 
0 
RAYNAUD'S PHEN0№N0N 
Secondary 
Connective 
t i s s u e disease 
21 ( 3 9 ) 
9 ( 1 7 ) 
1 ( 2 ) 
12 ( 2 2 ) 
2 ( 4 ) 
1 ( 2 ) 
1 ( 2 ) 
2 ( 4 ) 
1 ( 2 ) 
0 
Vascular 
occlusive 
disease 
20 ( 8 3 ) 
13 ( 5 4 ) 
6 ( 2 5 ) 
16 ( 6 7 ) 
2 ( 8 ) 
11 ( 4 6 ) 
2 ( β ) 
7 ( 2 9 ) 
2 ( 8 ) 
4 ( 1 7 ) 
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crease vasoconstriction (71), perhaps by an up-regulation of alpha-
adrenoceptors (72,73). 
In this study all females with VOD reported that their complaints 
started after menopause. So they were excluded from the part of the 
analysis dealing with hormonal influences. As shown in Table 6, the 
majority of patients with a regular menstrual cycle between 24 and 32 
days noticed cyclic variations of their complaints during one men­
strual cycle. This was particularly present in PRP-patients. In most 
of them (86й) the RP worsened around the day of menstruation, which 
makes the supposed relationship with high estrogen levels doubtful. In 
this study, only 14 out of 94 (15S) patients with RP found that the 
oral contraceptives they used in the past deteriorated their condi­
tion, whereas 40 (43й) did not notice any influence and 40 (43Я>) could 
not remember this anymore. Therefore, we consider the use of oral con­
traceptives not to be contra-indicated in RP-patients and advise a 
three months' try-out in those who are willing to test it. 
There was a clear improvement during pregnancy in 70й of the PRP-
patients who had been pregnant during the clinical course of their 
RP. The lack of improvement in the CTD-group could be due to a worsen­
ing of their underlying disease during pregnancy, which is a well-
known complication of for example SLE (74). It is unclear whether the 
improvement of RP during pregnancy can be attributed to hormonal 
factors because the cardiac output and the circulating blood volume 
increase to such an extent that these factors alone already consider­
ably increase the peripheral circulation (75). 
The number of patients with RP starting before menopause, who were 
clearly post-menopausal at the day of evaluation was too small to be 
able to draw conclusions regarding the influence of the menopause on 
digital vasospastic complaints in the PRP-group. As their underlying 
disease mostly progressed, no improvement of RP-complaints was noticed 
in the patients with CTO in the period after menopause. 
Associated cardiovascular risk factors and diseases 
The associated cardiovascular risk factors and diseases are listed in 
Table 7. All risk factors for, and all diseases associated with athe­
rosclerosis showed a higher prevalence in the VOD-group. Especially 
hypertension (54й) and smoking (83й) were often reported, whereas all 
but 2 patients out of the VOD-group had symptomatic cardiovascular 
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disease elsewhere, especially intermittent lower limb claudication 
(Ъ6%). 
Besides the patients that still smoked during the period of evaluation 
there were θ PRP-, 2 CTD- and 1 VGD-patients who had stopped smoking 
in the past. The total number of cigarettes smoked in the past 
(smokers and ex-smokers) was + 79.000 in the PRP-group, + 111.000 in 
the CTD-group and + 244.000 in the V0O-group. Although smoking is 
supposed to aggravate RP, not only by inducing atherosclerosis but 
also by causing intense vasoconstriction (24), one of the major 
reasons why RP-patients do not stop smoking is undoubtedly the fact 
that smoking only rarely (in 4 RP-patients') induced vasospastic 
attacks, whereas most (92%) of the RP-patients that definitely stopped 
smoking (n=11), or only succeeded in this for a short period (n=49), 
stated that the cessation of smoking did not influence their clinical 
course, conform the literature (34). 
Signs and symptoms during physical examination 
The physical signs and symptoms observed in Raynaud patients are shown 
in Table 8. On physical examination the QI in patients with V0D was 
significantly higher (p<0.001) than in the other groups, whereas it 
was lower in the female patients with PRP (p<0.01). Overweight (QI>25 
kg/m2) as defined by the Dutch "Gezondheidsraad" (18) was more often 
found in the VOD-group (67Й) whereas underweight defined as QI<18 
kg/m2 in the Dutch population (76) was most frequent (17й) in the PRP-
group. 
In nearly all Raynaud patients the radial arteries were felt (95й), 
whereas the ulnar arteries were less frequently palpable (84й), espe­
cially in the VOD-patients (65!«). When interpreting these results one 
should bear in mind that also in our group of normal controls the 
ulnar artery is sometimes not palpable (14%). A positive Allen's test 
(77) is very specific for SRP due to CTD or V0D (100Й), although the 
sensitivity (21Я>) is low. 
Even though in his thesis Maurice Raynaud (37) described symmetrical 
gangrene as a prominent feature of primary cases and minimal grades of 
cutaneous gangrene are allowed according to the criteria of Allen and 
Brown (8), ischaemic skin lesions are extremely uncommon (Зй) in PRP. 
However, one should realise that we included this item in our classi­
fication protocol when using the criteria of Allen and Brown. The one 
PRP-patient with major trophic skin lesions was included in the pri­
mary group because we strongly suspect that the fingertip ulcers that 
developed were due to automutilation. 
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Table β Physical signe and aynptons in nomala and in patienta with 
Raynaud's phenomenon. Absolute mmbers and percentage ( 5 ) . 
Quetelet index (kg/ni)· 
.nales 
.reinales 
Blood pressure (mHg)* 
.systolic: lying 
supine 
.diastolic: lying 
supine 
Heart rate (bpm)« 
.lying 
.supine 
Pslpable pulses 
.rsdial artery: 
right 
l e f t 
.ulnar artery: 
right 
l e f t 
Allen's test 
.radial artery 
right 
l e f t 
.ulnar artery 
right 
l e f t 
Visible color changes 
Prolonged capillary 
r e f i l l « 
Ischaenic skin lesiona 
.present: minor 
major* 
anputations 
.past 
CONTROL 
SUBJECTS 
2 3 . 7 * 1 . 5 
2 3 . 3 * 3 . 7 
1 2 3 . 4 * 1 6 . 7 
1 2 3 . 3 * 1 6 . 1 
7 4 . 7 + 1 0 . 8 
7 4 . 6 * 1 0 . 6 
7 2 . 3 * 7 . 6 
7 4 . 6 + 7 . 9 
50 ( 1 0 0 ) 
50 ( 1 0 0 ) 
42 ( 8 4 ) 
44 ( 8 8 ) 
0 
0 
0 
0 
0 ( 0 ) 
1 ( 2 ) 
-
-
-
-
Primary 
2 4 . 4 * 2 . 3 
2 0 . 6 + 3 . 3 
1 2 1 . 7 * 1 8 . 3 
116.7+19.7 
75.4+10.5 
7 4 . 4 + 9 . 5 
7 5 . ϊ + β . 1 
7 9 . 8 + 9 . 3 
96 ( 9 8 ) 
94 ( 9 6 ) 
88 ( 9 0 ) 
84 ( 8 6 ) 
0 
0 
0 
0 
23 ( 2 3 ) 
18 ( 1 8 ) 
2 ( 2 ) 
1 ( 1 ) 
-3 ( 3 ) 
RAYNAUD'S PtCNOtCNON 
Secondary 
ronnective 
t i s s u e disease 
2 4 . 8 + 2 . 2 
2 2 . 9 + 2 . 8 
1 2 7 . 9 + 1 6 . 3 
1 2 6 . 7 + 1 7 . 2 
7 8 . 5 + 1 2 . 4 
7 8 . 7 + 1 4 . 5 
7 2 . 4 + 9 . 1 
7 5 . 3 + 8 . 9 
50 ( 9 3 ) 
51 ( 9 4 ) 
46 ( 8 5 ) 
47 ( 8 7 ) 
6 ( 1 1 ) 
5 ( 9 ) 
18 ( 3 3 ) 
IB ( 3 3 ) 
20 ( 3 7 ) 
21 ( 3 9 ) 
14 ( 2 6 ) 
14 ( 2 6 ) 
8 ( 1 5 ) 
42 ( 7 8 ) 
Vascular 
o c c l u s i v e 
disease 
2 5 . 2 + 2 . 5 
2 5 . 9 + 1 . 8 
1 3 5 . 0 + 1 7 . 8 
1 3 1 . 1 + 1 8 . 8 
ββ.4+13.9 
8 8 . 3 + 1 4 . 0 
7 2 . 0 + 5 . 7 
7 6 . 3 + 6 . 5 
22 ( 9 2 ) 
22 ( 9 2 ) 
15 ( 6 3 ) 
16 ( 6 7 ) 
3 ( 1 3 ) 
3 ( 1 3 ) 
7 ( 2 9 ) 
6 ( 2 5 ) 
8 ( 3 3 ) 
7 ( 2 9 ) 
1 ( 4 ) 
3 ( 1 3 ) 
2 ( 8 ) 
7 ( 2 9 ) 
* mean + SO 
* longer than 2 seconda 
+
 necrosia or gangrene 
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Concluding remarks 
In this study, most patients with PRP and SRP due to VOD could easily 
be distinguished on clinical grounds. 
In accordance with a study of Birnstingl (78), VOD was present in 
older (onset usually above the age of 50 years), especially male 
Raynaud patienta with a high frequency of associated risk factors and 
associated cardiovascular disease elsewhere. In VOD-patients stress 
does not play an important role in initiating an attack, the feet are 
always involved, reactive hyperaemia is less often seen, there is more 
permanent discoloration, whereas Allen's test is more often abnormal. 
PRP-patients are younger, with an age of onset in females under 20 
years. Females predominate, pain is infrequent, reactive hyperaemia 
and excessive perspiration are often present, as also associated vaso-
spastic diseases. Psychosomatic and hormonal influences are striking. 
The involvement of earlobes and nose is rather specific for PRP, 
although only occurring in a minority of cases. In PRP, complaints are 
usually not progressive, whereas major ulceration is very rare. 
Table 9 shows the clinical signs and symptoms with a high sensitivity 
or specificity for the several subtypes of RP. Also listed are the 
prevalence and the positive and negative predictive values of each 
item. 
The differentiation between SRP due to CTD, and either PRP or SRP 
caused by VOD is far more difficult using the clinical signs and 
symptoms mentioned above, because in many ways the CTD-group behaves 
intermediately between truly spastic and truly obstructive vascular 
disorders. However, in our classification protocol ARA-cnteria werfc 
used to define this group and most of these criteria are simple 
clinical signs. Moreover, during tests dealing with vascular reactivi-
ty it was shown that patients with CTD are not a homogeneous popula-
tion (see chapter 9). Firstly, because on presentation the behaviour 
of their blood vessels seems more spastic in nature while during pro-
gression of disease a certain degree of organic vessel wall disease 
develops. Secondly, the pathophysiology and the vessel wall alter-
ations in CTD may show similarities but also large differences. The 
CTD's are grouped together because of common clinical and pathological 
features with connective tissue damage throughout the body and colla-
gen and blood vessel wall alterations that may lead to RP. The inci-
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Table 9 Sensitivity, speci Г icity, positive end negative predictive 
value оГ clinical signs and symptoms in patients with primary 
Raynaud's phenomenon (prevalence: 55.7%), connective tissue 
disease (prevalence: 30.7%) and vascular occlusive disease 
(prevalence 1).ÄS). 
Sensitivity 
Primary Raynaud's phenonenon 
Age at onset 20 yrs 37.В 
renale 81.6 
No pain 89.7 
Reactive hyperaefua present 86.7 
Increased sweating present Μϊ.β 
Face involved 34.7 
No trophic akin lesiona 96.9 
No progreaaion 70.4 
Paychoaocial problems 45.9 
Associated nigraine 41.В 
Poaltive f n i l y hiatory for 
vasospastic diseases 72.4 
Connective tissue disaaae 
Pain 55.5 
Permanent complaints 55.5 
Trophic sbin leaiona 77.7 
Progreaaion 64.В 
Vascular occlusive disease 
Age at onaet 50 yrs 62.5 
Male 54.2 
Riek Гactor(s) 95.8 
Associated cardiovaeculer 
disease(s) 91.6 
No stress provocation 87.5 
No reactive hyperaenia 87.5 
Feet involved 100 
Specificity 
94.9 
29.5 
47.4 
75.6 
92.1 
91.0 
62.В 
60.J 
84.6 
B2.1 
69.2 
B6.1 
77.9 
91.8 
66.4 
BO.9 
B1.6 
46.0 
96.0 
40.1 
66.4 
45.9 
Positive pre­
dictive value 
90.2 
60.2 
68.2 
81.7 
74.1 
82.9 
76.6 
69.0 
78.9 
75.9 
74.7 
63.8 
52.6 
ВО.В 
46.1 
34.1 
31.7 
24.7 
75.9 
18.9 
29.2 
22.4 
Negative pre­
dictive valui 
54.β 
56.1 
7B.7 
81.9 
52.4 
52.6 
94.2 
61.8 
55.5 
52.9 
66.7 
81.4 
79.8 
90.3 
81.0 
93.2 
91.9 
98.7 
98.6 
66.7 
97.1 
100 
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dence of RP may vary widely between the different CTD's with a high 
prevalence in SCL (79), the CREST-vanant and MCTD (12) and with a 
lower prevalence in SLE (62) and RA (80). Another complicating factor 
is that RP may sometimes be the initial manifestation of a CTD even 
for many years, before other clinical or immunological signs of the 
underlying disease become apparent. 
In patients with PRP no abnormalities of the finger skin blood vessel 
wall can be found (81), but in systemic connective tissue disease 
lesions of the vessel wall are mostly present, varying from small 
vessel wall vasculitis in SLE to intimai thickening and perivascular 
infiltration by mononuclear cells in SCL (82). This has led to the 
hypothesis of on the one side an excessive vasoconstriction in ana-
tomically normal blood vessels in PRP and oh the other side a normal 
vasoconstriction in an anatomically narrowed blood vessel in SRP due 
to more extensive CTD (83). However, both will result in temporary 
ischaemia. In early stages of CTD, excessive vasoconstriction may 
dominate with features of pure vasospastic disease (54,84) which has 
led to the microvascular hypothesis (85) in SCL. In this hypothesis 
the fibrosis is thought to be secondary to the longstanding ischaemia 
in severe cases of widespread RP. 
One of the important clinical features of SRP due to CTD are ischaemic 
skin lesions, especially in SCL and in the CREST-vanant. Pain is 
often present and the complaints are progressive and permanent (see 
Table 9). Although it is usually assumed that RP occurring in males 
should be suspected as secondary (23), this is holds only for VOD. 
The male to female ratio is 1:4 both in CTD and PRP-patients. 
An increased (re)activity of the sympathetic nervous system is suppos-
ed to play a pathogenetic role in the pure vasospasms that occur in 
PRP, while its role in SRP is only minor. This study gives some clues 
that support this hypothesis in PRP-patients: the important role of 
stress in provoking a Raynaud attack, the subjective notion of in-
creased sweating, the role of psychological factors, and the relation-
ship with other diseases in which the sympathetic nervous system is 
believed to play a pathogenetic role (essential hypertension, mitral 
valve prolaps, hyperventilation and other vasospastic syndromes such 
as variant angina and migraine). Whether the hormonal influences on RP 
are caused by modulation of the sympathetic nervous system by estro-
gens remains to be determined. 
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Major limitations are applicable to this study. 
Firstly, it should be emphasised that the cases included in this study 
have been subjected to various processes of selection. So, the clinic­
al features and the distribution of cases in each patient group may 
not be representative for the Raynaud population in general. Only 
severe cases or patients with differential diagnostic problems are 
referred to the specialist. Together with the extensive diagnostic 
evaluation protocol and the long duration of follow-up, this may have 
led to a high prevalence of secondary cases in our study. 
In a general population in a country with a cold climate patients with 
PRP predominate (86), whereas in a specialised clinic with primary 
interest in rheumatology or immunology, patients with CTD (6,54, 
Θ7,ΘΒ), or when the primary interest is cardiovascular surgery 
patients with VOD may prevail. From population studies ( 9) one may 
calculate that only about 1% of RP-patients are suffering from a CTD. 
On the other hand the occurrence of VDD in our Raynaud patients seems 
rather low since RP has been reported to occur in ^0% of the cases 
with arteriosclerosis obliterans (90). Yet, our patient group is quite 
well comparable to series of other hospitals reported in literature, 
with regard to the proportion of primary and secondary RP-patients and 
the age and sex distribution (21,34,91). 
Secondly, the conclusions drawn in this study apply only to classic 
cases of PRP, advanced types of CTD and clearly detectable VOD. All 
cases in which doubt existed about the diagnosis were excluded. Fur­
thermore, some uncertainties remain with respect to our classifica­
tion. An arteriography was only performed in cases in which VOD was 
already suspected. Likewise, in the PRP-classification some doubts 
remain. We know now that the period, after which signs of an under­
lying disease may appear, is often much longer than the two years in 
the criteria of Allen and Brown (92,93) and although our scheme to 
exclude an underlying disease is rather extensive, it is unknown which 
percentage of PRP-patients will eventually develop an underlying dis­
ease. However, we expect this number to be small since Gifford and 
Mines (21), using the Allen and Brown criteria without a further 
screening protocol, have found these criteria accurate in 95Й of cases 
after longterm follow-up. 
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In conclusion, clinical manifestations as detected by the experienced 
observer are essential in the diagnosis and understanding of patients 
with RP. When used in combination with immunological and noninvasive 
vascular tests a proper diagnosis is nearly always possible. 
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CHAPTER Α. 
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Abstract 
101 Patients referred because of Raynaud's Phenomenon (RP) were pro­
spectively followed for a mean period of 33 months. At presentation 
they were screened for signs and symptoms of CTD according to a de­
tailed protocol. At presentation, 37 patients had primary RP (PRP), 9 
had RP in combination with vascular occlusive disease (RP-VOD), 25 had 
one symptom of a connective tissue disease (CTD) (questionable PRP), 
13 had two or more symptoms (undifferentiated CTD; UCTD) and 17 had 
definite CTD. Progression from one of these groups to another was seen 
in 24 patients and from PRP, RP-VOD or questionable PRP towards a 
(U)CTD was seen in 19 patients. The presence of ANA, as detected by 
immunofluorescence and by immunoblotting at the start of the study, 
was associated with the future development of symptoms of CTD: 
positive predictive value 65% and 71% and negative predictive value 
93S and 83й, respectively. ANA testing by immunoblotting was of 
special help in predicting the development of scleroderma, the CREST-
syndrome and mixed connective tissue disease. In conclusion, testing 
for ANA by indirect immunofluorescence helps to discriminate between 
patients with persisting PRP and those who will develop a CTD, whereas 
testing for ANA by means of the immunoblotting technique helps to 
predict the development of a specific CTD. 
Introduction 
Raynaud's phenomenon (RP) may be a benign functional disorder of un­
known cause, designated as primary RP (PRP) or may be a symptom of a 
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more serious underlying disorder, usually a connective tissue disease 
(CTD) (1). In the latter situation it is called secondary RP (SRP). At 
presentation, patients with episodic digital ischaemia may pose a 
differential diagnostic problem, particularly because RP may precede 
other manifestations of a CTD by many years (2,3). The criteria most 
commonly used to diagnose PRP are those established by Allen and 
Brown, (4) although nowadays a more sophisticated diagnostic work-up 
makes the exclusion of secondary cases more certain (5). The search 
for underlying CTD is important because it has major implications for 
prognosis and therapy (1). In most of the patients with SRP due to 
CTD, an antinuclear antibody profile (ANA) can be found (6) that could 
be helpful in differentiating primary from secondary cases, and that 
may prove to be a marker for certain CTD or perhaps have prognostic 
value for the future development of a CTD. 
To investigate the differential diagnostic power, the predictive 
value and the specificity for certain CTD of immunological testing 
for ANA by means of indirect immunofluorescence (IF) and immuno-
blotting (IB) we clinically and immunologically classified 101 
patients who presented because of RP and followed them prospectively 
for a mean time period of nearly 3 years. 
Patients and aethods 
Patients 
One hundred and one patients (79 Females and 22 males; mean age 42.7 
years, range: 17-73) reFerred to the out-patient clinic in the period 
1983-1986 because of RP were available for clinical and immunological 
evaluation and were followed for 33.3 + 8.0 (SD) months (range 
12-51). In all patients, a detailed history and physical examination 
were performed according to a preassigned protocol with special atten-
tion given to signs and symptoms of CTD, as well as a number of 
studies including: chest rontgenogram, pulmonary function tests 
(diffusing capacity for carbon monoxide), esophageal motility studies 
in the horizontal position, serum creatinine, total blood count, 
creatine Phosphokinase, sedimentation rate, serum Immunoelectro-
phoresis, cryoglobulins and urine analysis. If indicated further 
rontgenological or biopsy studies were done. At the initial visit, 
serum was collected for the detection of ANA by means of IF and IB and 
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for determination of antibodies to extractable nuclear antigens (ENA) 
by means of counter Immunoelectrophoresis (CIE). The immunological 
assays were performed blind for the clinical classification. 
Patients with thoracic outlet syndrome, cryoglobulinaemia or using me­
dications known to induce RP were excluded. The patient was classified 
as having PRP if no, as having questionable PRP if one or as having 
undifferentiated CTD (UCTD) if two or more symptoms of a CTD were 
present. If, in case of PRP, signs or symptoms of vascular obstructive 
disease (VOD) were found, the diagnosis RP-VOD was used. 
Progressive Systemic Sclerosis (PSS), Systemic Lupus Erythematosus 
(SLE) and Rheumatoid Arthritis (RA) were diagnosed according to ARA 
criteria (7,8,9), CREST (calcinosis, Raynaud's phenomenon, esophageal 
motility disturbances, sclerodactyly, teleangiectasia) if all these 
symptoms were present, Sjogren's syndrome if a positive Schirmertest 
and xerostomia (sialogram or histology) and if symptoms according to 
Bloch et al (10) were present. MCTD was diagnosed according to the 
criteria of Sharp et al. (11) and dermatomyositis according to crite­
ria of Bohan and Peter (12). 
ANA was detected by IF using HEp-2 cells growing in monolayer cul­
tures. Antibodies to ENA were analysed by means of CIE as described by 
Kurata and Tan (13) using a saline extract of rabbit thymus powder 
(Pel-Freeze/Arkansas). Reference sera were used to identify precipita­
tion lines for Sm, RNP and La/SS-B. Immunoblotting was performed on 
nuclear protein fractions (14,15,16) from Hela S3 cells. The antibody 
specificities detected were: 
- Anti-(U1)RNP: antibodies against the 70K and/or A and/or С proteins 
specifically complexée! with U1 snRNA (16,17). See figure 1, lane 1. 
- Anti-Sm: antibodies against the B'/B and D proteins which are com-
plexed with U1, U2, U4, U5 and U6 snRNAs (16,17). See figure 1, lane 
1. 
- Anti-La/SS-B: antibodies against a 50.000 Dalton protein associat-
ed in the cell with precursors of RNA polymerase III products 
(15,16). See figure 1, Lane 5. 
- Anti-19K: anti-centromere antibodies as detected by irmiunofluor-
escence always decorate a 19.000 Dalton antigen band on nuclear 
blots (19)(W.J. van Venrooij: Analysis of 93 patients with anti-
centromere-antibodies, unpublished). This antigen band, referred to 
as CR-19, probably corresponds to the CENP-A antigen of Earnshaw and 
Rothfield (20). See figure 1, lane 3. 
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Figure 1: Immunoblot profiles of patients sera 
A nuclear protein fraction from the HeLa S3 cells was used for gel 
electrophoresis and protein blotting (14,15,16). 
The blot was incubated with the various patients sera and subsequent­
ly with horse radish peroxidase conjugated anti-human IgG. Peroxidase 
activity was detected as described (14). 
Lane 1: RNP/Sm serum, containing antibodies against the U1-snRNA asso­
ciated 70K, A and С proteins and antibodies against the U-
snRNA associated В1/В and D proteina. 
2: Serum from a PSS patient containing antibodies againat Topo-
isomeгase I (see Materials and Methods) 
3: Serum from a CREST patient containing anti-centromere (anti-
CR-19) antibody. 
4: Serum from an SLE patient containing antibodies against his­
torie 1. 
5: Serum from a patient with Sjogren's syndrome containing anti­
bodies againat the La/SS-B antigen. 
6: Serum from a patient with rheumatoid arthritis containing 
antibodies against the 56K antigen. 
7: Normal human serum control. 
Topo I . m 
7 0 K s b« 
A . 
С . • 
D _ 
- 56 К 
- La 
r Hisl 
_ CR-19 
1 2 3 A 5 6 7 
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- Anti-Topo I: recent results have shown that the originally describ­
ed Scl-70 antigen (21) was a degradation product of the 100.000 
Dalton protein DNA-topoisomerase I (22,23). At the same time it was 
demonstrated that the earlier described 5cl-86 antigen (24) was 
DNA-topoisomerase I as well (25). See figure 1, lane 2. 
- Anti-histone: this antibody specificity can easily be detected on 
nuclear blots as is demonstrated in figure 1, lane 4. 
- Undefined antibodies: antibody specificities against undefined and 
uncharactensed HeLa cell proteins are often found by immunoblot-
ting. In this study, only those undefined specificities were scored 
which gave a strong band using serum dilutions of 1:40 and were not, 
or very rarely, found in control sera. 
An example is given in figure 1, lane 6 where the 56K antigen speci­
ficity is shown. Antibodies against the 56K antigen are found in 
sera of patients with CTD with an incidence of about 8S. In 20!« of 
these cases this antibody specificity is accompanied by the presence 
in the serum of La/SS-B antibodies (WJ van Venrooij, unpublished 
results). 
All immunoblots with weak or indistinct results were considered to 
be negative. 
In case antibodies to ENA were positive for anti-RNP in CIE, the cli­
nicians incorporated this in their clinical diagnosis according to 
Sharp (11) because it had major implications for therapy with immuno­
suppressive agents. 
Results 
Table I shows the clinical diagnosis and the presence of ANA at pre­
sentation of 101 RP-patients, together with their sex-ratio, their age 
and the change in diagnosis during the follow-up period of 33.3 + 6.0 
months (range 12-51). For the whole group females predominate (female: 
male = 79:22). The age at presentation was 42.7 +_ 14.4 years (range 
17-73). There was a younger mean age in PRP (36.5 +_ 12.4) compared to 
the RP-V0D (55.5 + 9.9) subgroup. ANA, as detected by means of IF or 
IB was present in respectively 21 and 28й of the whole RP-group 
without CTD (PRP plus RP-V0D plus questionable PRP-group) and in 
respectively 73 and 87Й of the whole SRP-(UCTD plus CTD) group. During 
follow-up, a change of diagnosis was found in 24 patients, being 19 
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Table I Clinical diagnosis, sex, age and presence of antinuclear antibody (ANA) by 
immunofluorescence (IF) or immunoblotting (IB) at presentation and the 
change of diagnosis during follow-up in patients initially classified as 
having primary Raynaud's phenomenon (PRP), Raynaud's phenomenon due to 
vascular occlusive disease (RP-VOD), questionable PRP (one symptom of a 
connective tissue disease) or secondary RP (SRP) due to undifferentiated 
CUCTD) or well-defined connective tissue disease (CTD). 
clinical diagnosis 
PRP, n=37 
RP-VOD, n=9 
questionable PRP, n:25 
SRP-UCTD, n=13 
SRP-CTD, n=17 
AT 
вех 
m/ f 
8:29 
3:6 
4:21 
3:10 
3:14 
PRESFNTATION 
age (years) 
mean + SO 
36.5+12.4 
55.5+9.9 
41.7+12.7 
42.3+16.2 
4B.1+15.2 
presence of 
IF 
4 
0 
11 
В 
14 
IB 
6 
2 
12 
10 
15 
ANA 
DURING F0U0W-UP 
change in clinical 
diagnosis N {%) 
4 (10.8) 
1 (11.1) 
14 (56.0) 
5 (38.5) 
0 
Table II Clinical diagnosis at presentation and during follow-up and presence of 
antinuclear antibody (ANA) as detected by immunofluorescence (IF) or 
inmunoblotting (IB) in all Raynaud's patients presenting without signs of 
an (un)differentiated connective tissue disease: (U)CTD. 
CLINICAL DIAGNOSIS 
at presentation 
RP without CTD, ni71 
at follow-up 
PRP without CTD, n=54 
SRP, n=17 
UCTD n=6 
CTD n=11 
ANA AT PRESENTATION 
IF IB 
neg pos neg pos 
50 4 46 8 
6 11 5 12 
2 4 1 5 
4 7 4 7 
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patients of the whole RP-group without CTD {27%), whereas in 5 of 13 
patients with UCTD at presentation a change to a well-defined CTD was 
observed. 
The results of the change in clinical findings during follow-up in re­
lation to the presence or absence of ANA as detected by means of IF 
and IB is shown in Table II. In patients with PRP at onset, 33 (89%) 
did not and only 4 (11%) did develop signs or symptoms of a CTD. One 
male patient of this group with a positive ΑΝΑ-test at presentation 
(anti-centromere antibodies by IF and anti-19 К by IB) developed a 
full-blown CREST-syndrome after 17 months of follow-up. From the other 
3 patients with PRP at onset and a change in diagnosis at follow-up, 
one developed a questionable RP and had a negative IF and a positive 
IB analysis of ANA, whereas the other two developed UCTD. One of them 
had negative ΑΝΑ-testing by means of IF and IB, whereas the other had 
positive ANA-testing by means of IF and IB. In the group of patients 
with RP-VOD only one (IIS) male hypertensive patient with negative ANA 
by means of IF and IB changed diagnosis after 26 months of follow-up 
because of esophageal hypomotility. Fourteen out of the 25 patients 
(56%) with one sign or symptom of a CTD at presentation (questionable 
PRP) had a change in clinical diagnosis during follow-up. Four (16!!!) 
developed UCTD and 10 (40%) developed a well-defined CTD, namely MCTD 
(3), RA(2)t SS(2), PSS(2) and the CREST-syndromeO). Of the 4 patients 
that developed an UCTD, ΑΝΑ-testing by IF was positive at presentation 
in 3 whereas ΑΝΑ-testing by IB was positive at presentation in all 4. 
Of the 10 patients that developed a CTD, ΑΝΑ-testing at presentation 
was positive in б by means of both techniques (IF and IB). Eight of 
the 13 patients with SRP-UCTD did not have a change in clinical 
symptoms. Two patients developed the CREST-syndrome, one SS, one MCTD 
and one female patient with complaints of proximal muscle weakness, 
relapsing fever of unknown origin and a negative IB and IF at presen­
tation 4 years ago gradually developed skin rash, arthralgias, muscle 
pain and elevated CPK. X-rays of the muscle showed extensive calcium 
deposits and a fine needle biopsy revealed dermatomyositis. Recently 
the IB has become positive (undefined band). 
Seventeen patients were classified as SRP according to well-defined 
ARA-cntena at presentation. One of the SLE patients (female, 34 
years at presentation) died of sepsis after a progressive course of 
her disease 16 months after presentation. In two scleroderma patients 
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xerophtalmia developed. In 4 out of 6 of the SLE patients in this 
group, scleroderma-like skin changes of the hands gradually developed. 
The positive and negative predictive values of the presence of ANA at 
presentation in all patients with RP without CTD (n=71; PRP and RP-VOD 
and questionable PRP) for the development of (ll)CTD during a mean 
follow-up of 33 months was in case of a positive IF 64.7% and 92.6%, 
respectively, whereas in case of a positive IB 70.6% and 63.0% was 
found, respectively. 
The antibody-specificity of ANA in relationship to the presence or 
the future development of discrete CTD was evaluated for the fluor­
escence pattern in the IF and for the antigenic specificity of ANA as 
detected by means of IB. 
The only specific fluorescence pattern in the IF was the discrete 
finely speckled anti-centromere pattern which was found in all S 
cases of CREST and in one patient with UCTD with myositis at presenta­
tion who developed rash, teleangiectasia and calcinosis later on, 
which makes the development toward a CREST-like syndrome probable. All 
other fluorescence patterns (homogenous, nucleolar, fine speckle, 
coarse speckle) were not specific for a certain CTD. 
ΑΝΑ-testing by IB showed antibodies against the Cr-19.000 dalton 
antigen in all 5 patients with CREST, in the female patient mentioned 
above who developed a CREST-like syndrome and in one of the 4 patients 
with MCTD who had pronounced scleroderma-like features. Antibody 
against the topo-I (Scl-70) antigen was detected by means of IB in 6 
out of 10 scleroderma patients and was not found positive in any other 
patient. 
In all four patients with MCTD, anti-RNP (antibodies against 70K and/ 
or A and С dalton antigen) was detected by IB, which was also positive 
in 1 out of 14 UCTD-, in 1 out of 25 questionable PRP-and in 1 out of 
37 PRP-patients. Both patients had no change of diagnosis during their 
clinical course. Antibodies against the 50.000 dalton La/SS-B antigen 
as detected by means of IB was found positive in 2 out of 4 SS 
patients, in 1 out of 6 SLE patients, in 1 of 10 PSS patients and in 2 
out of 14 UCTD patients. In 5 of these 6 patients positive for La/SS-
B, complaints of a sicca syndrome were found. Antibodies against Sm 
(BVB and D dalton antigen) were detected by IB in 2 out of 6 SLE-, in 
2 out of 4 MCTD-, in 1 out of 25 questionable PRP- and in 1 out of 37 
PRP-patients. Of the 4 patients mentioned first (2 SLE and 2 MCTD), 3 
53 
had extensive signs of cutaneous vasculitis. Both patients latter men­
tioned had no change of diagnosis during their clinical course. Anti-
histone antibodies were detected by IB in 2 out of 14 UCTO and 1 out 
of 10 PSS-patients. None of these patients used medications associated 
with drug-related SLE (26) like procainamide or hydralazine. 
Discussion 
This study shows that ΑΝΑ-testing by means of IF helps to identify PRP 
patients at risk for the development of CTD, whereas ΑΝΑ-testing by 
means of IB helps to specify the disease entity the patient is likely 
to develop, especially in case of MCTD, CREST and PSS. Patients with 
one sign or symptom of CTD (questionable PRP) should have regular 
check-ups because of their high tendency (56%) to develop a (U)CTD, 
which was much lower (6%) in the group without any sign or symptom of 
CTD (PRP and RP-VOD). 
A retrospective clinical follow-up study was performed by Gifford 
and Hines (27) who could analyze the sequelae of 280 patients with 
PRP classified according to the criteria of Allen and Brown during a 
follow-up of 12 years. Only 4% developed evidence for a CTD. However, 
one may question the accuracy of their diagnostic protocol because 25% 
of these patients developed digital trophic changes, which is nowadays 
considered to be extremely uncommon in PRP (1). In two recent pro­
spective studies using diagnostic criteria comparable to ours, B% (2Θ) 
and 14% (29) of PRP-patients showed a transition towards (U)CTD after 
a mean follow-up of 2 and 9 years, respectively. 
From these studies and our study it is clear that the concept of 
Raynaud's disease, as defined by Allen and Brown (4) including the 
criterion of a 2 years follow-up without evidence for an underlying 
disease, warrants correction. In our study, most patients did have 
complaints of RP for a long time before presentation at the out­
patient clinic (mean 7.9 + 8.1 yrs), whereas a high incidence of a 
change from PRP to SRP (24%) was still found. 
In the study of Gerbracht et al. (29) many diagnostic changes were 
still seen after the initial 2 years of follow-up. One may even wonder 
whether the follow-up of 33 monts in our study was long enough to 
detect whether the PRP-patients that did not change clinical diagnosis 
will remain of the primary type in the near future. This is also con-
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firmed by our study in which 3 of the patients with an evolution of 
(questionable) PRP towards CTD did so after more than 10 years since 
they first had noticed Raynaud-attacks. 
The rather high incidence of underlying (U)CTD on presentation (ЗОЯ) 
and after follow-up (46%) in relation to the high incidence of PRP in 
population studies (30) may be explained by selection bias. Severe 
cases of RP or patients in whom differential diagnostic problems occur 
are more often referred to a specialised clinic (31), and among these 
CTD are more prevalent (32). Future studies on the pathophysiology of 
CTD and its early treatment before irreversible organ damage has 
occurred should be directed towards these groups at risk. 
In addition to immunological typing of RP-patients, careful clinical 
examination (32), measurements of digital blood flow (32), markers of 
platelet activation and capillaroscopy (33) may further help in the 
differential diagnosis between primary and secondary types. 
A major problem in these types of studies is the classification 
scheme used, because the clinical criteria are arbitrary and ar­
guable. For example, sclerodactyly is a much stronger symptom suggest­
ing CTD in comparison to arthralgia. Furthermore, some of the patients 
develop overlap syndromes with signs and symptoms of more than one CTD 
(34). Most of these patients have developed clinical characteristics 
of sclerodermatous skin changes of the hands. MCTD can be considered 
as such an overlap syndrome with a combination of features similar to 
those of SLE, PSS, RA and dermatomyositis with a good response to cor­
ticosteroid treatment. 
The predictive value of ΑΝΑ-testing by means of IF in comparison to IB 
for the development of CTD was slightly better for IF. Yet, IB proved 
to be useful for diagnosing or predicting specific disease entities 
like MCTD, PSS and CREST, although anti-centromere antibodies, spe­
cific for CREST, were equally well detected by means of IF, showing 
the characteristic finely speckled fluorescence pattern (35). No 
patient of the latter group had pulmonary, renal or cardiac disease 
confirming the speculations regarding the benign prognostic aspects of 
these antibodies (36). 
From this study one may speculate that antibodies against RNP and CR-
19 are sensitive and specific for MCTD and CREST, respectively, where­
as antibodies to Topo-I are less sensitive albeit specific for PSS. 
Although our sample is rather small and these data suggest that the 
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presence of anti-Sm 19 related to vasculitis and anti La/SS-B to the 
sicca-syndrome, both seem less valuable as disease markers, which has 
also been found by others (37,38). The meaning of antibodies against a 
number of as yet undefined antigens by IB warrants clarification in 
the near future. 
In conclusion, the presence of ANA as detected by IF in a patient pre­
senting with RP helps to predict progression towards СТО, while the 
antigenic specificity as detected by IB helps to characterize the syn­
drome that will develop, especially in case of PSS (Topo-I) (24), 
CREST (CR-19) (20) and MCTD (a-RNP) (14,16), which may be considered 
as marker antibodies. 
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The гоі of the sympathetic nervous system in 
the pathophysiology and therapy of Raynaud's 
phenomenon 
Η WOLLERSHEIM, Τ CLEOPHAS and TH THIEN 
Introduction 
The pathophysiology of acrotenc vasospastic at­
tacks, provoked by exposure to cold or emotional 
stress, is only poorly understood The statistical 
coincidence of Raynaud's phenomenon with 
variant angina and migraine headache [42] sug­
gests that a systemic factor affecting blood vessel 
wall reactivity may play an important role [16] 
However, up to now no generalized abnormality 
of vascular smooth muscle or of neural, humoral 
of haemo Theological properties has been identi­
fied In the literature several arguments are men­
tioned that support the pathogenetic importance 
of the sympathetic nervous system in Raynaud's 
phenomenon In the following these arguments 
will subsequently be discussed 
T h · physiologic rol· of t h · (ympathatic 
narvom tyatam In t h · regulation of «kin 
blood flow (see Fig 1) 
The sympathetic nervous system provides the 
predominant control of cutaneous blood flow 
and is responsible for the large variations which 
occur with thermoregulatory adjustment to dif­
ferent environmental conditions [1] The skin 
vasculature of the hands, feet, nose and earlobes 
of warm blooded animals contains large numbers 
of arteriovenous anastomoses, richly supplied by 
sympathetic nerve terminals [28] These shunt 
vessels act as a capacious radiator for the ex­
change of heat and are essential in body tempera­
ture homoiostasis Exposure to cold or emotion 
results in selective vasoconstriction of these 
anastomoses [14], while the relatively constant 
and much lower perfusion [25] through the more 
superficially located nutritional capillaries is 
preserved The contraction of vascular smooth 
muscle within the vessel wall of shunts is me­
diated by sympathetic stimuli and facilitated by 
the vasomotor nuclei in the medulla oblongata -
which are continuously adjusted by the thermo­
regulatory centers - located in the anterior hypo­
thalamus These react to the temperature of 
blood, flowing through it The information con­
cerning central core temperature is further in­
fluenced by a peripheral reflex emanating from 
cold receptors in the skin [50] As a result cooling 
impairs digital blood flow enormously and heat 
loss is anticipated [6] 
Because of this important physiologic vaso­
constrictive sympathetic reaction to cold and 
emotion, a relationship with the vasospasm in 
Raynaud's phenomenon, provoked by the same 
stimuli, is likely Moreover the distribution of 
arteriovenous anastomoses in the body is corre­
lated with the most frequent sues of cutaneous 
vasospastic symptoms 
An abnormal Іпсгмаа In aympathatlc 
outflow during normal raflu aympathatlc 
stimulation 
Ever since the initial description of digital vaso­
spasms by MAURICE RAYNAUD an increased sym­
pathetic outflow to the peripheral vascular bed 
has been considered to be of importance for its 
pathogenesis [46] Direct measurements of skin 
nerve vasomotor activity by microelectrode re-
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Fig 1 The link between the skin 
blood Dow and the thermoregula 
torv control mediated by the sym 
pathetic nervous system A de 
crease in the central blood 
temperature activates temperature 
sensitive cells in the hypothalamus 
resulting in a rise in sympathetic 
activitv to the cutaneous arterio­
venous anastomoses thus causing 
an enormous decrease in skin blood 
flow As a result heat loss to the 
surroundings is anticipated When 
the central blood temperature in 
creases opposite changes occur 
Thermosensiti\e receptors in the 
skin provide a second input into 
thisihermoregulaiors sistem 
Modified from SHEPHERD J Τ 
Л НОІТТЕ Ρ M In Shepherd 
J Τ Vanhoulte Ρ M (Eds I The 
human cardiovascular svslem 
Facts and concept Raven Press 
New >ork 1919 ρ 146 With per 
mission of the authors 
Hypothalamic 
thermoregulatory canter 
.ΓΛ \ Medullary 
^"^ ν cardiovascular center 
Skin of digit 
cordings for intraneural measurements in sym­
pathetic nervous fibers were made in the median 
nerve during contralateral cooling by FAGIUS and 
BLUMBERG [24] They found no difference in 
neural discharge between primary Raynaud's pa­
tients and normals In normal individuals they 
found a relationship between the increase in 
nerve activity and the reduction in blood flow 
Because this correlation was not found in Ray­
naud's patients a disturbance in the relation be 
tween the sympathetic nerve terminal and the 
vessel wall was suspected 
A local vascular hyperreactivity to normal 
•ympathetlc «tlmuH 
(see Table I and Fig 2) 
Besides an overactive sympathetic nervous sys­
tem, local hypersensitivity of the vascular smooth 
muscle wall to normal sympathetic nerve im­
pulses may play a pathogenetic role The «local 
vascular fault» [38] could be due to an increased 
catecholamine concentration within the synaptic 
cleft or to an imbalance between the density of or 
the affinity to adrenoceptors 
PEACOCK [44, 45] found a lower hand blood 
flow during cooling together with higher venous 
blood levels of norepinephrine in primary Ray­
naud's patients However, the chromatographic 
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Table 1 Causes of lovai tasiular hvpcrreaumn to SMTI 
paihenc stimuli 
1 Increased norepinephrine release per ner^e impulse 
2 Deireased latecholamine re uptake or k.atabolism 
3 Increased alpha adrenoLCptor densits or aftmiis 
4 Decreased beta adrenoceptor densnv or affiniti 
5 Altered activation/concentration of second messengers 
thkecAMP, cGMP Ca ") 
method used to determine the norepinephrine 
concentration is nowadays judged unreliable 
[30] In contrast, other investigators found a nor-
mal reflex vasoconstrictor response to indirect 
cooling with normal net arteriovenous brachial 
blood concentrations of norepinephrine in Ray-
naud's patients [33] The vascular response of 
finger skin vessels to infusions of catecholamines 
or its precursors had also yielded conflicting 
results [29. 33, 41] 
Recently m vitro experiments showed an in-
creased affinity of alpha-adrenoceptors for nor-
epinephrine at lower temperatures (58) and dur-
ing exposure to vibratory stimuli [2], resulting in 
an augmented contraction to sympathetic nerve 
stimulation A decreased catecholamine catabol-
ism within the synaptic cleft was hypothesized by 
VANHOUTTE et al [58] but an increased density or 
affinity of vasoconstrictive alpha-adrenoceptors 
as detected by KEENAM and PORTER [32] can also 
provide an explanation for these observations. 
Another hypothetical defect includes a decrease 
of vasodilating ß2-adrenoceptors [12, 18] Al-
though controversial [17, 35, 36], further 
evidence for a pathogenetic role of beta-adreno-
ceptors is suggested by the clinical observations 
that peripheral vasospasm may be a side-effect of 
beta-adrenoceptor blocking agents while beta 
Noradrenaline 
(presynaptic) 
(Extraeynaptiel | -
Second messengers + I 
I c A M P — 
Organs 
Lung Heart 
(Extrasyneptic) 
' I I? 
Smooth muscle 
(blood vessels) 
Fig 2 Postganglionic s>mpa(heiic nerveterminal in the heart and bloodvessels Pr«ynaptic bcta.adrenoceptors facidtatenor 
epinephrine release (+) when stimulated by adrenaline in low concentrations Presynaptic alpha, adrenoceptors inhibit nor 
adrenaline release (-) w hen snmulaled by noradrenaline or adrenaline in high concentrations 
Abbreviations CAMP = cyclic adenosine- 3,5 - monophosphate, cGMP=cvcl)Cguanosine-3,5 - monophosphate 
Modified from SCHALEKAMP M A D H . M A N I * ' τ VELD A J Monoammergic receptors and blood pressure Neth J Med 
2S 86,1983 
With permission of the authors 
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adrenoceptor agonists potentially improve finger 
skin blood flow [11,57] 
The beneficial therapeutic results of 
interventions that suppress the alpha-
sympathetic nervous system 
Indirect evidence for an hyper(re)activii) of the 
alpha-s\ mpathetic ner\ ous svstem is mediated by 
the benefit often caused by sympathicolvtic 
agents, surgical sympathectomy [3]or Pavlovian 
conditioning of the response to cooling (31) 
How ev er, complete relief is rare and perhaps any 
non specific intervention that partiallv increases 
finger skin blood flow may alleviate vasospastic 
attacks and not necessarily points to a pathophy­
siologic abnormality in the sympathetic neri ous 
system 
To summarize, no definite conclusions can be 
drawn from these studies This may be caused by 
methodological problems concerning the indirect 
methods for the measurement of the sympathetic 
nervous system (re )activity and the finger skin 
blood flow 
Pathophysiologic heterogeneity within the 
sludv population is another problem often over­
looked The above mentioned papers noi always 
deal with primary Raynaud's patients, in whom 
spasm occurs in structurally normal blood ves­
sels In patients with so-called secondary Ray­
naud's phenomenon, with underlying vessel wall 
disease leading to anatomical narrowing, a phy­
siologic vasoconstriction may already cause total 
occlusion [41] Thus, in them the sympathetic 
nerve activity could be normal and indeed several 
studies failed to find signs of an increased sym­
pathetic vasomotor tone in scleroderma [27,48], 
which is consistent with the disappointing long 
term results of sympathectomy [3] 
Last but not least attempts to induce vaso­
spastic attacks in a laboratory situation are 
notoriously unsuccessful [19], making it difficult 
to study haemodynamic events in relationship to 
sympathetic activity during an actual attack 
Sympathlcotytlc agents 
Because of this hypothetical role of the sym­
pathetic nervous system in the pathogenesis of 
Raynaud's phenomenon, surgical or pharmaco­
logical sympathectomy has been investigated in 
numerous studies 
A major disadvantage of most reports is the 
inadequate design and the lack of attention paid 
to side effects 
Most publications concerning the therapy of 
Raynaud's phenomenon are neither double blind 
nor placebo controlled Often they are retrospec­
tive, lack a homogeneous patient population and 
do not use prospectivelv well defined subjective 
or objective efficacy parameters [5] The varia­
tions in severeness of vasospastic disease, the 
variability of the natural course, the subjective 
character of the complaints, the differences in 
pathophysiology of several subtypes and the in­
fluence of environmental factors, hormonal ef­
fects, smoking pattern and emotion on the com­
plaints, make stringent scientific demands neces­
sary 
Another related problem in most studies is the 
lack of relationship between the subjective 
severeness of the vasospasm and the abnormal 
response registrated by objective blood flow 
measurements Besides, many different provoca­
tion tests and types of measurements are used, 
which make a comparison between studies diffi­
cult 
The next problem are the side effects (Table 
II), often incompletely reported Because the 
complaints are not severe in the majority of Ray­
naud's patients and the overall response rate to 
svmpathicolytic agents does not exceed бО^о. 
w hereas only a minority of patients become com-
Table H Side efffcls caused b\ drugs thai inhibit the s\in 
palhclic nerxous svslem 
A Central side effects depression 
sedation 
Parkinsonism 
tiredness 
В Peripheral side taihvcardia 
effects postural hvpolension 
oedema 
headache 
flush 
nasal congestion 
increased gastro intestinal mottlics 
diarrhoea 
urinar> incontinence 
impotence 
dr) mouth 
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pletely free of attacks, major attention should be 
given to the adverse effects of the drugs used 
Since the side effects depend largely on the inter-
ference with the sympathetic nervous system 
which is involved in the modulation of different 
bomoiostatic mechanisms (6], they can be dis-
cussed collectively 
Reflex tachycardia is an important side effect 
during exercise or standing up The hypotension 
stimulates the baroreceptor reflex, resulting in 
tachycardia mediated by beta1-adrenoceptors In 
Figure 2 it is shown that non selective alpha-
adrenergic blockade inhibits post-synaptic 
alphapadrenoceptors and pre-synaptic alphas-
receptors [34, 49] This causes an enhanced out-
put of norepinephrine per nerve impulse, because 
the negative feedback of norepinephrine medi-
ated by alpha2-adrenocepiors is blocked As a 
consequence norepinephrine within the synaptic 
cleft overrules its re-uptake and metabolic trans-
formation As a result overflow to the systemic 
circulation occurs which leads to an intensified 
sympathetic stimulation of the heart 
Postural hypotension is due to the impaired 
sympathetic regulation of the arterial and venous 
vasomotor tone, resulting in blood pooling in the 
legs in the erect position [55] 
Oedema may be caused by sodium retention 
due to a reduction of renal blood flow and (31-
adrenoceptor stimulation which both activate the 
renin angiotensin aldosterone system [8] 
Nasal stuffiness, headache and flush are all 
due to local vasodilation The impaired ejacula-
tion is due to a decreased possibility to contract 
the sympathetically innervated vas deferens Uri-
nary incontinence is the result of decreased sym-
pathetic innervation of the tngonum vesicae of 
the urinary bladder [56] Increased gastrointes-
tinal motility and diarrhoea is caused by pre-
synaptic stimulation of the neurotransmitter 
release from cholinergic neurons in the intestinal 
wall [61] 
Sedation, depression, tiredness and extrapyri-
midal symptoms like akinesia, rigidity and 
tremor are a result of inhibition of central nor-
adrenergic and dopaminergic neurons [61] The 
central side effects are also possible with periph-
erally acting alpha-adrenoceptor blocking agents 
if they are sufficiently lipophylic to enter the cen-
tral nervous system 
In general the above mentioned side effects 
limit the use of sympathicolytic drugs to a major 
extent 
Out of the many adrenoceptor blocking 
agents, reserpine and phenoxybenzamine have 
been extensively investigated in Raynaud's phe-
nomenon (Table III) To reduce the side effects 
several modifications of the above mentioned 
therapeutic modalities have been used 
Table lit Sympathicolytic agents investigated in Raynaud s 
phenomenon 
L Central and peripheral neuron blocking 
agents reserpine 
2 Centtallv acting agents methyldopa 
Clonidine 
3 Peripherally acting agents 
non selective phenoxybenzamine 
phenlolamme 
lolazolme 
thymoxamme 
seleclive alpha, prazosin 
indoramme 
Consecutively we will discuss the intra-artenal 
use of reserpine, the addition of a beta-adreno-
ceptor antagonist to phenoxybenzamine, the 
combined alpha- and beta-adrenoceptor blocker 
labetalol and the use of the selective alpha-adre-
noceptor antagonist prazosin in the treatment of 
Raynaud's phenomenon 
Centrally acting agenta that Interrare with 
adrenergic neuronal function 
Reserpine is a rauwolfia alkaloid that depletes 
stores of catecholamines, serotonin and dopamin 
at the presynaptic nerve terminal Its use is fre-
quently hampered by side-effects (Table II) of 
which psychic depression with a risk of suicide is 
especially notorious [61] Considerable contro-
versies remain on the association with breast 
cancer after long term administration [21] Be-
cause of the suspected lack of side effects during 
inlra-arlenal application and based on many 
open uncontrolled studies concerning a long term 
favourable effect with healing of skin ulcers, this 
type of treatment became the therapy of first 
choice in the sixties [20] In contrast, three recent 
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adequately designed studies failed to show a sig­
nificant improvement after intra-arterial reset· 
pine in comparison to placebo with a consider­
able number of systemic side effects [40, 51, 53) 
We conclude that the use of intra-arterial reser-
pine in the treatment of Raynaud's phenomenon 
should be abandoned 
Methyldopa exerts its central effects after con­
version to alpha-methylnorepinephnne, which 
is, like Clonidine, guanabenz and guanfacine, a 
potent agonist at alpha2-adrenoceptors in the 
vasomotor center [61] Paradoxically this results 
in a decrease of sympathetic outflow to the pe­
ripheral circulation Besides the side effects listed 
in Table II, bone marrow depression, auto­
immune haemolytic anaemia and liver function 
disturbances have been described These rare but 
severe adverse effects are not outweighted by 
only one uncontrolled and poorly documented 
study showing positive results in patients with 
Raynaud's phenomenon [59] 
Peripheral riph« «drtierglc blocking 
•senta 
Phenoxybenzaminc belongs just like phemola-
mine [4], tolazohne and thymoxamine to the so-
called non selective alpha-adrenoceptor blocking 
agents, introduced in the treatment of Raynaud's 
phenomenon after several uncontrolled studies 
[26] 
To evaluate the benificial effects of several 
alpha-adrenoceptor-antagonists and beta-adre­
noceptor agonists or combinations of them, we 
performed a double blind placebo controlled 
single dose study in 12 primary Raynaud's pa­
tients [11] As an objective measure of the thera­
peutic effect we used finger skin temperature and 
us recovery after a standard cooling test, con­
sisting of immersion of the hand in a waterbath of 
16 °C during 5 minutes [8] The appearance and 
the disappearance of cold induced vasoconstric­
tion serves as a model for a Raynaud's attack 
Previously we have demonstrated that finger skin 
temperature recovery in this test is reproducible if 
room temperature and smoking are controlled 
Raynaud's patients showed a much slower re­
covery of skin blood flow than healthy subjects, 
which was considered to confirm its validity as a 
model [7] In our study phenoxybenzaminc had 
the most favourable effect on the recovery of 
finger skin temperature 12 minutes after cold 
challenge The improvement was not negatively 
influenced by the addition of a beta-blocking 
agent [11] (Table IV) These results suggest that 
despite the presumed negative effects of beta-
adrenoceptor blockade on the peripheral circula­
tion, phcnoxybenzamine in combination with a 
beta-adrenoceptor blocker might be a suitable 
therapy which also prevents some of the beta-1-
mediated side effects of non-selective alpha-
blockade, ι e tachycardia and oedema [8] 
ТаЫеІУ Finger skin temperature in 12 patients with Ravnaud s phenomenon and in 23 normal subjects before immediate^ 
after and 12 minutes after finger cooling (mean ± SD) Table based on the results from reference [111 
Finger skin temperature 
Before 
cooling 
Immediately 
after cooling 
12 minutes 
after cooling 
Placebo 
Terbutaline (betaj adrenoceptor stimulator 5 mg) 
Prenalterol (beta, adrenoceptor stimulator, 3 mg) 
Orctprenaline (non selective beta adrenoceptor stimulator 10 mg) 
Phenoxybenzamine (alpha adrenoceptor blocker 20 mg) 
Phcnoxybenzamine (20 mg) + Prenalterol ( 10 mg) 
Phenoxybenzamine (20 mg) + Terbutaline (5 mg) 
Phenoxybenzaminc (20 mg) + Propranolol (40 mg) 
2 8 9 І 2 В Ч : 1 в 4 ± 0 5 ° С 2 2 0 i l 2 " C 
27 2 t 2 3 
29 9 i 2 6 
29 4 1 2 8 
3 0 8 1 2 5 · 
30 0 1 2 9· 
29 1 ± 2 5 
29 9 1 3 4 
1 8 6 x 0 4 
18 8 ± 0 S 
19 3 1 0 9 · · 
19 8 1 1 5 " 
19 8 1 1 2 0 
20 0 1 1 3 " 
20 0 1 1 3 · · 
22 0 1 1 2 
22 4 1 1 3 
22 9 1 1 5 · 
26 И З 8 " 
26 5 1 3 J " 
26 5 1 2 9 · · 
26 3 1 4 1 · · 
Normal subjects 3 2 9 ± 2 ] · · 21 4 ± 2 4 · 1 32 7 ± 1 7 · · 
Probabilities relaie to the signiñcance оГ difference berreen paired data in patients compared ю their placebo values (Wíl 
coxon s signed rank lest) and difference between unpaired data of normal subjects as compared to the placebo values in the pa 
tieni s (Wilcoxon's rank sum test) 
( • ) 0 0 5 < p < 0 0 1 · ρ < 0 0 3 • · ρ < 0 0 1 
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On account of these results phenoxybenza 
mine alone (10-20 mg daiK or in combination 
with the beta adrenoceptor blocker Sotalol (40-
80 mg daiU) »ere evaluated in a double blind 
placebo controlled cross o\er study of 24 weeks 
in 31 patients with Ra\naud's phenomenon (9] 
During phenoxv benzamine an alleviation of clin­
ical ssmptoms and an improved recoverv of fin 
ger skin temperature after cooling was demon­
strated и hich persisted during the addition of the 
beta adrenoceptor blocker (Table V) The fluid 
retention and tachv cardia observ ed during alpha 
adrenoceptor blockade alone disappeared after 
the addition of Sotalol 
However, other side effects like impotence, 
urine incontinence, exercise induced and ortho 
static dizziness were vers common and hampered 
long term use We found no difference m sus 
ceptibilitv to treatment between the primary and 
the secondarv Raynaud's patients with a connec 
live tissue disease in this study [10] Hence, also 
patients with a combination of vasospastic and 
obstructive vessel disease may respond to alpha-
adrenoceptor blockade 
The development of the combined alpha- and 
beta adrenoceptor blocking agent labetalol [37] 
could favourably influence patient compliance, 
but the fixed combination is also a disadvantage 
in the choice of an individual dosage schedule 
Because labetalol might be of importance in hy­
pertensive patients who developed Raynaud's 
phenomenon during treatment with a beta-adre-
noceptor blocking agent, we treated 8 of these pa­
tients during an open study w uh 400 mg labetalol 
daily, a dose too low to achieve sufficient alpha-
adrenoceptor blockade [37] 
We found a subjective allev ation of symptoms 
although the improvement assessed during cool­
ing was not significant Blood pressure remained 
adequately controlled These results are similar 
to those of ELIASSON et al [23] 
Table V TheinnuenceorUureLslreaimentuith phenoxv btnzamin« (20 mg dailv) alone or in combinations uh Sotalol (80 mg 
(lail> Ion finger skin lempcraiure(cO blood pressure (mmHg) heart rale (teals per mimitelandbodv weigh) (kg) in 31 patients 
» uh Ra\ naud s phenomenon (mean ν alucs ± SD) Table based on the results ot reference |9] 
Finger temperature before looting 
Immediatels aTter cooling 
12 mm after cooling 
Systolic pressure 
Diastolic pressure 
Heart rate 
Body weight 
Phenoxv benzam 
Before 
treatment 
27 2 ± 3 6 
Г 9 ± 10 
19 β ι 17 
127 I 14 
85 ±10 
75 ±11 
687±11 s 
ine 
8 weeks 
treatment 
28 6± 3 2 
18 8± 1 1 " · 
24 5 t 3 2 — 
125 ±13 
83 t 9 
'7 ±15 
70 7 ± 10 9· 
Phenoxvbenzam 
Before 
treatment 
27 4T 3 7 
18 3± 10 
20 4 i 19 
127 ±11 
85 ± 9 
76 ±10 
69 0 ± 1 1 7 
me * Sotalol 
8 weeks 
treatment 
29 2 ± 3 5· 
19 4± 1 9 " 
2 ' 3± 4 3 " · 
123 ±15 
81 -11 
70 ± 12 · · · 
68 5 ± 1 1 0 
Uilcoxon s test for paired data is used to compare 4 and β weeks values with the values prior to treatment 
•p<005 • · ρ < 0 ϋ 1 •••p<0001 
Table VI Theinfluenceof theterminationofabeta adrenoceptor blocking agent and the additionoCthecombinedalpha and 
beta adrenoceptor blocker labetalol (400 mg dail\)on blood pressure (mnHg) daiK vasospastic attack frequency (diar>) and 
mean linger skin temperature ( 'C) during the standardized cooling test in 8 patients with essential hypertension who developed 
Raynaud's phenomenon during treatment with a beta adrenoceptor blocking agent Unpublished observations 
Blood pressure systolic 
Blood pressure diastolic 
Daily attack rate 
Mean finger skin temperature 
During beta 
adrenoceptor 
blocker therapy 
1515±215 
9 0 1 ± 6 1 
5 1± 1 8 
22 9± 10 
3 months afta 
the termination of 
the beta adreno 
ceptor blocking 
agent 
161 5± 13 5 
9 8 6 1 1 0 2 
4 1± 2 0 
23 1 ± 16 
3 months after 
the addition of 
labetalol 
(400 mg daily) 
149 3 ± 12 8 
87 3 * 2 4 
2 9± 2 0· 
23 8± 11 
* p < 0 0J (Student Τ test) for paired samples 
66 
Table III Thediar\ results and the result ol the standardizad linger СООІІПЙ test (mean valuesr SEM un 24 Raviidud s patients 
during plaicbo and during 2 ueeks prazosin (3 mg dailv) Result ba^ ed on refcrenLC (62) 
Placebo period Prazosin period 
Finger cooling test 
- dailv number of attacks 
- duration o l anatks (minutes) 
- seventh оГ attacks (10 points stalet 
ambient temperature ( Q 
FST finger skin temperaiure 'C 
- bdsit value1 
- immediateh after tinger tooling 
- 12 minutes after finger cooling 
- mean le\elJ during test 
4 l i O 5 
29 9 1 5 1 
4 j i 0 4 
5 0 i 0 6 
J O O T O S 
18 -°^0b 
: 3 9 î 0 9 
24 O í 0 6 
2 ! i 0 З · · 1 
21 9 Í 5 6 · 
4 Ι ι 0 4 
4 8 ι 0 4 
31 3 ι 0 8 · 
20 6 î 0 5 · -
27 2 î l 1 " 
26 3 ι 0 S " 
Value obtained during prazosin - value obtained during placebo treat mem 
Student и teil lor paired samples 'p<-00* " * p < 0 0 l 
' Mean νalue of 3 observations wuhin 5 minutes beforecoolinji 
4
 Derived I rom the area under enure curve divided bv duration ol the test (30 minutes) 
The development of selective alpha,-adreno-
ceptor blocking agents like prazosin may de 
crease side effecis because of the preserved feed­
back control of norepinephrine release by pre­
synaptic alpha, adrenoceptors This might have 
the advantage of a more pronounced vasodila­
tion and the absence of tachycardia and oedema 
in comparison to non-selective alpha-blockers 
[52] Prazosin inhibits vasoconstriction by block­
ing posi-synaptic alphaj-receptors and several 
reports on its successful use in vasospastic disease 
have been published [42, 60] Therefore we per­
formed a randomized, double blind, placebo 
controlled cross-over study on the therapeutic ef­
ficacy of prazosin (3 mg daily) in 24 patients with 
Raynaud's phenomenon [62] Comparison of 
prazosin versus placebo showed a moderate sub­
jective improvement while finger skin tempera­
ture, assessed during the cooling test, revealed a 
beneficial effect of prazosin (Table VII) No dif­
ferences in reaction towards therapy could be 
found between primary and secondary Ray­
naud's patients Despite an overall good response 
in бОТо of patients, complete relief was only seen 
in 2 patients The eight patients who participated 
in both the prazosin and the phenoxybenzamme 
study judged them of equal effectiveness The 
check list of side effects showed an equal number 
of adverse effects but they seemed less severe dur­
ing prazosin Yet the total number of side effects 
during prazosin was disappointing and some 
were disabling, like urine incontinence, recurrent 
epistaxis, hypothermia, palpitations and 
oedema The latter two ju»i were expected to be 
less during selective alpha,-blockade This shows 
that alpha, selectivity has a more pharmacologi­
cal meaning than a clinical one The first-dose 
phenomenon of severe orthostatic hypotension, 
a well known side effect of prazosin, was not ob­
served, probably because of the low initial gift at 
bedtime (0 5 mg) followed by a gradual step-up 
schedule 
During a follow-up study, of which the analy­
sis is not yet completed, some doubts concerning 
the longterm efficacy of prazosin occurred The 
development of tolerance is well known of prazo­
sin, when used in the treatment of severe heart 
failure and has also been described in Raynaud's 
phenomenon by NIELSEN et al [43] Moreover, at 
higher dosages no further improvement was seen 
while the number of side effects increased 
Recently two controlled studies have con­
firmed Ihe positive results on the effectiveness of 
prazosin in the treatment of Raynaud's phe­
nomenon [47, 54] 
Conclualon 
The clinical efficacy of a wide varietv of thera­
peutic modalities in the treatment of Raynaud's 
phenomenon is disappointing [15] Despite phar­
macological progress to more effective and safer 
sympathicolytic agents, the ideal drug is not yet 
available A major problem is that both the side 
effects and the therapeutic effectiveness are a 
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consequence of the vasodilation and the block­
ade of the sympathetic nervous system Because 
of the widespread occurrence of alpha adreno­
ceptors [34], it seems impossible that blockade 
will result in selective vasodilation of peripheral 
vascular sktn beds 
In severe, mostly secondary Raynaud's phe­
nomenon, the circulatory disturbances are also 
located in the capillary nutritional vessels of the 
skin [13], which are responsible for the tissue 
necrosis These vessel walls are not or only spar-
sel> innervated b> sympathetic nerves. Thus an 
improved circulation through these capillaries 
can hardly be achieved by sympathetic nerve 
blocking agents 
Furthermore u is questionable whether per­
manent vasodilation should be the therapy of 
choice in a disease with intermittent vasospasm. 
Indeed sympathicolytic agents do not affect 
digital vasospasm at all in one third of patients 
while complete relief is achieved in less than 
10% The lack of pathophysiological under­
standing [19] makes therapy a matter of trial and 
error in stead of a well considered therapeutic 
answer to a comprehended problem The therapy 
of Raynaud's phenomenon with sympathicolytic 
agents is not an exception to this statement. 
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Discussion 
Question Do you have experience with isoxsupnne and 
toluoltnc tn the treatment of Raynaud's phenomenon'* 
Answer No. we have no such experience There is no rea­
son to believe however, that these non-selective alpha adreno­
ceptor blockers would have an effect differing from that of 
phenoxybenzamine, phentolanune or thymoxaminc 
Various true or unproved effects are ascribed to isoxsu­
pnne, such as ß-adrcncrgii and heme rheological properties 
We have no experience ourselves so far, but as you know the 
Groningen group observed reasonable effects of sublingual 
isoxsupnne 
Question You mentioned tolerance for prazosine in the 
treatment of hypertension I am not aware ofthat in hyperten-
sive patients but I do so in patients with congestive heart 
failure Could you give a reference9 
Answer Development of tolerance for prazosine, as a 
matter of fact, has been shown to occur more frequently in 
congestive heart failure than in hypertension Still, the litera-
ture indicates that such a process in hypertension in man and 
animals will be found 
CHAPTER 6. 
LASER DOPPLER VELOCItCTRY TO EVALUATE THE SKIN CIRCULATION. 
AN INTRODUCTION. 
A variety of noninvasive techniques for measurement of the peripheral 
cutaneous circulation have been introduced in the last decade (1). 
Skin blood flow monitoring by means of laser Doppler was originally 
developed by Stern (2). Laser Doppler measurements utilise the Doppler 
principle: light which strikes a moving object will undergo a frequen­
cy shift, proportional to the velocity of the moving subject. In the 
following studies the Penflux Pf-1 (Penmed; Sweden) is used. In this 
system laser light with a wavelength of 632.θ nm is generated by a 
helium neon laser (output power: 2 mW) and transmitted through a 
fiberoptic cable to the skin surface where it illuminates and per­
meates the skin with a maximal sensitivity level to 0.7 mm depth (3) 
below which the relative sensitivity decreases exponentionally. Laser 
light reflected from both non-moving tissue, i.e. the reference beam 
and moving red blood cells, the Doppler-shifted beam is collected and 
transmitted through a separate fiberoptic cable for analysis by two 
separate photodetectors. On their surface, optical heterodyning takes 
place and an electrical output proportional to the "beat frequency" is 
produced. This is analysed by differential amplification to improve 
the signal to noise ratio. The analogue output signal is then sub­
tracted from the control photocurrent power spectrum and finally a 
real-time continuous electrical signal is generated. This is expressed 
in volta or in arbitrary units and fed to a pen-recorder for con­
tinuous registration of skin blood flow. 
Zero flow calibration preceeds all recordings and is performed by 
placing the laser probe in the calibration clip on a static white sur­
face that contains no mobile structures. After 30 seconds the recorder 
pen is then moved to the zero position on the chart paper. Subsequent­
ly, the probe is attached to the skin by means of a probe holder and 
is always carefully localised in the center of the distal volar 
fingertip by double stick adhesive tape. We use an angle probe that 
better fits to skin surfaces and is less sensitive to movement arte­
facts. For all the measurements the Penflux was adjusted to a gain of 
3 and an upper frequency limit of 12 kHz. Unless stated otherwise the 
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time constant was set to 3 seconds, which means that the signal is 
averaged during this time period. 
Laser Doppler flux (LDF) values correlate well with other methods that 
determine skin blood flow (4), like the Xenon wash-out technique in 
skin devoid of shunts (5-8), the heat clearance technique (9), sodium 
fluoresceine perfusion studies (10) and strain gauge plethysmography 
(11). LDF showed a more sensitive reaction to intervention than photo-
plethysmography (12) or finger skin temperature (13). LDF measurements 
do not influence the flow being measured like volume plethysmography 
for example. Furthermore, LDF readings show a close response to 
stimuli with a predictable effect (6,9,13-15). LDF measurements have a 
higher diagnostic value when analysing several types of hand ischaemia 
during body warming or cooling than the xenon wash-out technique and 
the finger systolic pressure determined by venous occlusion plethysmo­
graphy (7,8). Besides, LDF monitoring has been reported to have an 
acceptable reproducibility if measured at the same site (Θ) and is 
suitable to monitor digital skin blood flow during pharmacologic and 
physiologic intervention studies (14,16-18). Because of these methodo­
logical advantages and the fact that it is a noninvasive, continuous 
measurement technique, which is easy to handle in daily practice and 
is inexpensive in purchase and maintenance costs, LDF-measurements are 
becoming increasingly popular in the evaluation of skin perfusion dis­
orders like Raynaud's phenomenon (19) or diabetes mellitus (20). 
To evaluate the possibilities and limitations of LDF monitoring, some 
basic principles related to skin circulation, skin histology, the 
laser Doppler signal and its interpretation must be considered. The 
microvascular structure starts with arterioles with a vessel cross 
section of about 10 m and a high smooth muscle content in their wall 
with a pronounced sympathetic innervation. These arterioles end up in 
a hairpinlike system of capillaries, rising from the papilla of the 
conum and returning to the subpapillary venous plexus. In true capil­
laries smooth muscle cells are absent, but in some the pericytes in 
the vessel wall are able to induce vascular contractions. In contrast 
to the vertical takeoff of the capillaries, the larger vessels in the 
lower dermis run parallel to the skin surface. At sites involved in 
thermoregulation, like fingers, toes, earlobes and nose arteriovenous 
anastomoses are present that permit the shunting of blood directly 
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from arterioles to venules (22). They have a huge dilatory capacity 
that allows a complete bypass of the capillary system. In contrast to 
the feeding capillaries, these shunts are richly supplied by sympathe-
tic nerve endings (23). At room temperature, they comprise about 90% 
of the total skin perfusion. The microcirculatory blood flow regula-
tion is mainly affected by vascular smooth muscle cells surrounding 
the vessels predominantly on the arterial side and to a lesser extent 
on the venous side. These smooth muscle cells are controlled by sympa-
thetic nerve fibres, possess activity without nervous stimulation 
(vasomotion) and are strongly influenced by metabolic, humoral and 
physical factors. 
The interpretation of the laser Doppler shifted signal from the cuta-
neous microcirculation is complex (24) because the energy beam that 
impinges on the microcirculatory system does not face a uniform, geo-
metrically well-defined vasculature but rather a network of vessels 
crisscrossing the measurement sanple size, whereas the light source 
reaches the red blood cells within the capillaries at a variety of 
different angles because of the random orientation of the capillary 
loops. In addition, significant scattering occurs before the beam 
reaches the capillary and all this is repeated before the reflected 
beam reaches the pickup system on its way back. The laser light usual-
ly penetrates to a depth of 1.5 mm corresponding with the localisation 
of the nutritive capillaries and at least part of the arteriovenous 
shunt system. The actual depth of penetration, however, is a function 
of technical parameters such as the output-power and the frequency of 
the light source, as well as of anatomic variables, such as skin pig-
mentation, thickness of the epidermis, skin properties and differences 
in the vasculansation pattern like the local capillary and shunt den-
sity (25). For example, in black skin more light is absorbed and less 
is scattered back. The same is true for skin with a thick horny 
layer. 
The resulting laser Doppler signal is a product of the number of red 
blood cells moving in the sample volume and their mean velocity, that 
is neither velocity nor flow but determined flux (24) which is diffi-
cult to compare with existing standard techniques of blood flow. Con-
sequently a reproducible standard skin blood flow measurement, against 
which the laser Doppler signal can be calibrated to enable inter-
experimental comparison is still lacking. At present, an arbitra-
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ry scale of units is used and only relative changes in blood flow can 
be determined. The laser Doppler is sensitive to all movements, which 
means for example, that movements of blood vessel walls and intra­
cellular or extracellular fluid motion will all affect the output 
signal. The influence of leucocytes or platelets on the recorded flow 
value has not been evaluated but their contribution is expected to be 
low, due to the small relative volume fractions of these cells (25). 
There is a non-linear relation to flow at high volume fractions of red 
cells in tissue, like in the fingertip for example (3). In blood 
vessels other than capillaries, the red cells are transported close to 
each other, often gathered in rouleaux formations, which act as larger 
particles producing a higher degree of light scattering. Consequently, 
when measuring fingertip or non-capillary blood flow the flux of cells 
is underestimated. Moreover, the haemoglobin content and the oxygen 
tension of red cells alter their optical properties and thus influence 
the fluxmeter response. 
Although the coefficient of variation is low in model experiments, in 
practical use on human skin the significant differences between adja­
cent probe sites and the wide day to day variations (26) seriously 
question the reproducibility of this method and all other methods that 
determine skin blood flow. Especially the evaluation of the extremely 
variable fingertip circulation with its capacity to enormous changes 
over a short period of time caused by the extreme sensitivity to endo­
genous and exogenous stimuli entails serious problems of standardisa­
tion. These fluctuations are responsible for the great inter-indi-
vidual and intra-individual variations. 
The reflected laser Doppler flux signal shows a rhythmical cyclic 
pattern with a frequency of 4-Θ min-1 in the fingertip due to vaso-
mot ion, pulse pressure and respiration (27), which makes it difficult 
to calculate a mean flux. The oscillations synchronous with the car­
diac rhythm are greatly reduced if a time constant of 3 seconds is 
used. To reduce these fluctuations, flux-values measured every second 
are averaged for 30 seconds periods. All these values are summed and 
then divided by thirty. Because this procedure was rather time con­
suming, we compared eighty of these calculations, performed during 
baseline laser Doppler registrations in 12 normals and in it Raynaud 
patients with an estimated value determined by the naked eye. Because 
there was an excellent correlation (R=0.9962; p<0.0001) between both, 
which is shown in figure 1, we continued to estimate the flux value 
henceforth. 
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Figure 1. The correlation between the estimated and the calculated 
laser Doppler flux (tDF). 
The laser Doppler method 13 sensitive to movement artefacts, but these 
can easily be recognised and are only troublesome in patients that are 
unable to lie quietly or during dynamic experiments with movements of 
the hands such as during hand cooling in a water bath for example. 
The output signal corresponds to the integrated motion of red cells in 
the volume measured. The contributions to this signal from small arte­
rioles, capillaries, arteriovenous anastomoses and venules cannot be 
distinguished and it is best to mention the signal total skin blood 
flow. The volume of tissue influencing laser Doppler readings is un­
certain, although the 2 mW helium-neon laser we use is supposed to 
penetrate to a depth of 1.5 mm tissue or less (3). So at least part of 
the arteno-venous shunt system is included in the measurements (28). 
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Some investigators, however, suppose that its penetration depth is 
less (29) which means that only capillary flow is included (30). More-
over, in highly perfused tissue such as a vasodilated fingertip a more 
shallow light penetration can be expected, since the light absorption 
in red cells is higher than in surrounding tissue and because the red 
cells "stand in the light for each other" (6,31). 
To determine whether shunt blood flow is included in LDF-readings, we 
compared baseline LDF during five minutes from several parts of the 
body consecutively with a decreasing shunt density, the fingertip, the 
toetip, the handpalm, the forearm and the thorax (32). For this pur-
pose the mean baseline LDF was measured after 20 minutes acclimatisa-
tion in a climate room (24.5+0.2 °C) in 8 control subjects and in 8 
patients with primary Raynaud's phenomenon (PRP) on the localisa-
tions mentioned above. In Table 1 this mean baseline LDF is shown in 
both groups. 
Table 1. Baseline-LDF (in AU; mean ^  SE) in 8 control subjects and in 
8 patients with primary RP measured on the fingertip, the 
toetip, the handpalm, the forearm and the thorax. 
baseline-LDF 
control subjects primary RP 
Fingertip 34.81+4.1 12.3+1.2 
Toetip 26.5+3.5 10.1+1.2 
Handpalm 22.3+2.2 11.8+1.5 
Forearm 13.5+0.8 9.8+1.0 
Thorax 10.5+0.6 9.1+1.0 
As can be seen in control subjects, the LDF-values decrease with lower 
skin shunt densities, which strongly supports the assumption that at 
least part of the shunt flow is included in the volume measured by the 
laser Doppler. Furthermore, the decrease is less in the primary RP 
group, which supports the concept of vasospasms that are mainly locat-
ed in the shunt system in patients with PRP. 
It could be of great value to perform laser Doppler fluxmetry simulta-
neously with measurements of capillary perfusion like dynamic capilla-
ry microscopy, the 133 Xenon wash-out technique or perhaps measure-
ments of tissue oxygen tension. If LDF really measures capillary and 
shunt flow, both vascular beds can be discriminated (33) in this way, 
75 
making a better understanding about the role of both systems in the 
physiology of skin circulation possible (34). 
One preliminary study performed with simultaneous measurements of LDF 
and capillary microscopy already showed differential behaviour of both 
skin vascular beds (33). 
In conclusion, one of the major problems of measuring skin blood flow 
is the existence of natural spatial and timely variations which make 
it difficult to compare skin perfusion recordings by means of for 
example laser Doppler in different individuals or on different occa­
sions. On the contrary, its continuous noninvasive fast-reacting 
nature makes LDF the method of choice to detect rapid changes in skin 
blood flow during short-lasting standardised provocation procedures. 
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CHAPTER 7. 
VASCULAR AM) HUMORAL SYWATHETIC NERVOUS SYSTEM REACTIVITY DURING 
MENTAL ARimCTIC IN PRIMARY RAYNAUD'S PHENOMENON. 
Introduction 
Primary Raynaud's Phenomenon (PRP) is characterised by attacks of 
vasospastic digital ischaenua, usually provoked by cold exposure or, 
less frequently, by emotional stress (1). More than a century ago, 
Maurice Raynaud (2) proposed an increased sympathetic outflow to the 
skin as a possible pathogenetic mechanism. 
The sympathetic nervous system plays an important role in the regula-
tion of cutaneous blood flow and is responsible for its enormous vari-
ations, serving thermoregulatory demands (3). The skin vessels of the 
hands, and to a lesser degree the feet, contain large numbers of 
arteriovenous anastomoses that are richly supplied by sympathetic 
nerve endings (3). Since exposure to cold or emotional stress results 
in physiologic vasoconstriction of these shunt vessels, a relationship 
with the vasospasms that occur in RP is likely. The finding of a 
normal local venoarterial sympathetic reflex in Raynaud patients 
together with an augmented central sympathetic response to changes in 
posture (5) supports Raynaud's original hypothesis. 
In constrast to this concept, Lewis (6) developed the "local vascular 
fault" theory proposing a local hypersensitivity of the peripheral 
vascular smooth muscle wall, because he was still able to induce a 
vasospastic attack after blockade of sympathetic nerve endings at the 
fingerbase. Indeed, fagius and Blumberg (7) found no evidence for cen-
tral hyperactivity during direct intra-neuronal measurements of sympa-
thetic nervous outflow to the hands in patients with PRP during cold 
challenge. Also the normal correlation between the increase in sympa-
thetic nerve activity and the reduction in blood flow is lost in 
Raynaud patients, suggesting a disturbance in the relationship between 
the nerve ending and the vessel wall. The local vascular fault theory 
is updated since increased numbers of alpha-2-adrenoceptor9 on throm-
bocytes were measured in Raynaud patients (8) which could explain an 
increased vasoconstrictor response to normal sympathetic stimulation. 
80 
Furthermore during in-vitro experiments, Vanhoutte and Janssens (9) 
showed an increased norepinephrine binding to alpha-adrenoceptors in 
normal vessels at lower temperatures. In addition they have found a 
decreased catecholamine degradation, a depressed re-uptake and have 
postulated a decreased overflow from the junctional cleft (9). 
To test the hypothesis of an increased sympathetic nervous system 
reactivity in PRP during stress we investigated the effects of a 
standardised mental arithmetic (MA) test on vascular and sympathetic 
nervous system reactivity in 12 patients with PRP in comparison to 12 
healthy control subjects. 
Patients and •ethods 
Twelve patients with PRP according to the criteria of Allen and Brown 
(10), supplemented by negative clinical, biochemical and immunological 
findings indicative for associated diseases were selected together 
with twelve age- and sex-matched controls without complaints of cold 
hands, peripheral vascular disease or RP. All gave informed consent to 
a protocol approved by the local Ethical Committee. They were asked to 
abstain from smoking 24 hours preceding the test and not to drink 
alcohol or drinks containing caffeine from 12 hours prior to the test. 
The investigations were performed with all subjects in the supine po-
sition in a climate room with a constant ambient temperature of 24.2 + 
0.3 (SD) centigrades and a humidity of 53 + U%. During the acclima-
tisation period of at least 20 minutes the measurement instruments 
were attached and a vein on the back of the right hand was cannulated 
for blood sampling and subsequent determinations of plasma epinephrine 
(E) and norepinephrine (NE) (11). 
Systolic and diastolic Blood Pressure (BP in mmHg; Arteriosonde Roche 
1225) was measured on the left upper arm. Left forearm blood flow (FBF 
in ml/100ml/min; Loosco Plethysmograph, Hoekloos) was determined by 
ECG-tnggered mercury strain gauge plethysmography (12), whereas the 
venous outflow of the hand was occluded by a wrist cuff. After cali-
bration, FBF was calculated by the mean of 3 subsequent measurements 
on each time period. Heart rate (HR in beats per minute; bpm) was 
determined by ECG-monitonng. On the second fingertip of the right 
hand, we measured Laser Doppler Flow (13); (LDF in AU; Penflux Pf-ld, 
Penmed KB, Stockholm, Sweden) by determining the area under the curve 
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during the 30 seconds around each time point. 
MA (14) was performed by asking the subject to repeatedly substract 17 
from 4000 as quickly as possible during 5 minutes, while a metronome 
speeded up the subject. After the acclimatisation period 3 baseline 
values of all parameters were measured at 2 minute intervals. Sub­
sequently, LDF was determined every minute, and BP, HR and FBF every 
second minute during and until 6 minutes after MA. Before and at the 
end of the MA test, blood samples were taken for determination of E 
and NE (15). Mean arterial pressure (MAP) was calculated as the sum of 
the diastolic and 1/3 of the pulse pressure. Forearm vascular resist­
ance (FVR in AU) was calculated by dividing MAP by FBF. 
Data were pooled for each group and expressed as mean +^  standard de­
viation (SD) unless stated otherwise. Statistical analysis was per­
formed by unpaired Student t-test if the variables were normally dis­
tributed or by unpaired nonparametnc Wilcoxon test if the variables 
showed an irregular distribution. Correlations were calculated by non-
parametric correlation analysis according to Passing and Bablok (16). 
A p-value of less than 0.05 (two-sided) was regarded as significant. 
Results 
There were no significant differences between both groups with regard 
to age (31+10 years in PRP, 28+7 years in controls), sex ratio 
( female:male = 9:3 in both groups), and Quetelet-index (21.2+2.4 kg/m? 
in PRP, 21.5+1.8 kg/m2 in controls). 
As can be seen in figure 1, in both groups a significant increase in 
BP and HR during MA was found. The increase in MAP was 12.θ + 6.0 mmHg 
in controls and 10.0 + 2.6 mmHg in patients (both p<0.0001), whereas 
the increase in HR was 13.7 + 9.9 bpm in controls and 21.7 + 18.4 bpm 
in patients (both p<0.005). The PRP-patients showed significantly 
higher baseline values of diastolic BP and MAP (both p<0.05). During 
MA, we found no significant difference in absolute BP and HR increase 
between both groups. 
The same holds for the proportional changes in MAP and HR. MAP rose 
with 11.1+3.3S> in controls and 14.9+7Ä in patients (for both 
p<0.0001). HR rose with 19.9+12.5SÍ in the control group and 31.7+29.0 
in the patients (for both p<0.005). The differences between the 
changes of the groups were not significant. 
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In both groups MA induced an increase in FBF; in controls from 4.4 + 
2.5 before to 6.9 + 4.3 ml/IOOml/min and in patients from 3.2 + 1.5 
before to 5.0 + 2.6 ml/100ml/min (p<0.001). Intergroup comparison 
showed no difference in the absolute increase of FBF. The percentage 
increase in FBF during MA was 56.4 + 36.4% (p<0.0005) in controls and 
79.1 + 66.4% (p<0.005) in patients, with no significant difference 
between them. Baseline LDF in Raynaud patients wag lower than in 
controls (17.8 + 18.9 AU versus 38.9 + 15.9 AD; ρ <0.01). The absolute 
changes in LDF during MA were not significant in both groups. In the 
lowest panel to the right of figure 1, the proportional changes in LDF 
during MA are shown. While there was a decrease in LDF during MA in 
controls, an increase was found in Raynaud patients. In the first 
minute of the MA, the LDF decreased 11.6 + 31.6% (NS) in controls, 
whereas it increased 46.6 +_ 74.3S (p<0.05) in patients, with a sig­
nificant difference between both groups (p<0.05). 
The baseline E concentration, as indicated in figure 2 differed not 
significantly between both groups. In both groups E increased during 
MA: in controls from 0.15 + 0.07 nmol/1 before MA up to 0.25 + 0.15 
nmol/1 during MA and in patients from 0.18 ¿ 0.10 nmol/l up to 0.26 + 
0.13 nmol/1; both changes being significant (p<0.001). A baseline 
difference in the NE concentration was found between both groups: 1.27 
+ 0.40 nmol/1 in controls versus 2.24 + 1.45 nmol/1 in patients 
(p<0.01). The NE concentration increased significantly in the con-
trols: from 1.27 + 0.40 nmol/1 up to 1.64 + 0.58 nmol/1 during MA 
(p<0.05) but the rise in PRP-patients from 2.24 + 1.45 nmol/1 up to 
2.41 + 1.64 nmol/1 was not significant (NS). 
The proportional increase in E was 72.0 + 60.6% (p<0.005) in the con-
trols and 60.5 + 51.7% (p<0.005) in the patients. The percentage in-
crease in NE was 37.6 + 60.Зй (p<0.05) in controls and 7.8 + 19.2% 
(NS) in patients. The relative changes of both catecholamines differed 
not significantly between the two groups. 
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axis) during the first minute oF the mental arithmetic test. 
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Figure 3 shows the significant correlation (R=-0.91; p<0.001) between 
baseline LDF (in AU) and the absolute change in LDF (in AD) in all 
subjects during the first minute of MA. There were no significant cor-
relations between changes in NE and changes in any of the circulatory 
variables during MA in any group. Increases in E were only correlated 
significantly with the increase in HR during MA (R=0.36; p<0.05; 
n=24). In the Raynaud patients, baseline E was significantly correlat-
ed with baseline HR (R=0.52; p<0.01; n=12). When both groups were 
taken together, a significant inverse correlation was found between 
baseline NE and baseline LDF (R=-0.47; p<0.01; n=24). 
Discussion 
This study shows that baseline haemodynamics and sympathetic nervous 
system activity differ significantly in normals and patients with PRP, 
whereas the vascular and the sympatho-adrenal reactivity during stress 
appear to be similar. The higher baseline levels of BP, HR and NE in 
the patients together with the decreased baseline LDF can all be ex-
plained by a higher central baseline sympathetic activity. Others also 
observed a decreased baseline skin blood flow in PRP, whereas during 
sympathetic stimulation there was no difference in vasoconstriction 
between patients with PRP and normal subjects (17-19). 
There are some alternative explanations for the higher baseline NE 
levels in Raynaud patients: a decreased NE catabolism or a decreased 
re-uptake, both caused by the lower temperature in the peripheral skin 
vessels of these patients (9). Moreover, the lower skin perfusion in 
Raynaud patients may increase the NE concentration. Furthermore, we do 
not know whether the arousal of the laboratory environment or the 
psychological effect of knowing that some kind of stress test together 
with blood sampling was going to occur may already have heightened 
baseline NE and E levels. Although there was at least a 20 minutes 
rest between the puncture and the first blood sampling from an in-
dwelling catheter, which is supposed to minimise these influences in 
control subjects (20), it could have been that pain or fear had a 
stronger or longer lasting effect on catecholamines in patients with 
PRP than in normal subjects. Venipuncture and the difficulties en-
countered with blood sampling may be uncomfortable (21), especially on 
the back of the hand in a state of low perfusion which was more often 
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seen in patients with PRP. 
The resulta of other investigators regarding NE concentrations in 
Raynaud's phenomenon are somewhat controversial. Peacock (22) also 
found higher baseline venous blood levels of NE in PRP-patients than 
in normals, while others (23) found normal arteriovenous concentra-
tions of NE in the forearm. In Peacock's study the chromatographic 
method was used to determine the NE concentration which is nowadays 
judged as unreliable. We used a recently improved radioenzymatic assay 
to determine plasma catecholamine concentrations (11,15). 
Because NE is a locally released neurotransmitter, we sampled blood 
from a vein on the back of the hand to obtain information regarding 
the regional NE release from finger skin vessels (24). Of course it 
would have been better to measure arteriovenous differences because 
this reflects the amount of NE release versus extraction more accu-
rately. 
The increase in BP and HR during MA shows that a generalised stress 
was really experienced during this test. Especially skin sympathetic 
nerve activity is markedly increased during mental activity as shown 
by directly intraneuronal measurements (25,26). Although this may lead 
to vasoconstriction, it is unknown how much the lowering of skin blood 
flow is counteracted by the increase in perfusion pressure. 
During mental activity Mishima et al (27) found an increased vasocon-
striction in Raynaud patients. On the contrary, Halperin et al (28), 
whose experiments were performed at the same ambient temperature as 
ours, found digital vasodilation in patients with PRP and vasocon-
striction in normal subjects. During MA Ludbrook and Vincent observed 
vasodilation in normal subjects in a cool environment with a lower 
baseline hand blood flow, whereas vasoconstriction occurred in the 
same individuals in a warm environment with a higher baseline blood 
flow (29). We have also found that vascular reactivity depends on 
baseline blood flow with vasodilation in subjects with a low baseline 
LDF and vasoconstriction in subjects with a high baseline LDF, ir-
respective of whether they belong to the Raynaud or to the normal con-
trol group. Cohen and Coffman (30) suggested the existence of an 
active vasodilatory mechanism in Raynaud patients and they ascribed 
this to beta-2-adrenoceptor stimulation by epinephrine. We were unable 
to support the hypothesis, since we could not find a relation between 
the MA-induced changes in epinephrine and skin perfusion. 
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Despite the fact that 9 out of the 12 patients with PRP mentioned emo­
tional stress as a cause of their vasospastic attacks, no actual RP 
was seen during MA and most (n=6) of these patients even showed vaso­
dilation. An explanation for this apparent contradiction could be that 
stress in a laboratory situation or stress during a MA test is not the 
same as the emotional experiences of everyday life that provoke a 
Raynaud's attack. Probably the high ambient room temperature during 
the experiments has influenced the vascular response (31), because 
stress is only able to induce a vasospastic attack at low ambient 
temperatures. During moderate warming sympathetic vasoconstrictor tone 
decreases and sympathetic stimuli only evoke sudomotor impulses and 
less vasoconstrictor activity (32). As mentioned earlier, different 
reactions of hand blood flow to MA have been reported in literature. 
Allwood et al noticed vasoconstriction in some and vasodilatation in 
other healthy subjects with profuse hyperhidrosis in the latter group 
(33). It is known that emotional sweating occurs during MA and may 
cause local vasodilation, induced by the release of bradykimn (34). 
In conclusion, this study confirms the existence of a baseline elevat­
ed sympathetic tone together with a decreased baseline skin blood flow 
in PRP. Irrespective of whether measured in patients with PRP or in 
normal subjects, the baseline skin blood flow determines the reaction 
to MA: when baseline skin blood flow is low a vasodilatory response 
occurs and when it is high a vasoconstrictive response is seen. 
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CHAPTER В. 
LASER DOPPLER EVALUATION OF SXIN VASOMOTOR REFLEXES DURING SYMPATHETIC 
STIMULATION IN NORMALS AM) IN PATIENTS NITH THE PRIMARY RAYNAID'S PHE-
NOCNON. 
Introduction 
Maurice Raynaud's original proposal that hyperactivity of the central 
sympathetic nervous system plays a pathogenetic role in digital vaso­
spastic attacks (1) is still disputed. 
Tests of autonomic function such as the valsalva ratio (2), variations 
of the R-R interval with hyperventilation (3), the heart rate and 
blood pressure response to standing (4), sustained handgrip (5) and 
cold (6) provide information regarding the sympathetic outflow to the 
heart and the muscle vascular beds. Moreover, they test the integrity 
of the baroreceptor reflex together with the complete afferent and 
efferent reflex arch of the sympathetic and the parasympathetic 
nervous system (7). Therefore these tests detect general rather than 
regional or focal abnormalities of the autonomic nervous system. The 
evaluation of skin vasomotor reflexes by laser Doppler flux (LDF) 
monitoring enables us to selectively study skin vascular reactivity to 
standardised sympathetic stimulation (Θ). To compere the autonomic 
skin reflexes in primary Raynaud's patients with those in normal 
control subjects laser Doppler monitored vascular reactivity was 
evaluated during several autonomic function tests. 
Patients 
We selected 12 patients (3 male and 9 female) with primary Raynaud's 
phenomenon (PRP) according to the criteria of Allen and Brown (9), 
supplemented by negative clinical, biochemical and immunological 
findings that further exclude underlying diseases. Mean age was 30.2 + 
10.0 (SD) years (range: 17-45 years). For a control population we 
selected 12 healthy subjects matched for age (mean* SD: 27.9 + 6.5 
years; range 22-43 years) and sex. They were screened for the absence 
of peripheral vascular diseases and complaints of RP or cold hands. 
None of the 24 investigated subjects used medications. All were asked 
to abstain from smoking for 24 hours, from alcohol and beverages con­
taining caffeine for 12 hours and not to eat and drink for 2 hours 
preceding the test. 
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Methods 
All tests were performed in a quiet climate room with an ambient tem-
perature of 24.2 + 0.3 °C and a relative humidity of 53+4%, after at 
least 20 minutes acclimatisation. All subjects were in a comfortable 
supine position, had previously been asked to empty their bladder 
and had been encouraged to relax. After the teat procedure had been 
explained, the subjects exercised the Valsalva maneuver and the in-
spiratory gasp test. Subsequently a vein was cannulated on the back of 
the right hand. After zero calibration the laser Doppler probe (Pen-
flux Pf 1, Penmed, Sweden) was attached to the distal volar surface of 
the second fingertip of the right hand by means of double sided ad-
hesive tape. The output signal was continuously recorded and expressed 
in arbitrary units (AU). For registrations, we selected a gain of 3, a 
time constant of 3 seconds and a frequency limit of 12 kHz. 
After a stable baseline value had been registered for 5 minutes, the 
following tests were performed: the Valsalva maneuver, inspiratory 
gasp, and the response to standing. The inspiratory gasp and Valsalva 
maneuver were performed in duplicate and each following test was not 
started until the Laser Doppler flow (LDF) value had returned to base-
line. There was an interval of at least 5 minutes between tests. The 
Valsalva maneuver (2) was started by asking the subjects to press and 
maintain a column of mercury at 30 mm Hg for 15 seconds. For the in-
spiratory gasp test, the subjects were asked to take a breath as 
quickly and deeply as possible end to hold it for 10 seconds. 
Before testing the response to standing, venous blood samples for de-
termination of catecholamines (10) were taken. After measuring the 
systolic and diastolic Blood Pressure (BP; in mmHg; Arteriosonde) on 
the left upper arm and Heart Rate (HR; in bpm; ECG) and the mean base-
line LDF, the subjects were asked to stand up actively and to remain 
standing for 6 minutes while the right hand was held at heart level 
and BP and HR were measured every 2 minutes. After standing upright 
for 5 minutes, blood was again sampled for determination of catechol-
amines. 
During all tests, LDF was continuously monitored and the absolute and 
percentage changes were calculated in comparison to baseline. The 
Valsalva ratio was determined by dividing the longest by the shortest 
R-R interval during the Valsalva and the inspiratory gasp maneuver. 
MAP was calculated with the formula: MAP = diastolic BP + 1/3 of the 
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pulse pressure. Data are expressed as mean ± SEM. Normally distributed 
data were evaluated by using the unpaired Student-t-test. Nongaussian 
data were analysed by using the unpaired Wilcoxon test. The repro­
ducibility of repeated tests was calculated as the standard deviation 
of the mean differences and as the standard error of a single obser­
vation by the formula: SESO = \ / Zdi2 
V 2n 
in which d is the difference between the first and the second test in 
subject ι and η the number of paired observations. Correlations were 
calculated by means of analysis according to Spearman. 
Results 
Table 1 shows the baseline LDF prior to each test in the control sub­
jects and in the Raynaud patients. Baseline LDF values before each 
test were significantly lower (p<0.01 in all tests) in PRP-pstients. 
Figure 1 shows the percentage change in LDF during all tests, whereas 
in table 2 the reproducibility of the Valsalva maneuver and the in­
spiratory gasp is depicted. Due to movement artefacts two readings, 
one in the second inspiratory gasp test and one during standing up­
right, could not be interpreted properly. 
During the Valsalva maneuver a significant decrease in LDF was seen in 
both groups of -4.4 ± 1.4 AU (-17.4+4.6!«) in normals and -3.4 + 1.9 AU 
(-20.7+6.9S) in PRP-patients. No significant differences in absolute 
or percentage decrease were found between both groups. The SESO of the 
percentage decrease in LDF was 12.3 AU in control subjects and 15.3 AU 
in Raynaud patients. 
During inspiratory gasp a significant decrease in LDF was seen in both 
groups: -12.4 + 3.6 AU (-30.4+8.23») in control subjects (p<0.01) and 
-4.5 +1.3 AU (-32.8+10.18) in PRP-patients (p<0.05). There were no 
significant differences in the absolute and proportional decreases 
between both groups. The SESO of the decrease in LDF was 18.1 AU in 
control subjects and 24.θ AU in Raynaud patients. 
94 
Table 1 Baseline laser Doppler flux (LDF) in arbitrary units (AU) 
prior to each test in healthy controls and in patients with 
Raynaud's phenomenon (mean + SEM). 
BASELINE-LDF (AU)0 
Healthy 
controls 
Raynaud's 
phenomenon 
Valsalva maneuver: first test 32.7+5.1 13.2+3.8* 
second test 37.6+4.6 13.3+3.7* 
Inspiratory gasp: first test 39.4¿4.4 13.5+3.6* 
second test 35.7+4.9 14.1+4.3* 
Standing upright: 30.2+4.θ 13.4+4.4* 
"Mean + SEM 
*p<0.01 
Δ LDF 
-10-
- 3 0 
- 5 0 -
VALSALVA 
MANEUVER 
first second 
test test 
INSPIRATORY 
GASP TEST 
first 
test 
second 
test 
I I control subjects 
E^ Roynoud patients 
STANDING 
UPRIGHT 
Figure 1 The percentage change in laser Doppler Flux (LDF) during all 
tests (mean + SEM). 
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-17.4+4.6 
-20.7+6.9 
-30.4+8.2 
-32.8+10.1 
-29.3+6.1 
-24.4+3.5 
-36.8+5.0 
-43.8+11.1 
13.4+11.5 
17.7+13.0 
17.1+19.9 
24.6+26.2 
12.3 
15.3 
18.1 
24.8 
Table 2 The reproducibility of the percentage change in laser Doppler 
flow in the Raynaud patients and in the control subjects. 
First Second Difference* SESO 
test" test" 
Valsalva maneuver 
control subjects 
Raynaud patients 
Inspiratory gasp 
control subjects 
Raynaud patients 
"Mean + SEM 
+Mean + SD 
There was no difference in Valsalva ratio between normal subjects and 
PRP patients during the Valsalva maneuver (1.8 + 0.1 for both groups) 
as well as during the inspiratory gasp test (1.2 +_ 0.2 for both 
groups). 
In the normal subjects a significant decrease in LDF was noticed, 
especially in the first minute after standing upright (-13.0 + 3.7 AD; 
-43.0+9.93»; p<0.01), which persisted until the end of the test. In the 
PRP-patients, the decrease in LDF was not significant (-4.7+1.6 AU; 
-35.7^9.9й; p=0.07). Intergroup comparisons showed no significant 
differences between the decrease in LDF. 
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When both groups were taken together, a significant correlation was 
seen between the baseline LDF and the absolute decrease in LDF after 
one minute of standing upright (R= -0.76; n=24; p<0.001; see figure 
2). 
There was no significant difference in baseline MAP between control 
subjects and PRP-patients (ΒΘ.4+1.7 and 91.3+2.9 mm Hg, respective­
ly). The increases in MAP in normal controls (6.8+1.2 nm Hg) and in 
PRP-patients (4.8+2.7 nm Hg) were both not significant. 
Baseline HR was significantly higher in the PRP-group (74.1+3.4 bpm) 
than in the control group (66.5+2.3 bpm; p<0.05). The increase in HR 
after standing was significant in both groups: 17.2+2.9 bpm in normal 
subjects (p<0.01) and 28.9+3.5 bpm in PRP-patients (p<0.01). The abso­
lute and percentage increases in HR during the first minute of stand­
ing upright were significantly (p<0.05) higher in PRP-patients 
(39.0+2.655) than in normal subjects (25.8+1 .B%). 
Baseline norepinephrine in PRP-patients was significantly higher than 
in normal subjects (2.25 + 0.33 versus 1.31 + 0.11 nmol/1; p<0.01). 
Also, baseline epinephrine was higher in PRP-patients (0.28 + 0.10 
versus 0.16 + 0.03 nmol/l) although this was not significant. After 
standing, the absolute and percentage increases in norepinephrine were 
significant (p<0.01) in normal subjects (1.27+0.14 nmol/l or 56.4+ 
6.25!) and in PRP-patients (1.17+ 0.41 nmol/1 or 89.3+29.6«) but these 
were not significantly different between both groups. The absolute and 
changes percentage increases in epinephrine were significant in the 
control group (0.15+0.03 nmol/1 or 53.6+1.11Ä) and in PRP-patients 
(0.18+0.19 nmol/1 or 64.3+67.9 %) (p<0.05 for both) but again there 
was no difference between both groups. 
Discussion 
This study confirms the results of most investigations that evaluate 
sympathetic nervous system reactivity in PRP. Baseline skin blood flow 
during rest is already decreased (11-15) in the presence of increased 
norepinephrine levels (16). During sympathetic stimulation vasocon-
striction occurs but the percentage decrease in blood flow is equal to 
that observed in normals (11-15,17). The increase in catecholamine 
levels is also within the normal range which has never been shown 
before. It could be that the decreased baseline skin blood flow in PRP 
is due to an increased baseline sympathetic activity, whereas vascular 
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change m LDF (AU) 
Figure 2 The correlation between the baseline Laser Doppler Flow 
(LDF) in Arbitrary Units (AU) and the change in LDF (in AU) 
after standing upright for one minute in 12 normal subjects 
(A) and in 11 PRP-patients (o). 
and autonomic reactivity are normal. The normal vasoconstriction in 
PRP superimposed on the lower resting blood flow values may ultimately 
lead to such low blood flow values after stimulation that transient 
ischaemia together with the characteristic discolorations may occur. 
The availability of the laser Doppler flux monitoring provides a tool 
to measure skin blood flow continuously and nomnvasively. Its short 
response time makes it an ideal technique for skin blood flow monitor­
ing during acute intervention studies.The skin vasomotor responses 
were fairly uniform with regard to different stimuli. The inspiratory 
gasp reflex consisted of an abrupt reduction in LDF after a latency of 
2 to 4 seconds with a rapid recovery despite continued breath hold­
ing. The sympathetic mediated vasoconstriction depends on a spinal 
sympathetic reflex (1B), with β pronounced increase in sympathetic 
outflow to the skin. The skin blood flow response to the Valsalva 
maneuver followed a pattern that corresponds to the four blood 
pressure phases known to occur during the Valsalva test (4): an acute 
rise in thoracic pressure induces a decrease in venous return result­
ing in an initial decrease in BP, which is counteracted by sympa-
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thetically mediated vasoconstriction to limit the BP fall. When the 
maneuver is stopped, the residual vasoconstriction further elevates 
BP. The resulting overshoot is limited by a vagal baroreflex response 
that causes bradycardia, returning the BP to normal (19). 
The Valsalva maneuver causes a pronounced increase in muscle sympathe-
tic nerve activity, whereas there is only a weak response in skin 
nerves (20). In contrast, respiratory stimuli such as an inspiratory 
gasp more easily evoke a skin sympathetic nerve response (21). This 
seems a logic explanation for the more pronounced vasoconstrictor 
response during inspiratory gasp in comparison to the Valsalva 
maneuver we found in normals as well as in PRP-patients. In general, 
all maneuvers that induce a fall in BP, like the Valsalva test and the 
response to standing, increase the sympathetic outflow to muscle 
nerves (22,23), whereas the increase in outflow to skin nerves is less 
(20). The haemodynamic reactions during change from supine to upright 
position are complicated and are characterised by an immediate with-
drawal of vagal tone causing initial tachycardia followed by a 
transient fall (24,25). The reactions occurring 30 seconds after 
rising are regulated by sympathetic nerve activity alone (24), which 
causes an acceleration of heart rate, a recovery of the blood pressure 
drop and a peripheral vasoconstriction. 
In contrast to our results, Olsen et al found an exaggerated postural 
vasoconstrictor reflex in patients with Raynaud's phenomenon (26) to-
gether with a normal local venoarterial reflex which is an argument 
that supports Raynaud's original proposal of hyperactivity of the cen-
tral sympathetic nervous system. However, they measured capillary 
blood flow by the 133 Xenon wash-out technique, whereas the laser 
Doppler flux technique also includes measurement of the flow through 
the arteriovenous anastomoses that are richly supplied by sympathetic 
nerve endings in contrary to the nutritive capillaries (27). 
We have not measured the catecholamine release during the Valsalva 
maneuver and inspiratory gasp because the sympathetic discharge during 
these tests does not persist long enough to permit a rise in the 
steady state level of venous norepinephrine with its short half life 
of 1-2 minutes (28). Because orthostasis is one of the most potent 
stimuli for norepinephrine release, we have determined venous nor-
epinephrine during standing up. Although we consider the venous plasma 
norepinephrine concentration as an index of cutaneous sympathetic ac-
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tivity, this assumption should be interpreted with caution. We have 
not measured arteriovenous plasma differences (29) ι nor performed 
clearance studies with tritiated norepinephrine (30). Because of the 
lower blood flow in PRP patients the released norepinephrine might 
accumulate, whereas their concentrations are further elevated by the 
lower skin temperature which reduces catecholamine breakdown (31). 
Further, norepinephrine is released at the synaptic cleft and only the 
overflow into the intra-vascular compartment minus the extraction can 
be measured. Although we could not exactly identify the sources of the 
released norepinephrine, we probably not only measured overall sym­
pathetic nervous tone but also regional skin specific increases by 
sampling the blood directly from the involved area, i.e. veins on the 
back of the hand, which are supplied by the fingerskin blood vessels. 
One should realise that already small increases of venous plasma nor­
epinephrine probably reflect a major increase in skin sympathetic 
activity, becauae the production by the skin is only 5S of the overall 
release (30). 
We have found that skin vasomotor réponses are dependent on the base-
line blood flow. Low et al (8) also found the vasoconstrictor 
responses damped in persons with a low skin blood flow. Also in states 
of higher baseline sympathetic nervous system activity the response to 
sympathetic drive is decreased (32-34). Because baseline skin blood 
flow was already lower and baseline sympathetic activity higher in the 
PRP-group this could have influenced our results. 
The great variability in skin vasomotor reflexes is understandable be-
cause skin sympathetic fibers are responsive to thermal, emotional and 
test stimuli (20,35), whereas spontaneous fluctuations in skin blood 
flow occur in innervated and in denervated skin as well (36). Even at 
rest direct recordings from skin sympathetic nerves show, in contrast 
to muscle sympathetic nerves, an irregular spontaneous activity 
without signs of pulse synchromcity (20). 
The HR-response during the Valsalva and the inspiratory gasp test is 
the result of the parasympathetic control of the heart (2) and can be 
judged as normal in the PRP-patients. The baseline HR аз well as the 
response to standing upright for one minute were increased in the 
patients with PRP. This could suggest an increased sympathetic outflow 
to the heart. In a previous study we also found a more pronounced HR 
response to vasodilation in PRP-patients (37). 
100 
In conclusion, this study shows the existence of an elevated sympa-
thetic tone at rest together with a decreased baseline skin blood flow 
in PRP. Skin sympathetic and vasomotor responses to sympathetic 
nervous stimulation were found to be normal. 
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CHAPTER 9. 
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Laser Doppler Velocimetry of fingertips during 
heat provocation in normals and in patients 
with Raynaud's phenomenon 
H W O L L E R S H E I M J R E V E N G A & Th T H I E N 
Department of Medicine Dmsion of General Internal Medicine Geert Grooteplein Zuid 8. 
Ρ Ο Box 9101 65(Ю HB Nijmegen The Netherlands 
Wollersheim Η Revenga J Thien Th Laser Doppler Velocimetrv of fingertips 
during heat provocation in normals and in patients with Raynauds pheno­
menon Stand J Clin Lab Invest 1988 48 91-95 
Measurements of Laser Doppler flow were performed on the fingertip dunng 
heating in a group of normals and in a group of patients with different types of 
Ravnaud s phenomenon During heating a group of 24 normals was distin­
guished from a group of 29 primary Raynaud s patients A group of 17 patients 
with secondary Ravnaud s phenomenon due to scleroderma and 8 patients with 
artenographuallv proven severe vascular occlusive disease of the fingers showed 
a significantly lower response in companion to the two above-mentioned 
groups Patients with or without slight or severe trophic skin lesions were 
identified In patients with scleroderma the maximal vasodilation during heating 
was inverselv related to the number of organs affected In conclusion. 
measurements of the hvperaemia during heating may play a role in determining 
the degree of obstructive vascular involvement m Raynaud s phenomenon 
Kev words Laser-Doppler flow, local heating test Raynaud s phenomenon. 
skin blood flow vasodilation 
H Wollersheim, Department of Mediane Diviston of General Internal 
Medicine Geert Grooteplem Ziud 8 PO Box 9101 6500 HB Ni/megen The 
Netherlands 
Patients with episodic digital ischaemia pose 
problems in differential diagnosis at presenta 
tion The symptoms are most often due to a 
benign functional vasospasm Primary 
Raynaud s Phenomenon (PRP) but in some 
patients they are secondary to a more scnous 
underlying disease in which RP may be the 
initial complaint [1] 
This Secondary Raynaud s Phenomenon 
(SRP) is due to vessel wall disease in which a 
physiological vasoconstrictive reaction to cold 
superimposed on a narrowed vessel wall may 
cause a temporary total occlusion (2) The 
entena most commonly used to diagnose PRP 
are those established by Allen and Brown [3] 
supplemented by vanous clinical biochemical 
and immunological exclusion entena [4| 
Uncertainty may remain, however even after 
extended and detailed work-up If the damaged 
vessel wall in SRP has limited vasodilating 
properties while the vasodilation in PRP is 
unimpaired a reduced hyperaemia during 
heating is detected by Laser Doppler Flow-
metry (LDF) in the former group which 
contributes to the discrimination between PRP 
and SRP LDF [5] is a non-invasive continuous 
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and cheap method to monitor digital skin blood 
flow during intervention studies (6-11] with a 
good reproducibility and a high sensitivity 
Therefore we investigated the vasodilation 
during heating, as monitored bv LDF in 
normals and in patients who presented with RP. 
to evaluate whether associated vessel wall 
disease could be detected 
P A T I E N T S 
We selected 24 normal healthv volunteers 
without known cardiovascular disease 29 
patients with PRP according to the criteria of 
Allen and Brown [3] 13 SRP patients with 
Connective Tissue Disease (CTD) due to 
Svstemic Lupus Ervthematosis (12) in 5 Mixed 
Connective Tissue Disease [ Π | in 1 Rheu­
matoid Arthritis (14) in V Sjögrens Svndrome 
(SS) 115] in 2 22 Scleroderma (SCL) patients 
(16] 17 with and 5 without RP all classified 
according to ARA or other appropriate criteria 
and 8 patients with artenographicallv proven 
severe obstructive arterial disease of at least 
one finger All gave informed consent to a 
protocol approved bv the local ethical com-
mittee All were of the white Caucasian race 
and none had anaemia Trophic skin lesions 
were graded as follows not present, minor 
trophic skin lesions pitting scars, nail abnor-
malities or small superficial lesions. ma|or 
trophic skin lesions ulceration or gangrene 
The seventy of organ damage in the SCL 
patients was classified from 0 to 5 in which one 
point was given for each organ affected Organ 
involvement was supposed to be present in the 
following organs lungs if the CO-transfer 
factor was 80% or less of the predicted value, 
oesophagus if barium swallowing showed 
disturbed peristalsis, kidney if serum creatinine 
was more than 125 μπιοΙ/Ι or proteinuria more 
than 0 5 g/24 h. skin if there was proximal 
scleroderma, joints if there were complaints of 
arthralgias for more than 6 weeks or complaints 
suggesting arthritis 
M E T H O D S 
All lightly dressed subjects had to acclimatize in 
the supine position for at least 20 min. in a 
climate room with an ambient temperature of 
24 8 ± 0 1 0C (SD), with a humidity of 5 2 ± 6 % 
Thev were asked to abstain from smoking for 
24 h. from caffeine or alcohol containing 
beverages for 12 h and to fast for 2 h preceding 
the test All the tests were performed by an 
investigator who was unaware of the classi­
fication of patients LDF was measured in 
Arbitrary Units (AU. Penflux Pf Id Penmed, 
Sweden) The Penflux was adjusted to an upper 
frequency limit of 12 kHz. a gam of 3 and an 
output circuit time constant of 3 s After zero 
calibration was carried out by placing the probe 
in the calibration clip on zero surface and 
moving the recorder pen to the zero position on 
chart paper, the probe was attached with a 
double-sided adhesive ring to the centre of the 
distal volar surface, either of the most diseased 
fingertip or if symmetrical complaints were 
present on the second fingertip of the right 
hand 
After acclimatization, a stable base-line value 
was determined during 5 mm of continuous 
registration Then the gloved hand to which the 
probe was applied was placed into a waterbath 
of 40 °C up to the wnst for 5 mm Because of 
the penodic fluctuations, the LDF was deter­
mined for 30 s around each time point by 
determining the Area Under the Curve (AUC) 
From this we calculated maximal LDF dunng 
heating, and the absolute and percentage 
increase in LDF during heating, with respect to 
base-line values 
In 14 normals a duplicate LDF test after 
heating was performed within a month and the 
reproducibility expressed as the standard error 
of a single observation (S) which was calculated 
by the formula 
s-\/îEI 
\/ * 
in which di is the difference between first and 
second tests of subject ι and π is the number of 
paired observations In nine PRP patients with 
symmetric complaints, base-line LDF registra­
tions were made from all five fingertips 
All results are expressed as mean ± Standard 
Deviation (SD), unless stated otherwise 
Between-group comparisons were made by 
Wilcoxon's signed rank test ρ Values of less 
than 0 05 were considered significant (two-
sided) 
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R E S U L T S 
The stud\ population consisted of six groups1 24 
normals (7 males. 17 females, age. 33 3±12.1 
vears). 29 PRP patients (8 males. 21 females: 
age 29 4+7 4 years). 13 patients with SRP due 
to CTD (1 male. 12 females, age. 43 1±17 5 
years). 17 patients with SRP due to PSS 
(4 males. 13 females, age· 56 6113 6 years). 
5 patients with scleroderma without RP 
(3 males. 2 females, age 50 0 ± 9 0 vears) and 8 
patients with AOD (4 males. 4 females, age. 
60.8±10 5 years) Of the nine patients with 
minor trophic skin lesions two had a CTD. si\ 
had SCL and one AOD Of the inpatients with 
major trophic skin lesions six had SCI. while 
four had AOD. 
The increase in LDF in relation to base-line 
values during the 5 mm heating is shown in 
Fig 1 Between-group comparisons showed the 
greatest differences if we used the parameter of 
the maximally reached LDF (I DF-ma\). .is is 
LDF 
5 0 -
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30 -
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10 
(AU) 
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time (min ) 
FIG 1 The increase in Laser Doppler Flow (LDF) in 
Arbitrary Units (AU) during 5 min of local healing, m a 
40 0C water bath ш a group of 24 normals (N). 29 pnmarv 
Ravnaud s patients (PRP). 13 patients with connective 
tissue disease (CTD). 22 paiicnis wiih scleroderma (SCL) 
with (n=l7) or without (n = 5) Ravnaud s phenomenon 
(SCL-) and 8 patients with arterial occlusive disease 
(AOD) 
shown in Fig 2. LDF-max significantly differed 
(p=0 0004) between normals (41 6±15 8 AU) 
and PRP patients (29 0±11 3 AU), between 
the PRP and the CTD group (p=0.022). 
between the CTD (20.4±6 5 AU) and SCL 
(11.1 ±5.2 AU) groups ( P =0.03) and between 
the SCL and the AOD (6.4±3.8 AU) patients 
(p=0.014) In Fig 2 the significant differences 
in the LDF-max during heating in the group 
with RP between the patients with no 
(24 6±11 3 AU, n=48). minor (12.1 + 3.9 AU: 
n=9) and severe (5.6±3.2 AU: n=10) trophic 
skin lesions are shown (p<0.001 for both 
differences) 
The reproducibility of the test in 14 normals 
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ни -
-
6 0 -
" 
4 0 -
-
20-
О 
8 
О 
О 
α 
о 
о 
QD 
О 
8 
4 
О 
О 
О 
О 
8 1 
со 
si 
ODOOt 
9· 
о 
Ι ­
ο 
' OD 
• 
Г 
1 
8. 
• 
•• 
— ι 
о 
ч 
I-
Ν 
PRP CTD SCL AOD 
FIG 2 The maximal increase in Laser Doppler Flow 
(LDF-max) in Arbitrary Units (AU) during 5 mm of 
local heating in a group of 24 normals (N). 29pnmar\ 
Raynaud's patients (PRP). 13 patients with connectée 
tissue disease (CTD). 17 patients with secondan 
Raynaud's phenomenon due to scleroderma (SCL) 
and 8 patients with arterial occlusive disease (AOD) 
Patients without (O). with minor (φ) and with se\erc 
(•) tropic skin lesions are indicated 
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was good with a LDF max during heating of 
31 6 ± 4 8 AU in the first test and of 31 0 ± ^ 2 
AU in the second test with a standard error of 
a single observation of 7 3% 
We found an inverse correlation between the 
maximal vasodilation during heating and the 
number of affected organs m SCL patients with 
S R P ( r = - 0 724 p«M)01) 
The base line LDF in PRP patients of all five 
fingers of the right hand was И H±6 1 AU for 
the thumb 14 1+4 ι AU for the second 14 1 
± 4 7 AU for the third 14 4±S 7 AU for ihe 
fourth and 14 3±4 3 AU for the fifth finger 
Figure I shows a nearlv normal percentage of 
vasodilation in SCL patients without RP in 
comparison to SCL patients with SRP 
During the whole reactive hvperaemia phase 
there was a difference of around 3(1' « in SCL 
patients without RP in comparison to normals 
Although we did not analvse the rhvthmical 
patterns of the LDF signal и was obvious that 
there were marked rhvthmical variations m the 
normals which were less pronounced in PRP 
patients and absent in SCL patients but became 
more apparent after heating in the PRP group 
Fight persons were excluded from the studv 
because of practical problems with the registra­
tions One normal person was unable to he 
quiet and extensive movement artefacts made 
interpretation impossible Detachment of the 
laser within the probe holder after manipula 
tion was seen in five patients while too much 
flexion of the glass fibre which interferes with 
the registration was seen in two patients 
D I S C U S S I O N 
This study shows that heat induced hvpcr 
aemia as measured bv LDF can differentiate 
between groups with normal blood vessels or 
with vasospastic and obstructive vascular 
disease of the hands Patients with and without 
slight or severe trophic skin lesions can be 
distinguished However no absolute separation 
between groups is possible using this test 
In their extensiv e studies Lewis and Pickering 
[17) in 1931 found that a patient with thrombo­
angiitis obliterans showed less rise in fineer skin 
temperature during bodv heating m comparison 
with two patients with PRP More recent 
investigators (IK-20) found a near normal 
vasodilation during local or bodv hcalinc in 
PRP patients with less vasodilation if associated 
CTD or ischaemic skin lesions were present 
Additional bodv heating might have given a 
better discrimination because at a room 
temperature - of 25 "C a certain degree of 
sympathetic nervous svstem outflow to the 
hand mav still be present [21) In addition 
heating for longer than 5 mm may be worth­
while because no constant plateau phase was 
reached after 5 mm and because Downey el 
al [19] found a higher degree of vasodilation 
after 20 mm than after 5 mm of hand immersion 
in a waierbath of 44 °C 
Our results support the hypothesis that there 
is a pure functional spastic disorder in anatomi-
callv normal blood vessels in patients with PRP 
[22| while there is a gradual increase in struc­
tural vessel wall defects in SRP ranging from 
CTD to SCL which has also been found in 
angiographic [23) and in microscopic biopsv 
studies [24] The relationship between maximal 
LDF during heating and the extent of organ 
damage in SCL patients suggests a gradual 
increase in vessel wall disease during the clinical 
course 
We found a 30% decrease of the LDF signal 
in SCL patients that could be caused hv a 
change in skin quality because a normal circula­
tion was present with an almost normal vaso-
dil.itorv capacitv Gustici al [ІЦ also noticed a 
decrease in Doppler shift obtained from sclero­
derma skin which was independent of flow 
disturbances 
In conclusion LDF is a sensitive method to 
register heat induced vasodilation The simple 
heat test described is of clinical importance in 
RP to help in the differential diagnosis It 
should be emphasized that only patients classi­
fied according to ARA entena were included 
In general these patients represent more exten­
sive disease while the greatest problems in 
classifving patients are encountered in cases 
with clinicallv less overt disease Studies of 
patients with a clinically questionable tvpe of 
RP will be performed in the near future 
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CHAPTER 10. 
POSTOCCLUSIVE REACTIVE HYPERAEMIA OF FINGERTIPS, MONITORED BY LASER 
DOPPLER VELOCIMETRY IN THE DIAGNOSIS OF RAYMAID'S PHENOtCNON . 
Submitted 
Wollersheim H, Reyenga J, Thien Th. 
Abstract 
Measurement of Laser Doppler flux on the fingertip was evaluated be­
fore and after occlusion of the fingerbase for 5 minutes by suprasys-
tolic compression in normal control subjects and in patients with 
several types of Raynaud's phenomenon (RP). 
Baseline flow values differed significantly (p<0.002) between the 24 
normals and the 29 primary Raynaud patients but there was a consider­
able overlap between the primary and the secondary Raynaud group. The 
postocclusive reactive hyperaemia parameters showed an improved dis­
crimination between the patients with primary RP and the 3Θ patients 
with secondary RP. The patients with scleroderma and those with arte­
rial obstructive disease of the finger had the lowest increase in 
flow. 
Of all the indices analysed, none showed an optimal discrimination 
between the several subtypes of fingerischaenua, although the para­
meters that represent the increase in Laser Doppler values after oc­
clusion differentiated best between primary and secondary types, 
(p<0.02) whereas time variables after the peak were more suitable to 
differentiate scleroderma-patients from those with arterial obstruct­
ive disease (p<0.002). 
The reproducibility of the Laser Doppler monitored postocclusive 
response in normals is moderate (standard error of a single observa­
tion vanes between 7 and 43% for different parameters). 
We conclude that postocclusive reactive hyperaemia may be useful in 
determining the degree of obstructive vascular disease in groups of 
patients presenting with RP, but it is not sensitive enough to dis­
criminate adequately between individuals in the several subgroups. 
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Introduction 
Raynaud's phenomenon (RP) may be either a benign complaint due to 
intermittent vasospasms that are supposed to occur in an anatomically 
normal vessel wall or a symptom οΓ a more severe underlying disease 
with organic vessel wall alterations (Rodnan, 1980). In the latter, 
designated secondary RP (SRP) connective tissue diseases, vasculitis 
or atherosclerosis may all limit the capacity for vasodilation 
(Wollersheim, 19ΘΘ) that could be identified by a reduced hyperaemia 
after occlusion. In primary RP (PRP), the functional defect is 
supposed to be due to either an increased vasoconstrictor activity or 
to an impaired vasodilating capacity of the vessel wall. 
Finger skin blood flow monitoring by Laser Doppler Flux (LDF) is a 
simple noninvasive method to evaluate the cutaneous circulation con­
tinuously (Nilsson, 19Θ0 a,b) in normal subjects (Holloway and 
Watkins, 1977) and in patients with skin perfusion disorders 
(Wollersheim, 19ΒΘ). The evaluation of the skin blood flow is diffi­
cult because of the large inter- and intra-individual variability in 
dermal perfusion. 
To evaluate the functional vascular reserve, we determined the LDF-
monitored postocclusive reactive hyperaemia (PORH) by parameters 
deacribed by Ninet and Fronek (1985) in patients with several subtypes 
of RP and in normals and determined the reproducibility in the latter 
group. 
Patients 
We selected 24 normal healthy volunteers without known cardiovascular 
disease, 29 patients with PRP according to the criteria of Allen and 
Brown (1932), 30 patients with SRP due to Connective Tissue Disease 
(CTD) being: Systemic Lupus Erythematosus (Tan, 1982) in 5, Mixed Con­
nective Tissue Disease (Sharp, 1972) in 3, Rheumatoid Arthritis 
(Ropes, 1959) in 3, Sjögrens Syndrome (Bloch, 1965) in 2 and Sclero-
derma (SCL) in 17 patients (Subcommittee for scleroderma criteria, 
1980) all classified according to ARA or other appropriate criteria 
and θ patients with arteriographically proven severe arterial ob­
structive disease (AOD) of at least one finger. All gave informed con­
sent to a protocol approved by the local ethical committee. All were 
of the white Caucasian race and none had anaemia. 
Ill 
Methods 
All lightly dressed subjects had to acclimatise in a comfortable 
supine position for at least 20 minutes in a climate room with an 
ambient temperature of 24.8 + 0.1 °C (SD) and a humidity of 52 + 6%. 
They were asked to stop all vasoactive medications for 10 days, to 
refrain from smoking for 24 hours, from caffeine or alcohol containing 
beverages for 12 hours and to fast for 2 hours prior to the test. All 
tests were performed by an investigator who was unaware of the classi-
fication of patients. LDF was measured in Arbitrary Units (AD; Pen-
flux Pf Id; Penmed, Sweden). The Penflux was adjusted to an upper 
frequency limit of 12 kHz, a gain of 3 and an output circuit time con-
stant of 3 seconds. After zero calibration, the probe was attached 
with a double sided adhesive ring to the center of the distal volar 
surface, either of the most diseased fingertip or on the second 
fingertip of the right hand if symmetrical complaints were present. 
After acclimatisation, a stable baseline value was determined during 5 
minutes of continuous registration. 
Subsequently, a standardised finger pneumatic cuff, applied around the 
fingerbase between the MCP and the PIP joint, was inflated to a supra-
systolic pressure of 200 mm Hg to arrest the digital circulation for 5 
minutes, followed by sudden deflation. The following parameters (see 
figure 1) were calculated: mean baseline LDF; peak-LDF during hyper-
aemia; the absolute and percentage increases in LDF; Ti-recovery which 
is the time (in seconds) to reach 50% of the preocclusion value; T-
recovery which is the time to ret-ch the mean baseline value before 
occlusion; T-peak, which is the time to the peak after occlusion; the 
recovery half time of the overshoot (TJ-overshoot) being the time for 
the LDF to return to 50!« of its peak response and the hyperaemic 
response time (HRT) which is the time to return to the initial base-
line value. 
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Figure 1 : 
Laser Doppler Flux (LDF in arbitrary units; AU) estimated parameters 
during the postocclusion reactive hyperaemia test. 
Τ means time. HRT means hyperaemic response time. 
In 14 normals a duplicate test was performed within a month and the 
reproducibility was expressed as the standard error of a single obser­
vation (SESO) in percentage of the first test calculated by the 
formula: 
SESO w 
in which di means the difference between first and second test of sub­
ject ι and η means the number of paired observations. 
All results are expressed as mean + standard deviation (SD), unless 
stated otherwise. 
Comparisons between group were made by the nonparametnc Wilcoxon 
signed rank test. P-values of less than 0.05 (two-sided) were con­
sidered significant. 
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Results 
The clinical characteristics of the groups are shown in table 1. As 
can be seen females predominate in all groups except for the patients 
with AOD. Patients with SRP were older than those with PRP and the 
control subjects. 
Table 1 Clinical characteristics of the study population 
SEX 
M:F 
AGE 
YEARS 
DURATION 
OF 
RAYNAUD'S 
PHENOMENON 
Normals 7:17 33.3+12.1 
Primary Raynaud's phenomenon 8:21 29.4+7.4 6.9+4.2 
Connective tissue disease 1:12 43.1+17.5 6.3+3.5 
Scleroderma 4:13 56.6+13.6 8.4+3.2 
Arterial occlusive disease 4:4 60.8+10.5 4.1+1.0 
Figure 2 shows the individual and mean baseline LDF-values. Table 2 
shows the results of the PORH-test in all groups analysed according to 
both the four LDF-critena and the five time parameters mentioned 
above. The PORH-parameter that discriminated most favourably between 
normals and PRP-patients was the T-recovery (3.9 + 2.4 sec. versus 5.2 
+_ 3.4 sec; pO.01). However none of the parameters discriminated 
better than the baseline value (27.6 + 13.9 AU versus 16.2 + 8.4 AU; 
p<0.005). The absolute increase in LDF after occlusion was similar in 
PRP-patients and in normal control subjects (around 25 AU). 
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Figure 2: 
Mean (+ SO) and individual baseline Laser Doppler Flux (LDF) values in 
Arbitrary Units (AU) in all subgroups: N means normals; PRP means pri­
mary Raynaud's phenomenon; CTD means connective tissue disease; SCL 
means scleroderma; AOD means arterial occlusive disease. 
There was nearly no difference in baseline LDF between PRP- and CTD-
patients. The difference between these two groups became highly sig­
nificant in all the peak LDF-values after occlusion and in the reco­
very times (Ti-recovery and T-recovery). 
For the discrimination between patients with CTD and SCL, the baseline 
LDF-values (14.8 + 7.3 AU versus .6 + 5.0 AU; p<0.01; see figure 2) 
were as informative as PORH-critena. From the latter, only peak-LDF 
after occlusion and its absolute increase differed significantly 
(p<0.005). 
40-
20 
Table 2 
Between group comparisons of parameters used in the postocclusive hyperaemia test. 
LDF-values (AU): 
baseline-LDF 
LDF-increase: absolute 
percentage 
peak-LDF 
Time values (sec): 
Tj-recovery 
T-recovery 
T-peak 
Hyperaemic response Τ 
Tj-overshoot 
NORMALS 
27.6+13.9 
24.3+11.6 
128.6+149.2 
51.9+20.4 
2.0+1.1 
3.9+2.4 
14.8+9.0 
143.4+74.1 
72.7+33.8 
*· 
# 
* 
#» 
»» 
* 
* 
Primary 
16.2+8.4 
23.8+12.6 
174.9+115.4 
39.4+13.0 
2.7+2.2 
5.2+3.4 
13.0+7.2 
105.2+79.6 
52.0+39.5 
#» 
*» 
»* 
RAYNAUD'S 
connective 
tissue disease 
14.8+7.3 
8.1+4.8 
55.1+27.8 
23.0+11.0 
4.3+1.8 
7.8+3.0 
18.9+17.4 
92.2+61.1 
52.0+32.1 
#* 
*# 
** 
PHENOMENON 
Secondary 
scleroderma 
8.6+5.0 
3.7+2.7 
41.3+25.5 
12.3+5.8 
4.7+1.9 
7.7+3.0 
12.1+4.0 
67.7+57.4 
39.1+29.5 
# • » 
·* 
** 
arterial occlu­
sive disease 
6.1+3.8 
2.8+1.0 
65.5+53.5 
8.9+4.2 
6.5+1.3 
13.4+2.1 
18.8+4.7 
216.8+57.1 
99.1+37.9 
* p<0.05 
**p<0.01 
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There was a considerable overlap in baseline LDF and LDF-monitored 
PORH-response criteria between SCL and AOD patients. However the time 
variables of the PORH-test differed significantly between both groups 
with both a more gradual increase and a more gradual decrease of the 
LDF curve in AOD-patients. 
In Figure 3, the parameters are shown with the most optimal discrimin­
ation between groups, except for these between normals and PRP-
patients (baseline LDF), which has already been shown Figure 2. These 
parameters are respectively: the absolute increase in LDF between PRP-
and CTD-patienta, the peak-LDF between CTD- and SCL-patients and the 
T-recovery between SCL- and AOD-patients. Deapite the highly signi­
ficant differences between groups there is a considerable overlap. So 
all parameters are unable to discriminate for an individual patient. 
LDF 
(AU 
60 π 
-
40-
20-
increase 
) 
• 
Λ 
A l 
tt 
Λ 
• 
ι 
ι 
• 
• 
V i l 
I 
· · 
M 
1 
- peak-LDF 
(AU) 
" 
-
• 
• • 
· · 
• 
• 
1 
· · 
• 
1 
• 
• 
t 
r 
• 
• 
• 
«¿S· 
• M 
! 
• 
-T-recovery — 
(seconds ) 
30 -, 
-
20-
10-
1 
• 
• 
• M T 
M · 
· · ' 1 
· · • M 
· · 
· · M 
• · 
M 
• 
CTD CTD SCL SCL AOD PRP 
Figure 3: 
The individual values of the postocclusive reactive hyperemia para-
meters that discriminated best between the subgroups: the absolute in-
crease in Laser Doppler Flux (LDF in Arbitrary Units; AU) between 
patients with primary Raynaud's phenomenon (PRP) and patients with 
connective tissue disease (CTD); peak-LDF (in AU) between CTD-patienta 
and patients with scleroderma (SCL); T-recovery (in seconds) between 
SCL-patients and patients with arterial occlusive disease (AOD). 
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Table 3 shows the reproducibility as SESO for all the PORH-test para­
meters. The percentage SESO varied from 7 to 4355, the absolute LDF 
parameters being clearly better reproducible (7; 11 and 155) than the 
percentage LDF-increase (41й) or the time-related parameters (19-
43й). The T-recovery was the most acceptable of the time parameters 
(19Й). 
Table 3 The reproducibility of the post-occlusive reactive hyperaemia-
test in 14 normals for the calculated parameters, shown by the 
mean + SD in the first and in the second test with the 
standard error of a single observation (SESO). 
mean b a s e l i n e -
absolute LDF-: 
•LDF 
increase 
percentage LDF-increase 
peak-LDF 
T j - r e c o v e r y 
T-recovery 
T-peak 
HRT 
Tj-overshoot 
(AU) 
(AU) 
(Я) 
(AU) 
( s e c ) 
( s e c ) 
(sec) 
( s e c ) 
(sec) 
F i r s t t e s t 
mean+SD 
2 6 . 2 + 6 . 6 
2 2 . 0 + 9 . 3 
9 4 . 6 + 7 2 . 9 
4 8 . 0 + 1 1 . 6 
1.6+0.8 
3 . 7 + 1 . 2 
1 2 . 1 + 4 . 3 
1 3 8 . 8 + 8 5 . 7 
7 6 . 5 + 4 3 . 5 
Second t e s t 
mean+SD 
2 5 . 4 + 7 . 4 
2 1 . 8 + 9 . 0 
9 1 . 6 + 4 9 . 7 
4 7 . 2 + 1 3 . 5 
1.8+0.8 
3 . 6 + 1 . 9 
1 3 . 4 + 1 0 . 6 
1 2 1 . 1 + 7 4 . 9 
6 0 . 6 + 3 0 . 1 
SESO 
3 . 0 ( m ) 
3.4 (15Й) 
3 8 . 9 (41S) 
3 . 4 ( 750 
0 . 6 (38%) 
0 . 7 (1950 
5.2 (43Й) 
3 1 . 7 (23S) 
2 7 . 3 (36Й) 
Discussion 
To study skin blood flow under conditions of maximal peripheral vaso­
dilation, we used a postocclusive hyperaemia test monitored by LDF. 
The hyperaemia produced by reinstituting blood flow after a period of 
ischaemia is an accepted method to assess the functional seventy of 
obstructive arterial disease (Sumner, 1979). Since LDF is a rather 
simple technique to evaluate the skin perfusion in a continuous mode, 
can be applicateci to any accessible skin area, has a good reproduci­
bility (Sundberg, 1984), a short response time (Low, 1983) and poten­
tial benefits in comparison to other measurement techniques (Ninet, 
1985; Sundberg, 1986) it provides a convenient method to quantify the 
hyperaemic response. 
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From a diagnostic point of view, none of the parameters used in our 
study was fully informative in discriminating between normal control 
subjects and Raynaud patients or between the several subtypes of 
finger ischaemia. Furthermore, no single parameter could completely 
differentiate between groups. Baseline LDF was the most adequate 
method to differentiate between normals and Raynaud patients. PRP-
patients had a normal vasodilatory capacity which is in agreement with 
the concept of absence of structural vessel wall alterations in PRP 
(Rodnan, 19B0). The delay in maximal hyperaemic response and the lower 
peak value after occlusion could have been due to vasomotor dys-
function because an increased sympathetic tone may still be present at 
a room temperature of 25 centigrades, damping the response to the 
PORH-test (Hsieh, 1959). 
The vasodilation parameters (peak-LDF, increase-LDF, recovery times) 
were shown to be better diagnostic parameters than the resting base-
line LDF values in the clinical classification of different subtypes 
of RP. In the presence of obstructive arterial disease, we observed a 
delayed response and little or no increase during peak reactive hyper-
aemia. This may be caused by a stiffened arterial wall and a consider-
able degree of vasodilation in less affected vessels to compensate for 
the decreased blood flow imposed by the arterial obstruction. This re-
duced peak flow and delay in hyperaemic response was also found by 
Kvernebo et al (1984) using LDF measurements in the toes of patients 
with atherosclerosis. In our study, return times to baseline values 
after peak hyperaemia did not provide major information except for the 
AOD-patients. SCL-patients showed low and delayed maximal responses 
but also a short return time. This could be due to the altered skin 
properties in scleroderma suppressing the whole LDF-signal (Gush, 
1984; Wollersheim, 1988). 
Perhaps even more marked differences between Raynaud subtypes might 
have been obtained if we had chosen a longer duration of ischaemia 
than 5 minutes (Fewings, 1970), although already after 3 minutes oc-
clusion, 80% of the maximal forearm vasodilation observed after 15 
minutes occlusion is obtained (Patterson, 1955). Further experiments 
are needed, because it is unknown whether these observations are also 
applicable to fingertip skin vessels. 
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All parameters used in this study have been derived from literature 
(Ninet, 1985). Since the variability in our patients was striking, we 
looked for the reproducibility of these parameters in the PORH-test. 
If we presume a S-value of 25% as the limit for an acceptable repro-
ducibility of a biological variable, the percentage LDF-increase, the 
Ti-recovery, the T-peak and the Ti-overshoot should no longer be used 
as parameters to evaluate this test. 
In conclusion the PORH-monitonng by LDF is an easy and rapid noninva-
sive diagnostic test that may be of clinical value in studying the 
extent of vessel wall alterations in groups of patients with inter-
mittent finger ischaemia. It is of no importance with regard to the 
differentiation of normal subjects from patients with PRP and its 
value is less in individual cases. 
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CHAPTER 11. 
NONINVASIVE EVALUATION OF THE CUTANEOUS CIRCULATION BY TRANSCUTANEOUS 
OXYGEN TENSION MEASUREMENTS (ТсРОг). AN INTRODUCTION. 
Despite the accessibility of the skin, up to now no ideal method has 
been available that permits a quantitative evaluation of skin per­
fusion. There is a great need for methods that adequately measure 
capillary nutritional skin blood flow to perform diagnostic and patho­
physiologic investigations and to monitor therapeutic studies in, for 
example, the diabetic foot, atherosclerotic obstructive vessel wall 
disease or scleroderma. Although dynamic capillary microscopy (1) and 
epicutaneous 133 Xenon clearance studies (2) are such methods, both 
require special technical facilities, whereas their interpretation and 
the conversion into flow units are difficult. A simple and cheap 
alternative could be the determination of the transcutaneous partial 
oxygen tension. This technique was first applicated in neonatology by 
Renate Huch and coworkers (3) for the noninvasive analysis of blood 
gases in premature newborns to determine optimum ventilatory 
transport. In persons with a normal arterial p02, it could be an in­
dicator of oxygen transport to the skin, which depends on skin 
capillary blood flow. 
The electrode design (4) is based on the original Clark oxygen elec­
trode, which uses three 15 μ platinum cathodes surrounded by a common 
silver ring anode. The temperature of the heating coil adjacent to the 
anode is controlled by a servosystem, sensed by a thermistor that con­
stantly monitors the actual skin temperature. During heating above 43 
"C the induced local skin vasodilation promotes artenalisation of 
capillary blood, which causes a constant linear ratio of transcuta­
neous p02 to arterial рОг close to 1 (5). This technique uses the 
principle of "cutaneous respiration" with oxygen diffusion through the 
intact surface of the skin (6), which is optimal when the skin is 
heated up to 45 "C. The Clark electrode is placed behind a membrane 
which is permeable to oxygen. The diffused oxygen is reduced at the 
cathode when a voltage of approximately 850 mV is applied between the 
cathode and the reference anode. The electrochemical reaction results 
in a reduction current that is proportional to the number of oxygen 
molecules. The reduction current has been calibrated against a stan-
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dard and a ТСРО2 value can be read off (7). Because TcP02-measurements 
have the advantage of continuous, long-lasting, noninvasive observa­
tions of regional skin blood supply, are relatively cheap and can be 
used during intervention studies with simultaneous measurements of 
total skin blood flow to differentiate between capillary and shunt 
blood flow, we use this technique in the evaluation of skin perfusion 
disorders. 
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Transcutaneous p0 2 measurements in Raynaud's 
phenomenon. Value and limitations 
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Abstract. To determine whether measurements of transcutaneous pO, (TcPO,) by Tacomette 
(Novametrix Medical Systems Ine, Connecticut, U S.A.) could be a valuable method to 
evaluate nutritive skin perfusion, baseline TcPO, was measured under standardized conditions 
in normals and in patients with several types of Raynaud's phenomenon (RP). The control 
group (n = 41; TcPO, = 34.4 ± 14.3mm Hg) and the patients with primary RP (n = 81; 
TcPO, = 25.0 ± 9 7mmm Hg) had a significantly higher baseline TcPO, (p < 0.05) in 
comparison to the secondary RP-patients with a connective tissue disease (n = 54; 
TcPO, = 10.5 ± 7.9 mm Hg). In RP patients the group with trophic skin lesions showed a 
significant lower TcPO, (p < 0.01).The reproducibility expressed as the standard error of a 
single observation was moderate (13-27%). After 20 minutes acclimatization it took 32 
minutes before a stable baseline value was reached which makes the procedure a lengthy one. 
Its non-invasive nature is severely hampered by the skin injuries observed in 3 patients, 
while the abolition of vascular tone induced by the heating makes the interpretation of 
intervention studies difficult. 
In conclusion baseline TcPO, measurements were found lower in patients with disturbances 
of nutritional skin blood flow. However, because of the overlap of values between groups the 
discriminative value of this method is limited. Comparative studies with other techniques that 
determine capillary perfusion like the '"Xenon wash out technique and dynamic capillary 
microscopy are necessary to validate this technique as a reliable alternative. 
Introduction 
Skin necrosis and gangrenous lesions localized to the fingertips are an 
uncommon but severe complication of secondary Raynaud's phenomenon 
(RP), caused by severe impairment of the nutritional skin circulation [1]. A 
vanety of methods to assess capillary skin perfusion, like isotope clearance 
methods by '"Xenon gas [2] and video television monitored dynamic nail-
fold capillary microscopy [3], have been used. However, these techniques are 
rather expensive, not easy to perform and difficult to quantify. Although 
transcutaneous oxygen tension monitoring (ТсРОг) was originally de­
veloped for use in neonatal care [4], it has recently been successfully utilized 
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for local tibiuc perfusion studies by measuring 02-diffusion from skin 
capillaries that are maximally vasodilated by heating the skin below the 
electrode to 45 С It is proposed as a technically simple, cheap, non-invasive 
and continuous method that is easy to perform, and that correlates well with 
capillary density studies in patients with chronic venous incompetence as 
shown by capillaroscopy [5] or with radioisotope clearance studies of the 
skin [6] 
We further evaluated TcPO,-measurements of skin perfusion and deter­
mined its reproducibility, its standardization, its relationship to ischaemic 
skin lesions and its value in the discrimination between several types of RP. 
Patients and methods 
We selected 41 normal healthy volunteers, 81 patients with primary RP 
(PRP), according to the criteria of Allen and Brown [7] supplemented by 
negative clinical, biochemical and immunological screening tests for under­
lying diseases (8] and patients with secondary RP (SRP), subdivided accord­
ing to A.R.A. entena into. 19 patients with connective tissue disease (CID), 
being systemic lupus erythematosus (SLE) И mixed connective tissue 
disease (MCTD) [10], rheumatoid arthritis (RA) [11], Sjögrens syndrome 
(SS) [12], poly- or dermatomyositis (PDM) [13], 25 patients with sclero-
derma (SCL) [14] or the CREST-syndrome (calcinosis, Raynaud's 
phenomenon, esophagal motility disturbances, sclerodactylia, teleangiec-
tasia), 10 patients with undifferentiated CTD (UCTD) and in 14 patients 
with RP while using a ^-adrenoceptor blocking agent for hypertension or 
complaints of angina. All patients were divided into 3 subgroups: no trophic 
Table I Clinical characteristics of the study population 
41 
81 
54 
19 
10 
25 
14 
M/F 
26 15 
22 59 
1044 
4 15 
19 
5 20 
59 
yean 
29 2 ± 7 2 
376 + 1 3 2 
47 8 ± 15 0 
43 2 ± 15 1 
406 + 128 
542 ± 137 
544 + II 1 
Lesions 
0 
41 
76 
20 
10 
3 
7 
12 
+ 
0 
4 
17 
7 
5 
5 
0 
+ + 
0 
1 
17 
2 
2 
13 
2 
Normals 
Primary Raynaud's phenomenon 
Secondary Raynaud's phenomenon 
Due to connective tissue disease 
undifferentiated connective 
tissue disease 
progressive systemic 
sclerosis 
Raynaud s phenomenon during 
/J-adrenoceplor blocker 
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skin lesions, minor lesions (non healing cuts, pitting scars, nail abnormalities 
or small superficial lesions) and major lesions (ulcers or gangrene) In Table 
1 the clinical characteristics of the study population are shown During 
follow-up the healing time (in months) was noted All Raynaud patients 
were asked for the mean daily number of attacks, their mean duration (in 
minutes) and the severity of pain (on. a ten point scale) in the month 
preceding the TcPO,-determination Apart from the group that used a 
beta-adrenoceptor blocker, none of the patients used vasoactive medications 
at the time of evaluation Excluded were 3 patients with severe lung disease 
(pOj < 9kP/m2 by blood gas analysis, performed in all patients with 
(U)CTD or SCL), 4 patients with anaemia (Hb ^7mmol/l), 11 persons (3 
normals and 8 RP-patients) in whom the electrode could not properly be 
fixed to the fingertip because of a small finger circumference (<4cm), air 
leak, flexion contractures or loss of fingertip pulp The reproducibility was 
assessed in 41 normal healthy volunteers, in 65 PRP-patients and in 52 
patients with SRP by repeating the measurement within one month and so 
calculating the standard error of a single observation (S) by the formula: 
- J ? 
in which di is the difference between first and second test in subject ι and η 
the number of paired observations 
Pnor to the test all persons had to refrain from smoking for 24 hours, 
from drinking alcohol or caffeine containing beverages for 12 hours and they 
were asked not to eat or dnnk within the hour preceding the test. 
The TcPOj was measured in mm Hg by a heated (45 0C) Clarke electrode 
with the probe (seríes С electrode; Novametnx Medical Systems Ine, Con­
necticut, U.S.A.) adjusted to a portable transcutaneous oxygen monitor 
(Tacomette; no 809; Novametnx) The electrolyte solution (TCOjM, oxy­
gen electrode preparation kit, Novametnx; cat no- 8286, lot No: D 743) was 
renewed every 7 days according to the guide lines in the Operating Manual 
(1981; Novametnx) 
After 20 minutes acclimatization to a constant ambient temperature of 
24 8 ± 0.ГС in a climatized room (humidity 48 ± 4%) the TcPOj mem­
brane was cleaned and calibrated with fresh zero solution (Heilige no 
91920071, 1 tablet in 20 ce saline solution) High calibration was performed 
after adjustment for the local ambient temperature and barometric pressure 
Subsequently a droplet of contact gel (Novametnx oxygen electrode contact 
gel P/N 8200) was applied to the center of the Clark-electrode which was 
fixed to the cleaned skin of the distal volar surface of the third fingertip of 
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the right hand in the middle of the tingerprinl by a double stick adhesive ring 
(electrode adhesive ring. TcO-, M. TM, cat no. 8285; Novametrix) and tape. 
If asymmetric complaints were present the most diseased finger was 
chosen. The hand was supported at heart level without flexion of the elbow. 
Special care was given whether an airtight seal between the electrode and the 
skin surface was maintained and not to fasten the electrode too firm or too 
loose to avoid compression of skin capillaries or shifting away of the 
electrode. After application the time to allow stabilization, i.e. no change of 
the TcPO, value within one minute, was measured in 121 procedures. In 3 
scleroderma patients prostacyclin was intravenously infused with a step-wise 
increase in infusion rate of 2, 4 and óng-kg"1 •min"', each dose being 
administered for 30 minutes while TcPO, was measured at the most diseased 
fingertip. 
All results are expressed as mean ± SD unless stated otherwise. Com-
parisons between groups wre made by unpaired Wilcoxon's test (two-sided) 
and significance was presumed if ρ < 0.05. Correlations were calculated 
with linear regression. 
Results 
Figure 1 shows the different baseline TcP02-values in the group of normals 
(n = 41; 34.4 ± 14.3mm Hg), PRP-patients(n = 81; 25.0 ± 9.7mm Hg) 
the RP-patients who used a beta-adrenoceptor blocking drug (n = 14; 
26.1 ± 12.3 mm Hg), the CTD-patients (n = 19; 16.6 ± 7.0mm Hg), the 
PSS-patients (n = 25; 6.3 ± 5.6 mm Hg) and the patients with UCTD 
(n = 1 0 ; 11.7 ± 5.1mm Hg). No significant differences were found 
between these groups except for the PSS- and the UCTD-patients who 
differed significantly from the group of normals (p < 0.01) and the group 
of PRP-patients (p < 0.05). 
Figure 2 shows the different baseline TcP02 -values in all Raynaud's 
patients subdivided by the absence (n = І08;ТсРО2 = 24.6 ± 9.2 mmHg) 
or presence of slight (n = 21; TcP02 = 11.0 ± 6.3 mm Hg) or severe 
(n = 20; TcP02 = 3.4 + 2.4mm Hg) trophic skin lesions (p < 0.01; for 
both). A TcP02-value below 8 mm Hg was often found in patients with 
trophic skin lesions (sensitivity 65.8%; specificity: 96.3%). There was a 
significant inverse correlation between the degree of ischaemic skin lesions 
and the TcP02-value (r = -0.40; ρ < 0.001). Furthermore there was a 
significant but weak inverse correlation between the baseline TcP02-value 
and the healing time of ischaemic skin lesions (r = —0.26; ρ = 0.04) or the 
degree of pain (r = -0.43; ρ < 0.001). 
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Fig I Transcutaneous oxygen tension (TcPO,) in normals (η), patients with primary 
Raynaud's phenomenon (PRP), patients with Raynaud's phenomenon during /{-adrenoceptor 
blockade therapy (RP/B), patients with connective Ussue disease (CTD), patients with pro­
gressive systemic sclerosis (PSS) and patients with undifferentiated CTD (UCTD) 
Neither a significant correlation was found between the number or dura­
tion of attacks and the baseline TcPO,, nor a significant correlation between 
TcP02 and the age in the group of 41 normals. 
No signficant differences between males (33.9 ± 16.1mm Hg) and 
females (35.1 ± 11.8 mm Hg) was found in the group of normals. S as 
expression of reproducibility was 7.1 mm Hg (21%) in 41 normals, 3.3 mm 
Hg(13%)in65PRP-patients, 1.7 mm Hg (27%) in the PSS-group (n = 25), 
2.3mmHg(14%)intheCTD-group(n = 17) and 1.5 mm Hg( 13%) in the 
UCTD-group (n = 10). 
The adaptation time before a constant baseline TcPOj was reached was 
31.9 ± 11.7 minutes (range 11-57) and was inversely related to the baseline 
value (r = -0.76; ρ < 0 001). 
In 6 patients with a low initial finger skin temperature ( below 23.4 0C) 
the heated electrode caused pain. In three of them (2: PSS; 1 : UCTD) blisters 
on the side of the probe were seen afterwards. Although all blisters healed 
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Fig 2 Transcutaneous oxygen tension (TcP02) in 149 Raynaud s patients subdivided accord-
ing to the absence (o) or presence of minor [1] or major [2] ischaemic skin lesions 
within a week one of these patients developed minor skin necrosis that took 
nearly 8 weeks to heal completely 
In the 3 scleroderma patients in whom prostacyclin was administered, this 
agent caused an increase in the TcP02 values from 2, 5 and 6 mm Hg up to 
5, 8 and 14 mm Hg, respectively, at the highest infusion rate 
Discussion 
This study shows that baseline ТсЮг-measurements give significantly lower 
values in patients with SRP and/or trophic skin lesions Because of its 
moderate but acceptable reproducibility for clinical use and the great mter-
individual variations within one group careful search for vigorous standar­
dization is warranted The time required to reach a constant baseline value 
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is rather long especially in patients with a low baseline value, and together 
with calibration and acclimatization it may sometimes take over 90 minutes 
before the baseline Tc02 can be read. The technique is not applicable in 
about 10% of all Raynaud's patients and can even be dangerous in patients 
with a low skin blood flow. 
If pain occurs at the site of the probe, especially in patients with SRP and 
a low skin perfusion (i.e. skin temperature below 24 °C), the procedure 
should be stopped immediately because of the risks of blisters and skin 
lesions. 
It should be emphasised that the groups were not comparable in terms of 
sex distribution and age. The latter may not be relevant as we found no 
correlation between TcPO^ values and age. Moreover, although women 
mostly have colder hands than men, the TcP02 values in our group of 
normal females was even slightly higher as compared to men. In the group 
using beta-adrenoceptor blocking agents five out of fourteen patients had a 
considerable degree of occlusive vascular disease on the angiography of the 
hands which may in part explain the low TcP02 values and trophic skin 
lesions observed in some of these patients. It was not possible to apply the 
technique in 3 normals, 3 PRP-patients and 5 patients with SRP. Because 
the latter group had severe disease with pulp atrophy or flexion contractures 
this could have influenced the results. 
Our data resemble those from studies in arterial occlusive disease of the 
lower limbs either due to atherosclerosis [15-19] or diabetes mellitus [20-21] 
with values below 40 mm Hg in patients with complaints of claudication, 
below 20 mm Hg in extremities at risk, below 10 mm Hg in necrotic toes 
while in cases with values below S mm Hg no healing tendency of ischaemic 
skin lesions was found. 
One shuld be aware of the many ambushes and pitfalls that can attend the 
use of this new technique. The measurements are influenced by the heating 
of the electrode to 45 °C which makes dynamic experiments difficult to 
interpret because of the maximal heat-induced vasodilation which may 
hardly be influenced by any intervention. The heat application is supposed 
to be necessary to give a close relation to arterial p02 if local blood flow is 
arterialized by local heat-induced hypcraemia. We are currently performing 
studies in which heat application is not used. 
TcPOj is also influenced by skin properties such as skin thickness, fibrosis, 
callosity and loss of water that may all hamper oxygen diffusion through the 
skin. Furthermore the blood haemoglobin content, the actual PaOj and 
0 2 -diffusion from the heat induced maximally vasodilated shunts and veins 
[22-23] may also affect the TcP02. However, because the skin capillaries are 
located more superficially than shunt vessels and in contrast have a very thin 
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wall, TcPO,-values are not supposed to be predominantly influenced by 
shunt blood flow Besides a diminished capillary blood flow the decreased 
baseline TcPO ; in PSS could be due to a decreased capillary density or by 
increased skin thickness and fibrosis, which both impair O,-diffusion 
through the skin It is also known that the obstructed precapillary vessels in 
PSS patients are already maximally vasodilated and no further vasodilation 
may be induced by heating The low TcPO, values (18 + 3 6 mm Hg) in 4 
PSS-patients without RP in comparison to normals and this high level in 
comparison to patients with PSS and RP, show that these factors may play 
an additional role 
Because of the low but significant correlation between the baseline TcP0 2, 
pain score and time for healing of the skin lesions, it may be of value m 
determining the prognosis in patients with necrosis and/or gangrene 
In the near future studies comparing TcPOj-measurements with other 
reliable techniques to measure capillary blood flow, like the radioisotope 
clearance technique with '"Xenon gas diffusion [6, 23] and the dynamic 
nailbed capillaroscopy [24] are necessary to determine the real value of the 
ТсРОз If it proves to be a reliable technique it may not only improve our 
understanding of the pathophysiology and therapy of RP but also of the 
diabetic foot and of claudication [25] This is particularly sinking because 
there is great need to develop therapeutic agents that improve the nutntive 
status of the ischaemic skin Whether prostacyclin meets these demands 
remains to be determined 
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CHAPTER 13. 
Clinical Pharmacology and Therapeutics. 1986; 40: 219-225. 
Double-blind, placebo-controlled study of 
prazosin in Raynaud's phenomenon 
We perfonncd a randomized, doubk-blind. placcbocontrollcd, OOSSOVCT study of tbc therapeutic efficacy 
of prazosin (1 mg t.i.d.) in 24 patients with Raynaud's phenomenon. Comparison of prazosin vs. placebo 
showed a moderate subjective improvement with a reduction of the daily number (P « 0.003) and 
duration (P = 0.02) of attacks. Patients showed a marked preference (P = 0.0002) for prazosin. Finger 
skin temperature and laser Doppler estunatcd finger skin blood flow, assessed during a standard finger 
cooling test, revealed a beneficial effect of prazosin (P = 0.0001 and Ρ = 0.003, respectively). No 
differences in reaction to therapy could be found between patients with Raynaud's disease and sccoodaiy 
Raynaud's phenomenon. We conclude that prazosin is useful m the treatment of digital vasospastic disease, 
with an overall good response in two thirds of patients. (CLIN PHARMACOL THEK 19β6;40:219-25.) 
H u b Wol lershe im, M . D . , T h e o Thien, M . D . , Jan Fennis , M . D . , 
Phi l ip van Eiteren, P h . D . , and Albert van 't Laar, M . D . Nijmegen, The Ncthcrlamb 
Raynaud's phenomenon is charactenzed by parox­
ysmal vasospasms of aeratene skin vessels, induced by 
cold or emotional stimuli In most cases, designated as 
Raynaud's disease, no underlying disorder can be de­
tected Vasospasm superimposed on an underlying dis­
ease is indicated as secondary Raynaud's phenomenon 
When Raynaud's phenomenon is seveie enough to war­
rant medical treatment, the therapeutic effìcacy of the 
currently available drugs is disappointing ' ' Although 
we previously have shown a beneficial effect of the 
nonselective a-adrcnoreceptor blocker phenoxybenza-
mine,' its long-term use is hampered by the frequent 
side effects, such as postural hypotension, tachycardia, 
impotence, and retention of sodium and water The 
development of selective α,-adrenoreceptor blockers' 
such as prazosin may decrease side effects because of 
preserved feedback control of norepinephrine release 
by presynaptic a.-adrenorcceptors ' Prazosin was ex­
pected to be effective in Raynaud's phenomenon, as it 
inhibits vasoconstriction by blocking postsynaptic a,-
receptors' and because of several reports of its suc­
cessful use in vasospastic disease ' " However, confir-
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mation of these findings is needed, because none of the 
studies was performed as a randomized, double-blind, 
p!acetK>controlled ma! We here report the first con­
trolled study of prazosin in the treatment of Raynaud's 
phenomenon 
METHODS 
Twenty-four normotensive adult outpatients were se­
lected who had at least one Raynaud's attack per day 
All gave informed consent They were classified as 
having Raynaud's disease if they fulfilled the entena 
of Allen and Brown '' Secondary Raynaud's phenom­
enon caused by connective tissue disease was deter­
mined by use of Amencan Rheumatism Association 
entena "•" All patients stopped taking drugs at least 4 
weeks before the study period, which lasted from De­
cember until March The study design consisted of a 
randomized, double-blind, crossover protocol with four 
penods of 2 weeks each After 2 weeks without drugs 
the patients were allocated at random to receive either 
prazosin ( 1 mg 11 d ) or placebo in a double-blind fash­
ion for 2 weeks, followed by a 2-week withdrawal 
penod before they crossed over to the final 2 weeks 
with the alternative regimen To minimize side effects 
such as first-dose fainting.6 a step-up schedule was 
used This consisted of 0 S mg before retiring on the 
first day, followed by 0 5 mg b i d on the second day 
and 0 5 mg 11 d on the third day, before the ultimate 
dose of 1 mg 11 d was given 
On each day of the study the patients recorded their 
daily number of attacks, the mean duration (in minutes), 
and the seventy (on a 10-point scale) in a standardized 
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ТяЫе I. Clinical characteristics of 24 patients with Raynaud s phenomenon 
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diary The daily ambient temperature at 4 PM according 
to the National Weather Service was noted 
Dunng the follow-up visits, which took place after 
each 2-week period, the patients were asked to compare 
drug effectiveness with the preceding penods by use of 
a five-point scale much ( - 2) or slightly ( - 1 ) wt rse, 
no difference (0). and slightly ( + 1 ) or much ( + 2) 
better Changes in ischemic lesions in the hands and 
the spontaneously mentioned side effects were noted 
A preassigned checklist on side effects was also filled 
in by the patients From this we calculated the algebraic 
product of the frequency (seldom = I point, more of­
ten = 2 points, and very often = 3 points) and ihe 
seventy (mild = I point, moderate = 2 points, and 
severe = 3 points) of adverse effects, which were 
summed for all the side effects to result in an "adverse 
effect score " At the end of the study, the patients were 
asked to choose between placebo, prazosin, or no ther­
apy at all Compliance was determined by tablet 
counting 
At each visit a number of objective measurements 
was obtained We advised the patients to take their last 
tablet 3 hours before the visit and to eat no meal within 
this time penod They were asked not to smoke within 
24 hours and to dnnk no caffeine-containing beverages 
within 12 hours before the visit We measured body 
weight rectal body temperature, blood pressure (with 
a legally stamped sphygmomanometer), and heart rale 
in the supine position and after 1 minute of standing 
upright We also checked for the presence of edema 
Subsequently, a finger cooling test was performed ac­
cording to the method of Hanstcen" as modified by 
Cleophas et al " with the patient in the supine position 
Measurements were started after 20 minutes of equil­
ibration at a constant room temperature of 25е ± 0 1° 
C ( X ± SD) and humidity of 40% Dunng finger cool­
ing we measured finger skin temperature (FST) by a 
thermocouple and finger skin blood flow (FSBF) by 
laser Doppler equipment " Laser Doppler flowmetry 
measures the frequency shift of back-scattered laser 
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ТаЫс II. Diary results and results of the finger cooling test 
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Ρ 
value* 
0 003 
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0 03 
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<0 001 
0 13 
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light by moving blood cells in the outermost layer of 
the skin14 and correlates well with other methods of 
blood flow measurements, such as the xenon washout 
technique20 and the heat clearance technique : ' It proved 
to be an excellent method to estimate digital blood flow 
dunng therapeutic interventions " FST and FSBF were 
determined every 2 minutes on the distal volar surface 
of the second and third fingers of the right hand The 
average of the three initial measurements performed 
after the equilibration penod was used as the basic 
value Then the patient's nght hand was placed in a 
well-fitting plastic glove and immersed to just beyond 
the metacarpophalangeal joints for S minutes in water 
at 16е С After the gloves were removed, measurements 
were continued for 20 minutes Because we previously 
found the most pronounced differences between normal 
subjects and patients with Raynaud's phenomenon 12 
minutes after cooling, this value was used as the ref­
erence point to define recovery " To detect systemic 
effects of the cooling procedure, blood pressure (arter-
tosonde) on the left arm and heart rate (ECG) were 
measured three times before and three times after 
cooling 
The significance of means of pair differences was 
tested by Student's paired-sample t test, and the sig­
nificance of the difference between two group means 
was determined by Student's two-sample t test Results 
are stated as Ρ \alues of the two-sided tests If the 
variables had very discrete or irregular distributions. 
nonpanunetnc tests were applied (Wilcoxon's signed 
rank test for pair differences and Wilcoxon's two-sam­
ple test for two groups) 
The mean difference between the values of a variable 
X measured dunng prazosin and dunng placebo therapy 
is considered to be the effect of prazosin on X These 
effects have been calculated irrespective of the order 
of dosing (first prazosin or first placebo) because pre­
liminary test results to compare the groups according 
to therapy received first did not differ significantly 
All vanables of this study were also measured in the 
initial penod (2 w-eks before the ñrst dosing) and in 
the washout penod (2 weeks between the first and sec-
ond dosings) Values in these penods did not differ 
significantly from (hose in the placebo penod Details 
about results of the order of dosing and about the initial 
or washout penods are not presented in this article 
To obtain a measure for the overall level of FST 
dunng (he cooling test, the area under the FST curve 
between the start and the end of the expenment was 
divided by 30, the length of that penod (in minutes) 
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Flg. 1. The effect (X ± SE) of the fìnger cooling test on 
FST and FSBF The dashed hue represents values during the 
placebo period and the solid tine represents values during the 
prazosin penod 
The resulting quotient is a weighted average ot the FST 
value with weights proportional to the lengths of the 
penods for which each FST value is representative The 
measure is called "mean level dunng lest " A similar 
measure is used for the overall level of FSBF dunng 
the recovery penod (20 minutes) and is referred to as 
"level after fìnger cool.ng " 
Unless otherwise staled, data are presented as the 
X ± SD 
RESULTS 
Clinical characlensties of the 24 patients who par-
ticipated in the study are listed in Table I Mean age 
was 44 2 ± 15 3 years Raynaud's disease was present 
in 14 and secondary Raynaud's phenomenon occurred 
in 10 patients The mean duration of Raynaud's phe-
nomenon was 62 ± 49 years, with a mean daily at-
tack rate of S 6 ± 2 2 The mean Quetelet index was 
23 5 ± 2 9 Nutritional skin lesions were seen in 
nine patients (38%) Thirteen patients (54%) had pre-
viously received vasoactive agents without a satisfac-
tory response 
Results of the diary analysis are shown in Table II 
There was a significant reduction dunng prazosin ther-
apy in both the daily number of vasospastic attacks 
(P » 0 003) and their duration (P = 0 02), whereas 
the seventy of attacks was not significantly influenced 
Dunng all penods the mean daily ambient temperature 
did not change significantly (5 0° ± 0 6° С dunng the 
placebo penod and 5 Г ± 0 5 е С dunng the prazosin 
penod) 
The effects of finger cooling on FST and FSBF dunng 
both regimens are shown in Fig 1 and Table II The 
mean level of FST dunng the entire test and of FSBF 
dunng the recovery penod improved significantly 
(P < 0 0001 for both. Table II) dunng prazosin ther­
apy Also, before (P = 0 02), immediately after (P < 
0 001), and 12 minutes after (Ρ = 0 001) fìnger cool-
ing, FST was significantly higher dunng the active drug 
penod (Table II) Even if we corrected for differences 
in initial values, the decrease in FST 12 minutes after 
cooling remained significantly (P = 0 03) smaller dur-
ing prazosin as compared with placebo dosing (Table 
II) Investigation of the vanation in effect of prazosin 
revealed that patients with a good recovery after cooling 
(increase > 2 4° С within 12 minutes) in the initial pe­
nod showed a better response to prazosin than slow 
recoverers 
The therapeutic results in patients with Raynaud's 
disease and patients with secondary Raynaud's phe­
nomenon arc compared in Table III There were no 
significant differences between baseline values for ef­
ficacy parameters No differences in reaction to pra­
zosin therapy could be found between the two groups 
The effect of prazosin on supine and upnght blood 
pressures and heart rate, body weight and rectal tem­
perature is listed in Table IV Body weight tended to 
be higher dunng prazosin dosing because of a weight 
gam of 5 9 and 8 9 kg with overt edema in two patients 
Rectal temperature fell dunng prazosin therapy, with 
hypothermia (34 8° C) in one patient 
The reported subjective effectiveness of prazosin was 
impressive (P = 0 000001) Of the nine patients with 
trophic skin lesions, two reported no difference. 
whereas seven noticed improvement dunng prazosin 
dosing that was significantly better than that dunng 
placebo (P = 0 03) At the end of the study penod. 
17 patients decided to continue prazosin, one decided 
for placebo, and six preferred to stop therapy which 
indicates a highly significant preference for prazosin 
(P = 0 00014) Compliance was excellent, as 23 of 24 
patients used between 90% and I lOtt of the presenbed 
number of tablets dunng both dosing penods 
Side effects were spontaneously mentioned by 50% 
of the patients receiving prazosin and by 29% receiving 
placebo Dizziness with standing and palpitations were 
mentioned most often The palpitations disappeared 
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Table HI. Effect of prazosin (assigned as values dunng prazosin minus values dunng placbo) on the results of the 
fìnger cooling test in pnmary Raynaud's as compared with secondary Raynaud's phenomenon 
No ofpanems 
FST С С) 
Basic valuet 
Immediately after finger cooling 
12 mm after ñnger cooling 
Mean level dunng tesl§ 
F S B F ( 1 ) 
Mean level after finger cooling§ 
Primary 
14 
06 ± 06 
22 ± 05 
24 i 06 
20 ± 04 
4 8 ± 1 1 
Secondarv 
10 
24 ± 09 
1 4 î 04 
45 ± 18 
27 i 10 
99 ± 3 5 
Ρ value· 
0 10 
0 25 
0 31t 
0 5lt 
0 19t 
»Student i two-umpk I t n l ihc Ρ vtlue* mirited with * have been obtiincd with Welch & venion of the ι m i for uneqmJ ν m i n c e s 
ÎMtan value of I h m otaervairaru within 3 minutes before cooling 
(Derived from the AUC divided by the duruton of the meuurcinents 
Table IV. Blood pressure. 
Blood pressure (mm Hg) 
Supine 
S)stolic 
Diastolic 
Standing 
Systolic 
Diastolic 
Change ader standing (ОД 
Systolic 
Diastolic 
Heart rate (bpm) 
Supine 
Standing 
Change after standing (%)( 
Rectal body temperaluie (° C) 
Placebo ptnod 
123β ± 2 2 
77 5 ± 2 0 
121 7 î 22 
77 2 ± 2 1 
- 2 1 î 1 3 
- 0 3 ± 0 8 
67 2 ± 1 3 
70 8 ± 1 4 
3 6 ± 1 0 
36 97 ± 0 005 
Prazosin 
period 
120 4 î 2 3 
78 4 ± 2 0 
117 2 î 24 
77 6 î 2 0 
3 2 ± 1 6 
- 0 8 ± 10 
70 4 i IS 
75 0 ± 18 
4 5 î 1 2 
36 69 * 0 12 
Eßta of pra-
zosin 
- 3 3 * 2 4 
10 ± 1 5 
- 4 5 ± 2 1 
0 4 ± 1 5 
- 1 1 ± 1 7 
- 0 4 ± 1 3 
3 2 ± 1 7 
4 2 ± 1 9 
1 0 г 1 6 
0 28 ± 0 13 
Ρ value* 
0 17 
0 52 
0 0 4 
0 79 
051 
068 
0 07 
004 
0 56 
0 09i 
•Si uden ι i ι KU for paired u m p l « the 9 vilue maited with * was obtained uuh Wikonon ч vifned rank li 
^Values obtained after Minding upright for I minute 
with continuation of therapy In the checklist on side 
effects, both the number (54 vs. 23) and the adverse 
effects score (210 vs 70 points) were higher dunng 
prazosin dosing. 
DISCUSSION 
We used a crossover design because of the advantage 
of paired compansons between prazosin and placebo 
within each patient Such a design contains the potential 
bias of carryover effects and time effects 2* However, 
the short prazosin ti/2 (4 hours),6 the rather constant 
ambient temperature dunng the study, and the accli­
matization time at 25° С before the standardized finger 
cooling test17 should minimize these effects Indeed. 
we found no differences between the effects of prazosin 
applied as first or as second therapy or between values 
before both dosing penods 
A standard finger cooling test with measurements of 
the opearance and disappearance of cold-induced va-
soconstnction served as a model for a Raynaud's attack 
Previously we demonstrated that finger skin temperature 
recovery in this test is reproducible if room temperature 
and smoking are controlled.'" and that it is significantly 
lower in patients with Raynaud's phenomenon than in 
healthy subjects, which was considered to confirm its 
validity as a model : i Prazosin already increased the 
baseline FST, recorded after equilibration to 25° С am­
bient temperature, with an average of I 3° ± 0 5° С 
It could be argued that the higher level of the entire 
temperature curve dunng prazosin dosing is a mere 
consequence of the initial decreased vascular tone 
However, in the recovery phase ihc difference in FST 
between the prazosin and placebo penods became 
larger, reaching a maximum of 3 3° С after 12 minutes, 
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which is significantly more than the difference in the 
initial value Moreover, the measurement of blood flow 
by the laser Doppler technique indicated a faster re­
covery after cooling during prazosin therapy 
Our present study shows that short-term selective ot,-
blockade by prazosin is supenor to placebo in the treat­
ment of Raynaud's phenomenon. It significantly de­
creases the number and duration of vasospastic attacks 
Furthermore, prazosin increases FST before, during, 
and after cold water challenge and increases FSBF after 
cooling The overall response rate to prazosin of 60% 
is in agreement with previous studies in which doses 
from 1 to 6 mg/day, usually administered on a twice-
daily basis, were used ' " Our results can be considered 
as fair if it is taken into account that the condition of 
our patients should be classified as severe, as appears 
from the companson with other studies,2*2* the high 
frequency of nutritional skin lesions, and the fact that 
most of the patients had been refractory to other treat­
ment modalities 
We chose a fixed dose of 1 mg 11 d. because of the 
prazosin d
 :
 (4 hours),6 the reported effective dose be­
tween 2 and 6 mg in Raynaud's phenomenon,1 " and 
the small range in Quetelet index However, some of 
our patients might have achieved greater benefit with 
larger doses 
The cause of the differences in individual responses 
cannot be determined from our data Until now, studies 
have failed to predict which patient will show a favor­
able response to a certain type of therapy The differ­
ences are not a result of the seventy of vasospasms, 
because the patients with severe attacks in their diary 
or nutnlional skin lesions reacted at least as well as less 
senous cases Yet patients without a tendency to recover 
after cold water challenge in the initial test without drug 
dosing reacted less well (P = 0 01) The existence of 
an underlying disease could be expected to cause a 
limited potency for vasodilation in patients with sec­
ondary Raynaud's phenomenon (Table 111) Even if we 
analyzed the patients with progressive systemic scle­
rosis as a separate group, no differences as compared 
with the other patients in reaction to therapy could be 
demonstrated Previously we also found the efficacy of 
Donselective α-blockade to be equal in Raynaud's dis­
ease and secondary Raynaud's phenomenon 7 This is 
in contradiction to some reports in literature " At the 
least, our findings indicate that it may be possible to 
relieve vasospasm in a damaged vessel wall 
The occurrence of side effects after prazosin was 
generally in agreement with reports in the literature* 
and never prompted patients to withdraw from the 
study The incidence depended on the method of re­
porting, with a far more impressive number in the 
checklist than was spontaneously mentioned Some side 
effects were rather severe, such as unne incontinence,^ 
recurrent epistaxis, and palpitations and edema, the lat­
ter two of which are less expected in selective α,-block-
ade The hypothermia might be caused by heat loss 
from disproportionately vasodilated arteriovenous anas­
tomoses in the skin or by centrally acting mechanisms * 
This raises concern about the long-term use in higher 
dosages tn a disease that is not Severe in general Pre­
viously we found a pronounced orthostatic hypotensive 
effect of prazosin with higher dosages in patients with 
hypertension * Therefore, we used a gradual step-up 
schedule and a low initial dose of 0 5 mg at bedtime 
With this regimen the influence of prazosin on blood 
pressure (and heart rate) appeared to be negligible, with 
no first-dose orthostatic faint ness 
Although we did not perform a comparative study of 
prazosin and the nonselective α-blocker phenoxyben-
zaimne. the eight patients who used both drugs judged 
them to be of equal effectiveness, with less side effects 
during prazosin therapy 
To summarize, our study supplies further confirma­
tion that low-dose prazosin therapy helps alleviate va­
sospastic attacks and increases skin blood flow in pa­
tients with Raynaud's phenomenon Despite an overall 
good response in 60% of patients, complete relief was 
seen only in two patients (8 3%) Future controlled 
trials should compare prazosin with other new thera­
peutic modalities, such as nifedipine.:s ^ captopnl," 
and ketansenn : : The optimal dosage of prazosin, its 
long-term efficacy, its effect on the prognosis of va-
sospastic-dependent tissue damage, and the predictors 
of clinical responsiveness have yet to be established 
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CHAPTER 14. 
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Abstract 
In a dose response study of prazosin in 24 patients with Raynaud's 
phenomenon, we compared the clinical effectiveness and the side 
effects of 3, 6 and 12 mg prazosin daily. 
Diary analysis and measurement of finger skin blood flow and tempera­
ture before, during and after cold challenge showed no major differen­
ces between these three dose regimens. 
Standing systolic blood pressure decreased significantly during the 12 
mg period in comparison to the б mg (p<0.05) and to the 3 mg period 
(p<0.02), whereas heart rate increased in the two last mentioned 
periods (p<0.05). In the higher dosage ranges, spontaneous mentioned 
side effects were noticed most often, which was in accordance with the 
results of a checklist analysis on adverse effects. 
Three patients withdrew from the study because of complaints that 
might be due to orthostatic hypotension. 
Most patients that wanted to continue prazoain after this study (n=13) 
did so on a 3 mg base (n=10). 
Because we have previously shown that prazosin 3 mg daily is more 
effective in the treatment of Raynaud's phenomenon than placebo, this 
study shows that in a dose of 3 mg daily the best balance between 
clinical effectiveness and side effects is obtained. 
Introduction 
Selective, a1-adrenoceptor blockade is supposed to be effective in the 
treatment of Raynaud's phenomenon (RP), as it inhibits vasocon­
striction by blocking postsynaptic nl-adrenoceptors (1) and because of 
several reports of its successful use in digital vasospastic disease 
(2-11). Although we have previously shown a moderate beneficial sub-
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jective and objective effect of the selective αϊ-adrenoceptor blocking 
drug prazosin in a relatively low dose of 3 mg daily (11), we wondered 
whether higher doses would be more effective with still an acceptable 
side effect profile. Therefore we performed an open dose-response 
study comparing 3, 6 and 12 mg prazosin daily in the treatment of RP. 
Patients and Methods 
Twenty-four normotensive adult outpatients were selected who had at 
least one Raynaud attack per day. All gave informed consent. They were 
classified as having primary Raynaud's phenomenon (PRP) if they ful­
filled the criteria of Allen and Brown (12). Secondary Raynaud's phe­
nomenon (SRP) caused by connective tissue disease was determined by 
use of American Rheunatism Association criteria (12,13). All patients 
stopped taking drugs at least 4 weeks before the study period, which 
lasted from December until May. The study design consisted of a proto­
col with four periods of 2 weeks each connected to a double blind pla­
cebo controlled study reported elsewhere (11). After 2 weeks of 1 mg 
t.i.d. of prazosin daily, the patients received prazosin in a dose of 
2 mg t.i.d. for 2 weeks, followed by a final 2 weeks period with a 
regimen of 4 mg t.i.d.. To minimize side effects such as first-dose 
fainting, a step-up schedule was used in the initial 2 weeks period. 
This consisted of 0.5 mg before retiring on the first day, followed by 
0.5 mg b.i.d. on the second day and 0.5 mg t.i.d. on the third day, 
before the ultimate dose of 1 mg t.i.d. was given. 
On each day of the study, the patients recorded their daily number of 
attacks, the mean duration (in minutes) and the severity (on a 10-
point scale) in a standardized diary. The daily ambient temperature of 
4 PM according to the National Weather Service was noted. 
During the follow-up visits, which took place after each 2-weeks 
period, the patients were asked to compare drug effectiveness with the 
preceding periods by use of a five-point scale: much (-2) or slight­
ly (-1) worse, no difference (0), and slightly (+1) or much (+2) 
better. Changes in ischemic lesions in the hsnds and the spontaneously 
mentioned side effects were noted. A preassigned checklist on side 
effects was also filled in by the patients. From this we calculated 
the algebraic product of the frequency (seldom = 1 point, more often = 
2 points, and very often = 3 points) and the seventy (mild = 1 point, 
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moderate = 2 points, and severe = 3 points) of adverse effects, which 
were summed for all the side effects resulting in an 'adverse effect 
score' . At the end of the study, the patients were asked to decide 
which dosage of prazosin they preferred. 
At each visit, a number of objective measurements were obtained. We 
advised the patients to take their last tablet 3 hours prior to the 
visit and to eat no meal within this time period. They were asked not 
to smoke within 24 hours and not to drink any caffeine-containing 
beverages within 12 hours before the visit. We measured body weight, 
rectal body temperature, blood pressure (with a legally stamped sphyg­
momanometer), and heart rate in the supine position and after 1 minute 
of standing upright. We also checked for the presence of edema. Sub­
sequently, a finger cooling test was performed according to Cleophas 
et al. (16) with the patient in the supine position. Measurements were 
started after 20 minutes of equilibration at a constant room tempera­
ture of 250C + 0.1oC (mean + SD) and a humidity of 42 + 6%. During 
this test we measured finger skin temperature (FST) by means of a 
thermocouple (Ellab Instruments, Copenhagen, Denmark) and laser 
Doppler estimated finger skin blood flow (LDF) by using laser Doppler 
equipment (Penflux Pfl, Penmed, Sweden) which proved to be an ex­
cellent method to estimate digital blood flow during therapeutic 
interventions (17,18). FST and LDF were determined every 2 minutes on 
the distal volar surface of the second and third finger of the right 
hand. The average of the three initial measurements performed after 
the equilibration period was used as the baseline value. Then the 
patient's right hand was placed in a well-fitting plastic glove and 
immersed to just beyond the metocarpophalangeal joints for 5 minutes 
in a waterbath of 160C. After the gloves were removed, measurements 
were continued for 20 minutes. Because we have previously found the 
moat pronounced differences between normal subjects and patients with 
the Raynaud's phenomenon 12 minutes after cooling (16), this value was 
used as the reference point to define recovery. To detect systemic 
effects of the cooling procedure, blood pressure (ΘΡ by Artenosonde, 
Roche, Connecticut, USA) on the left arm and heart rate (HR by ECG) 
were measured three times before and three times after cooling. 
The significance of mean differences was tested by the Student's t-
test for paired samples. P-values of less than 0.05 (two-sided test) 
were considered to be significant. If the variables had very discrete 
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or irregular distributions, the Wilcoxon's signed rank test for un­
paired differences was applied. To obtain a measure for the overall 
level of FST and LDF during the cooling test, the area under the curve 
between the start and the end of the experiment was divided by 30, 
which is the length of that period (in minutes). The resulting 
quotient is a weighted average of the FST and LDF-value with weights 
proportional to the lengths of the periods for which each value is 
representative. The measure is called 'mean level during test' (11). 
Unless stated otherwise, data are presented as the mean +_ SO. 
Results 
The 24 patients (14 with PRP and 10 with SRP due to connective tissue 
disease) who participated in the study (17 females, 7 males) had a 
mean age of 44.2 + 15.3 years (range 17 - 70) and a mean Quetelet 
index of 23.5 + 3.0 kg.tir2 (range 17.6 - 29.0). Nutritional skin 
lesions were seen in 9 patients (ЗвЖ). Thirteen patients (54SÍ) were 
previously treated by vasodilating agents without a satisfactory 
response. Three patients withdrew from the study due to side effects; 
one patient in the period of 6 mg prazosin daily and two patients in 
the final period of 12 mg daily. These patients were not included in 
the analysis of diary and of the objective measurements. Table 1 shows 
the diary analysis and the results of the FCT in all four periods. 
There were no significant differences between the 3 dose regimens of 
prazosin when regarding daily attack rate or their mean duration and 
seventy. This was even more striking because the daily ambient tem-
perature increased slightly but significantly while on a higher dose 
of prazosin (p<0.05). 
No significant improvement was observed during the FCT when comparing 
FST or LDF before, during or after cooling or during the whole test 
(mean level) between the 3 dosages regimens. If we corrected for dif-
ferences in baseline values, no different reaction during cooling or 
recovery were observed either. 
The effects of the different prazosin dosages on BP, HR, body weight 
and rectal body temperature are shown in table 2. Significant effects 
were seen on systolic BP and on HR in the standing position. Systolic 
BP decreased in the supine position when using 12 mg prazosin daily 
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Table 1 Diary results and results of the cooling test during the prazosin 
periods of 3,6 and 12 mg daily (mean + SE) in the 21 patients that com-
pleted the trial 
Prazosin 
placebo 3 mg daily 6 mg daily 12 mg daily 
Diary: 
Attacks: daily number 
duration* 
seventy" 
Outdoor temperature C O 
4.0+0.5 2.4+0.4* 2.3+0.3 2.0+0.2 
29.4+5.0 21.0+5.7* 20.6+5.2 20.1+5.1 
4.8+0.5 4.1+0.6 3.9+0.4 3.9+0.4 
5.0+0.6 4.B+0.4 5.3+0.5* 5.8+0.7* 
Finger cooling test 
Finger Skin Temperature (°C): 
baseline value 
immediately after cooling 
12 min after cooling 
mean level during test+ 
Laser Doppler Flow (AU): 
baseline value 
immediately after cooling 
12 minutes after cooling 
mean level during recovery* 
30.1+0.9 
18.8+0.6 
24.0+0.9 
24.0+0.8 
26.1+4.2 
7.1+1.8 
11.8+3.7 
10.3+2.7 
31.B+0.9* 
20.9+0.6* 
27.2+1.1* 
26.5+0.9* 
27.6+3.9 
12.9+2.1* 
16.8+4.4* 
17.2+3.3* 
31.7+0.8 
20.6+0.6 
28.0+1.2 
26.8+0.9 
27.8+4.1 
13.1+2.4 
17.5+4.7 
17.5+3.5 
31.6+0.8 
20.5+0.5 
27.9+1.2 
26.6+0.8 
27.8+4.1 
12.8+2.2 
17.2+4.6 
17.3+3.4 
x
 duration in minutes 
* seventy on 10-point scale 
+
 derived from the entire area under the curve, divided by duration of the test 
or of the recovery period 
* p<0.05 in comparison to the previous period 
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but this was only significant in comparison to the 3 mg period 
(p<0.05). 
The decrease in systolic BP after standing upright for one minute was 
more pronounced during the 12 mg period (-4.9Ä) in comparison to the 3 
mg period (-2.6%), whereas there were no significant differences 
between the 6 mg (-4.65») and 12 mg daily periods. HR in the standing 
position gradually increased by 3.5 and 5.0 bpm when using higher 
dosages of prazosin (p < 0.05 between the 3 and 6, and between the 6 
and 12 mg periods). Although body weight increased during the 12 mg 
dosage period by 1.4 kg, the differences never reached significance. 
At the end of the study, eight out of the twenty-one patients that 
completed the trial preferred to stop therapy, thirteen patients de-
cided to continue prazosin of which ten on a 3 mg, two on a 6 mg and 
one on a 12 mg daily base. The majority of patients (75й) found the 6 
mg dose more effective than 3 mg daily. Only 3 patients judged the 12 
mg daily dose more effective than the 6 mg dose. The spontaneously 
mentioned side effects and the results of the checklist analysis are 
shown in table 3. There was a gradual increase in side effects in the 
higher dosage range. Dizziness with standing, palpitations and head­
ache were mentioned most often. Most side effects were found in the 
PRP-group: adverse effects score in PRP patients 11.1; 19.1; 23.1 
points per patient and in SRP patients 5.4; 6.6; 9.6 points per 
patient at 3,6 and 12 mg respectively. One patient withdrew from the 
trial while taking 6 mg a day because of permanent headache and dizzi­
ness on exertion with two collapses during a football match. One 
patient stopped on the first day of the 12 mg period because of perma­
nent dizziness that might have played a role in a car accident on that 
day. The third patient that withdrew from the study did so on 12 mg 
daily because of progressive anginal pain resulting in myocardial in­
farction with a low blood pressure at admission (90/50 mm Hg) that 
improved within two days. 
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Table 2 Blood pressure, heart rate, rectal body temperature and body weight 
during the prazosin periods of 3,6 and 12 mg daily (mean +_ SE) in the 
21 patients that completed the trial 
Prazosin 
placebo 3 mg daily 6 mg daily 12 mg daily 
Blood pressure (mm Hg) 
Supine 
Systolic 123.9+2.4 120.6+2.4 ΙΙβ.6+2.2 115.7+2.9 
Diastolic 77.5+2.0 78.4+2.1 78.6+2.1 77.3+2.0 
Standing* 
Systolic 121.8+2.4 117.5+2.4 113.1+2.6* 110.0+2.8 
Diastolic 77.4+2.2 77.5+2.1 77.7+2.1 75.3+2.4 
Heart rate (bpm) 
Supine 67.0+1.5 70.6+1.8* 71.3+2.0 72.5+2.3 
Standing* 70.8+1.5 75.2+1.9 78.7+2.0* 82.7+3.4* 
Rectal body temperature C O 36.9+0.1 36.7+0.1 36.8+0.1 36.7+0.1 
Body weight (kg) 69.7+3.1 69.9+3.2 69.9+3.0 71.3+3.5 
+
 after standing upright for 1 minute after 10 minutes supine rest 
* p<0.05 in comparison to the previous period 
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Table 3 Side effects during the prazosin periods of 3,6 and 12 mg 
daily 
3 mg daily 6 mg daily 12 mg daily" 
.number of patients that 
spontaneously mentioned 
side effects 12(50S) 18(75!S) 19(83*) 
.checklist 
number 54 64 79 
adverse effect score 210 326 397 
•discontinuation of therapy* 0 1 2 
"only 23 patients évaluable 
•all three due to side effects 
Discussion 
This study clearly shows that the optimal dosage of prazosin for 
treatment of patients with Raynaud's phenomenon is 3 mg daily. 
Although most patients subjectively found 6 mg daily to be most 
effective against vasospastic attacks, side effects became far 
more prominent whereas objective measurements of finger skin blood 
flow did not improve further. 
A standard finger cooling test with measurements of the appearance 
and disappearance of cold-induced vasoconstriction served as a 
model for Raynaud's attacks. Previously we have demonstrated that 
finger skin temperature recovery in this test is reproducible if 
room temperature and smoking are controlled (16) and that it is 
significantly lower in patients with Raynaud's phenomenon than in 
healthy subjects (19). Furthermore we were able to distinguish 
hypertensives with complaints of cold hands when using beta-adre-
noceptor blocking agents from hypertensives without complaints 
(20), which was considered to confirm its validity as a model. 
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We used a standardized questionnaire on side-effects, which revealed a 
greater number of side-effects than was spontaneously mentioned. The 
types of side-effects noticed were in agreement with the literature 
and were mostly due to generalized sympathetic blockade and/or vasodi-
lation. As could be expected, the number and the severeness of side-
effects increased with higher dosages overruling the greatest clinical 
effectiveness obtained with a dose of 6 mg daily. Some side effects 
were rather severe, for exanple the dizziness on standing or on exer-
tion, encountered by two of the patients who were withdrawn from the 
study. One of them found that a car accident was due to the ortho-
static complaints, whereas the other patient was hypotensive on ad-
mission after a myocardial infarction. Although we cannot prove 
whether the myocardial infarction or the prazosin caused the hypo-
tension, it calls for caution when dealing with high dosages of prazo-
sin. Previously we found a pronounced orthostatic hypotensive effect 
of prazosin with higher dosages in patients with hypertension (21). 
Therefore, we used a gradual step-up schedule and a low initial dose 
of 0.5 mg at bedtime at the start of the treatment. With this regimen 
the influence of the initial gift of prazosin on blood pressure (and 
heart rate) appeared to be negligible, with no first-dose orthostatic 
faintness. 
The concern regarding orthostatic fainting seems justified by the de-
crease in systolic BP observed in the standing position. In comparison 
to their baseline standing systolic BP (121.8 + 2.4 mm Hg) before 
prazosin treatment, there was a decrease of more than 4; 8 and 11 mm 
Hg during 3; 6 and 12 mg prazosin respectively (see table 2). This is 
even more striking if one realizes that the three patients who with-
drew from the study are not included in this table and they all three 
had complaints of dizziness. Four out of 21 patients that could be 
analyzed regarding BP response had a fall of more than 20 mm Hg when 
standing up. 
Far more side effects were noticed by the PRP patients in comparison 
to the SRP patients, which we also found in a study of nicardipine, a 
slow calcium influx blocking agent, in RP (22). Perhaps this is due to 
a different vascular reactivity (23) or to psychological factors that 
are supposed to play a role in primary RP (24). 
The subjective results of this study should be interpreted with 
caution because patient and doctor were not blinded. Especially the 
issue concerning the subjective nature of the side-effects mentioned 
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in table 3 could have been influenced by the patients knowledge of 
using a higher dosage of prazosin. In an attempt to reduce the sub­
jective nature of these side-effects, we tried to objectify them as 
much as possible by calculating an adverse effect score. Furthermore 
the rise in ambient temperature throughout the study may have in­
fluenced the diary results. 
Because we have shown in a previous double-blind, controlled study 
that prazosin in a dose of 3 mg daily decreases the number and dura­
tion of vasospastic attacks with an improved finger skin blood flow 
during and after cold challenge in comparison to placebo, prazosin in 
the treatment of Raynaud's phenomenon has an optimal dosage of 3 mg 
daily. Future controlled trials should compare prazosin with nifedi­
pine, which is nowadays considered the treatment of choice (25). 
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Intravenous Nicardipine in Raynaud's Phenomenon: 
A Controlled Trial 
H van Heereveld, H Wollersheim, *K Gough, and Th Thien 
Department of Mediane Division of General Internal Mediane St Radboud Hospital Nijmegen The Netherlands 
and'Syntex Research Centre Research Park Henot Watt Uni\ersiry Riccarton Edinburgh UK 
Summary The hemodynamic cfTects of intravenously 
administered nicardipine (5 mg/h dunng 83 mm) were in­
vestigated in 12 Raynaud patients and in 12 healthy vol 
untecrs in a double blind placebo-controlled cross over 
study In both groups we found no change in systolic 
blood pressure but a significant fall in diastolic blood 
pressure of 7 mm Hg(p < 0 001) Heart rate increased 14 
beats/mm (p < 0 001) and forearm blood flow increased 
1 0 ml/100 ml/mm (p < 0 01 ) with a concomitant decrease 
of 10 arbitrary units (AU) in Forearm vascular resistance 
(p < 0 001) In healthy volunteers the recovery of the 
finger skin temperature after cold challenge improved sig 
Although Raynaud's phenomenon was described 
by Maunce Raynaud in 1862, its pathophysiology is 
still unclear and treatment has been disappointing 
(1-3) Nicardipine is one of the recently developed 
calcium-entry blockers from the dihydropyndine 
group (4-7) All these drugs show pronounced va· 
s od 11 at ing properties, because of their inhibitory 
action on the slow-channel calcium influx into the 
vascular smooth muscle cell (8) This results in a 
relaxation of the vessel wall and may thus relieve 
arteria] vasospasm To evaluate the immediate ef­
fects of intravenously administered nicardipine in 
Raynaud's phenomenon, a standardized finger 
cooling test (FCT) was used to estimate its effect on 
cold induced vasoconstriction in Raynaud s pa­
tients and in a control group of healthy volunteers 
PATIENTS AND METHODS 
Twelve healthy volunteers and 12 untreated patients 
with Raynaud s phenomenon were studied dunng the 
winter months All were normótensive with no other 
nificantly (p < 0 05) In patients with primary Raynaud s 
phenomenon we observed a significant (p < 0 001) in 
crease in skin temperature of 4 60C before cooling to-
gether with a better recovery after cold induced vaso-
spasm (p < 0 001) In secondary Raynaud s patients ni 
cardipine caused no vasodilatation within the skin 
vessels There were no significant correlations between 
the plasma nicardipine concentration and any of the ob-
served pharmacological effects Key Words Raynaud s 
phenomenon—Nicardipine—Cooling lest—Finger skin 
temperature—Laser Doppler flow 
known cardiovascular disease All gave written informed 
consent to a protocol approved by the local ethics com 
mittee Six of the patients were classified as having pn 
тагу Raynaud s phenomenon according to the с т е п а of 
Allen and Brown (9), and the six others as having sec­
ondary Raynaud s phenomenon due to connective tissue 
disease according lo A R A entena (10-12) All va 
soactive drugs had to be stopped at least four weeks prior 
to the study The subjects were asked to take no meal 
within 2 h not to smoke within 24 h, and to dnnk no 
caffeine containing beverages within 12 h of the start of 
the FCT A randomized double blind placebo-controlled 
cross-over design was used with the time between the 
two infusions being at least 3 days 
All tests were performed in a climate room (tempera 
ture 24 8 ± 0 20C constant humidity of 40%) after at 
least a 20 mm acclimatisation penod Nicardipine (state 
formulation, Syntex Research) was administered intrave­
nously through an indwelling catheter in an antecubital 
vein, at a constant infusion rate of 5 mg/h dunng 85 mm 
On the distal volar surface of the second third and 
fourth fingertip of the right hand we measured respec 
lively finger skin temperature (EST) in aC by thermo-
couple (Ellab Instruments), finger skin blood flow (LDF) 
Received January 28 1997 revision accepted Apnl 17 1987 Internal Medicine St Radboud Hospital Geert Grooteplein 
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in arbitrary units (AUl by laser Doppler Penflux (Pen-
med). and the transcutaneous oxygen tension (TcPO
:
) 
with the skin below the electrode heated up to 450C. in 
mm Hg by a Tacomeue (Novameinx) Also assessed 
were heart rate (HR) by ECG systolic and diastolic 
blood pressure (SBP and DBF) in mm Hg by an auto­
matic device (Anenosonde. Roche) on the left arm. and 
forearm muscular blood flow (FBF) in ml I0Q ml - 1 
mm'
1
, by strain gauge venous occlusion plethysmog­
raphy (Loosco BVp%) while using a wnsi cuff The mean 
arterial pressure (MAP) m mm Hg was calculated by the 
formula MAP = (SBP + 2DBP)/3. and the forearm vas­
cular resistance (FVR) m AU by the formula FVR = 
MAP FBF 
For all measurements the average of six pretest values 
performed after (he equilibration period were used as a 
baseline value During the first hour of infusion, mea­
surements were performed every 10 mm. followed by the 
cold challenge The FCT was performed according to the 
method of Hansteen (13). modified by Cleophas et al 
(14). to study cold induced vasoconstriction and the re­
covery of the finger skin blood flow thereafter The nght 
hand was immersed into a waterbath of 160С for 5 mm. 
during which FST and TcPO. were measured every 
minute During the recovery period FST. LDF. and 
TcPOi were measured every 2 mm. whereas HR. BP. and 
FBF were measured every 10 mm 
Blood samples for determination of the plasma concen­
tration of nicardipine were taken at the beginning of the 
test and following 30. 60. and 85 mm of infusion from a 
catheter in the aniecubital vein of the arm contralateral to 
the infusion The plasma concentration of nicardipine 
was determined by high pressure liquid chromatography 
after several extraction procedures (15) 
The patients were instructed to volunteer all subjective 
side-effects dunng the infusion penod After the tesi a 
preassigned check list dealing with side-effects was 
filled m 
Statistics Each parameter was analyzed by repeated-
measures analysis of variance ( 16) for the mean effect, 
and the effect at each (ime point, of the drug in compar­
ison to placebo, averaged over all groups and between 
the three groups The statistical significance was as­
sessed by F-tests (16) To calculate the change over time 
and the dmg-time-group interaction, a Huynh-Feldt 
(17) adjustment was performed. To stabilize the variances 
in the FBF and the LDF, a logarithmic transformation 
was used Differences from the baseline average of six 
values at 0. 2. 4. 6. 8 and 10 mm were analyzed for all 
parameters The results of peripheral circulatory param­
eters (FST. LDF. TcPOj) before the FCT were analyzed 
separately from those dunng and after cooling The dif­
ferences between groups at baseline were analyzed by 
unpaired Student's Mesi The results are given as mean 
± SEM. unless stated otherwise p-Value s <0 05 (two-
sided) were considered ю bc significant. 
RESULTS 
The clinical charactenstics of the 12 Raynaud's 
patients are shown in Table I. The mean age in the 
volunteer group was 27 * 8 (SD) years and 38 ± 13 
years in the patients with Raynaud's phenomenon 
Both groups consisted of seven women and five 
men In Fig 1 the effects of nicardipine infusion on 
BP. HR, FBF, and FVR are shown Because there 
were no major differences among these four param­
eters in the normal volunteers and (he pnmary or 
secondary Raynaud's patients, all results were 
pooled Dunng nicardipine infusion the systolic BP 
showed no change, while diastolic BP fell progres­
sively from 70 ΐ 1 9 mm Hg to 63 ± 1.7 mm Hg (p 
< 0.001) Nicardipine caused an increase in HR in 
the whole group from 66 = 2.1 to 80 r 2 9 bpm (p 
< 0.001). The FBF increased 4 1 % with nicardipine 
from 2.37 ± 0 17 to 3.34 ± 0.32 ml 100 ml"1 min" l 
TABLE 1- Clinical charactensius of ¡2 Rasnaud's patients 
Patient 
Wtu, 
SD 
Aie 
(years) 
42 
40 
57 
31 
26 
27 
)3 
49 
59 
21 
43 
27 
38 0 
12 5 
Sei 
F 
M 
M 
F 
F 
M 
F 
M 
F 
F 
M 
F 
M F 
57 
Quetclct 
index' 
22 7 
21 0 
22 6 
22 1 
19 2 
22 2 
18 8 
22 0 
26 3 
21 4 
24 2 
16 5 
216 
26 
Diagnosis' 
PRP 
PRP 
PRP 
PRP 
PRP 
PRP 
SLE 
CREST 
RA 
CREST 
UAID 
UAID 
Duration of 
RP (yean)· 
5 
30 
3 
2 
6 
4 
2 
21 
4 
5 
4 
17 
86 
9 0 
Mean daily 
frequency of 
attacks dunng 
winter summer 
5 1 
4 1 
12 4 
I I 5 
33 
53 
82 
52 
10 0 
20 10 
3 0 
5 0 
7 6 2 6 
5 0 2 8 
Nutritional 
skin 
lesions 
.4. 
-
-
-
-
-
• » -
-t-
-+ 
-
-
• Quetekt inden bw/H1 body weight (bw) m kilograms, height (H) in meters 
* Diagnosis PRP, pnmary Raynaud's phenomenon. SLE systemic lupus erythematosis. CREST calcinosis, Raynaud's phenom-
enon, esophageal motility disturbances, sclerodactylia, letanpeciasia. RA. rheumatoid anhntii UAID, undasstfiaWe autoimmune dis-
ease 
r
 RP, Raynaud's phenomenon 
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ПО. 1 The eftecla of intravenoue nicardipine In com-
parlaon with placebo on ihe systemic hemodynamics 
In all 24 volunteers SBP systolic blood pressure 
DBP diastolic blood pressure HR heart rets MAP 
mean arterial pressure FBF forearm blood flow FVR 
forearm vascular resistance » ^ nicardipine O-O 
placebo Values represent mean ± SE 
(ρ < 0 01), and the FVR decreased 26% from 38 8 
± 2 1 t o 2 8 8 ± 2 3 A U ( p < 0 001) There were no 
significant differences in the baseline values of BP, 
HR, FBF, and FVR among the groups 
In Fig 2 the effects of nicardipine on the FST are 
shown The baseline values of FST were signifi­
cantly higher in the volunteers (32 5 ± 0 7°C) in 
companson to patients with Raynaud's phenom 
enon (27 7 ± 1 4°C) (p = 0 001) Before the cold 
test the effect of nicardipine on the FST varied sta­
tistically significantly with time and group The vol 
unteers and secondary Raynaud's patients showed 
no effect of nicardipine at any tune, whereas in the 
primary Raynaud's patients the FST remained con­
stant with placebo and rose steadily with nicardi­
pine from 27 3 ± 2 4 to 31 9 ± I ГС (p < 0 001) 
During cooling no effect of nicardipine was ap­
parent, but in the recovery penod there appeared to 
be a drug effect In the secondary Raynaud s pa­
tients the FST recovered from 18 0 ± 0 2 to 21 6 ± 
0 4°C during placebo infusion, whereas with nicar­
dipine the FST rose from 18 3 ± 0 5 to 25 4 ± 
2 3°C (p = 0 04) In the volunteers the FST recov­
ered from 19 2 ± 0 5 to 25 5 ± I 5°C with placebo, 
whereas with nicardipine the temperature rose from 
19 5 ± 0 5 to 29 1 ± 1 6°C, reaching significance 
dunng the last S min of the recovery penod In the 
group of primary Raynaud's patients the FST was 
significantly increased by nicardipine immediately 
after the cold challenge until the end of recovery 
Dunng nicardipine an increase of 10 9°C in the FST 
was noticed dunng recovery (19 3 ± 0 4 to 30 2 ± 
2 6°C) in contrast to the lower increase dunng pla­
cebo of 5 5°C (18 4 ± 0 5 to 23 9 ± 2 ГС, ρ < 
0 01) There was a significant difference in drug ef­
fect dunng the recovery penod between the two pa­
tient groups, of whom the secondary Raynaud's pa­
tients recovered less 
In Fig 3 the effects of nicardipine on the LDF 
are shown The baseline value in healthy volun­
teers (40 ± 5 6 AU) was higher in companson to 
the Raynaud's patients (21 ± 9 0 AU), although 
this difference did not reach statistical significance 
Before, dunng, and after the FCT there was no in­
dication of an effect on the LDF in the volunteers 
and in the secondary Raynaud's patients In pri­
mary Raynaud s patients the LDF increased 
steadily dunng the nicardipine infusion from 21 ± 
15Θ 
FST C C ) -
R Q 2 The effeele ol intravenous nicardipine 
in comparison with placebo on finger sHin 
temperature (FST) before and after cold 
provocation (waterbath of 16gC) in 12 
healthy volunteers and m six patients with 
primary and six with secondary Raynaud s 
phenomenon · · · nicardipine infusion 
C - 0 placebo infusion Values represent 
mean ± SE 
| M CAWQiP WC » Smg/br 
RAYNAUD S PATIENTS 
ч іг 
НІСДКОІРІНЕ 
RAYNAUDS PATIENTS 
N б 
SEC RAYNIUDS PATIENTS 
8 5 to 35 ± 7 6 AU (ρ < 0 Ol) Dunng the recovery 
penod the LDF improved significantly during drug 
treatment, being 113% higher after nicardipine than 
after placebo (p < 0 001) 
The baseline values of the TcPO¡ were higher in 
tne group of volunteers (33 ± 2 5 mm Hg) than in 
pnmary Raynaud's patients (20 ± 4 I mm Hg) and 
secondary Raynaud's patients (13 ± 8 6 mm Hg) 
There was one primary Raynaud's patient (with 
trophic ulcers) who had the lowest TcP02 (14 mm 
Hg) In the group with the secondary Raynaud's 
phenomenon there were three patients with trophic 
skin lesions, their TcP02 values being, respec-
tively, 2 and 8 mm Hg, and one technical failure 
There was no indication that nicardipine alTected 
the ТсРОг before, dunng, or after the FCT in any 
of the three groups 
Side-effects, calculated from the checklist, al­
though often reported dunng nicardipine infusion 
(88%), were not severe Flushing (76%) and head­
ache (25%) were the most frequently encountered 
complaints In the group of Raynaud's patients, 7 
of 12 (58%) also mentioned side-effects during pla­
cebo infusion, whereas none of the volunteers did 
In one patient the nicardipine infusion had to be 
terminated after 20 mm because of palpitations and 
a heavy feeling on the chest without signs of isch­
emia on the ECG and concomitant HR of 120 beats/ 
mm 
The plasma levels of nicardipine were 41 1 ± 
20 2 (SD) ng ml" ' at 30 mm, 54 1 ± 24 2 (SD) ng 
ml"' at 60 mm, and 84 7 ± 59 7 (SD) ng ml" 1 at 85 
min after the start of the nicardipine infusion, 
without differences between the normals and the 
Raynaud's patients There was no significant corre­
lation between the change in hemodynamic param­
eters and the plasma concentration of nicardipine 
DISCUSSION 
This study shows that intravenous nicardipine in 
comparison to placebo causes a decrease in dia­
stolic BP and an increase in HR as is expected from 
a drug with vasodilating properties Furthermore, 
we observed an increase in blood flow through 
forearm muscle and finger skin vessels The finger 
skin blood flow showed a better recovery after cold 
induced vasoconstnction 
Other studies dealing with the acute effects of a 
calcium-entry blocker in Raynaud's phenomenon 
were done by Kahan et al (18), Winston el al (19), 
and Wollersheim et al (20) The first study was a 
randomized placebo-controlled double-blind Inai of 
an oral dose of 20 mg nifedipine, which gave signifi­
cant protection against a vasospastic attack dunng 
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FIO. 3 The effects of Intravenous mcsrdipme 
in comparison with placebo on laser Doppler 
flow (LDF) before and after cold provocation 
(waterbath of 16"C) in 12 healthy volunteers 
and In six patienta with primary and SIK pa 
tients with secondary Raynaud s phenom 
enon · - · nicardipine ОС placebo mlu 
slon Values represent mean ± SE 
a cooling test in 16 Raynaud's patients The pa­
tients with primary Raynaud s phenomenon 
showed a better response in comparison to patients 
with the secondary type The study by Winston et 
al was not placebo controlled and the number of 
patients (seven) was too small for statistical anal­
ysis However, they could not find an increase in 
finger blood flow as measured by finger venous oc­
clusion plethysmography after sublingual adminis­
tration of 10 mg nifedipine Our own previous study 
was a placebo-controlled single-dose study on the 
hemodynamic effects of IO mg nifedipine given 
subhngually We found a pronounced increase in 
Tinger skin blood flow after a standard FCT Acute 
studies to investigate the effect of nicardipine in 
Raynaud's phenomenon have not been previously 
reported Two long-term studies about the chronic 
effects of oral nicardipine in Raynaud's phenom­
enon were done by De Trust et al (21) and Scott et 
al (22) The first study was a double-blind cross 
over study They found no objective improvement 
of the finger skin blood flow as measured by ple­
thysmography, but did find a significant improve­
ment of symptoms In a double-blind cross over 
tnal of nicardipine vs placebo Scott et al found no 
subjective or objective improvement before and 
after cold provocation 
As a model to induce a Raynaud's attack, we 
used a standardized finger cooling test with mea­
surement of the appearance and disappearance of 
cold induced vasoconstriction by a mild cold chal­
lenge of 160C Previously we demonstrated that 
finger skin temperature recovery in this test is re­
producible if room temperature and smoking are 
controlled Recovery is significantly lower in 
Raynaud's patients than in healthy subjects and 
this was considered to confirm its validity as a 
model (14) 
Besides FST we measured LDF and TcPOj be­
fore dunng and after finger cooling LDF is sup­
posed to represent total skin blood flow by mea-
sunng the frequency shift of back scattered laser 
light by moving red cells in the outermost layer of 
the skin (23) The total skin blood flow consists of 
the capillary blood flow and the flow through arte­
riovenous shunts which are important in the regula 
Hon of body temperature (24) TcPO; is used as an 
indicator of capillary perfusion (25) and represents 
nutritional blood flow (26) LDF-values correlate 
well with other methods of skin blood flow, like the 
Xenon wash-out technique in skin devoid of shunts 
(27), and the heat clearance technique (28) It has 
proved to be an excellent method to estimate skin 
digital blood flow dunng intervention studies (29) 
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The m j^or disadvantage of the LDF in comparison 
with the FST is the great mtenndividual. day to-
day. and rhythmical variation (23) Capillary perfu-
sion was not influenced by acute nicardipine in any 
of the groups, whereas LDF significantly improved 
in healthy volunteers and even to a greater extent in 
primary Raynaud s patients However, the changes 
in LDF for the latter group should be interpreted 
cautiously because the improvement is a result of 
large changes in two patients (numbers 4 and S) and 
little change for the other four The improvement in 
LDF may be ascribed to an improved flow through 
the arteriovenous shunts This Tits also with the 
finding that the secondary Raynaud's patients 
showed no significant increase of finger skin blood 
flow at all In these patients structural changes out-
weighed the vasospasm, and the nutntional skin 
blood flow seemed to be the major affected system 
(30) The low baseline TcPO¡ values in secondary 
Raynaud's patients are in accordance with these 
findings and may explain the high incidence of tro-
phic skin lesions Similarly, the only primary 
Raynaud's patient with minor trophic skin lesions 
had the lowest baseline TcPO¡ value of that group 
(14 mmHg) Lindsey et al (31) found a decreased 
penpheral blood flow and an increased vascular re-
sistance in scleroderma patients with Raynaud s 
phenomenon in whom the objective flow measure-
ment even deteriorated after treatment with nifed-
ipine, probably due to a steal effect caused by max-
imally vasodilated shunts We also did not find an 
objective increase in blood flow during nicardipine 
in secondary Raynaud's patients, although we did 
not observe a decreased penpheral blood flow after 
nicardipine as Lindsey et a] found with nifedipine 
The difference in the effects of nicardipine between 
the primary and the secondary Raynaud's patients 
could be due to the fact that there is a decreased 
vasodilatory capacity within the damaged vessel 
wall in the latter group An alternative explanation 
is based on the observations that capillary skin per-
fusion is largely decreased in patients with sec-
ondary Raynaud's phenomenon (30), and that this 
more superficially located circulatory system is not 
influenced by nicardipine, as we showed 
The side-effects, all due to the vasodilatory prop-
erties of nicardipine, were numerous but not se-
vere Most side effects dunng nicardipine and pla-
cebo infusion were mentioned by Raynaud's pa-
tients, perhaps due to their increased emotional 
(32) or vasomotor hyperreactivity (33) 
To summarize, intravenously administered nicar-
dipine improves finger skin blood flow especially in 
primary Raynaud s patients, but also in healthy 
volunteers, whereas no improvement in secondary 
Raynaud's patients was Found Whether chronic 
oral nicardipine causes a similar improvement has 
to be studied In clinical trials that deal with 
Raynaud's phenomenon, inclusion entena should 
clearly differentiate primary and secondary 
Raynaud's phenomenon, and these two groups of 
patients should be analyzed separately 
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CHAPTER 16. 
Journal of Clinical Pharmacology. 1987; 27: 907-913. 
Nifedipine in Primary Raynaud's 
Phenomenon and in Scleroderma: Oral 
Versus Sublingual Hemodynamic Effects 
H Wollersheim, MD, Th Thien, MD, and A van 4 Laar, MD 
In 16 pal ten Is ivilh floinaud s phenomenon o placebo controlled smgie-dose study was 
performed on (he he mod* namic effects oí 10 mg nifedipine sublmgually administered 
/oliowed b\ an open eight «eek stud; on the therapeutic efficacv of chronic oral ni/edi 
pine JO mg qid А Пег (he acule sublingual nifedipine administration a pronounced 
objective improvemcnl o|/ingerskin (P »- 013J and forcarm muscle blood flow fP = 04) 
during a standard finger cooling (est was found During the chronic oral study the 
improvement in objeclne efficaci parameiers disappeared except /or laser Doppler 
estimated shun! /lun (P = 07) The acule hemodvnamic effects did not predict the 
Jong term results in individual patients Patients »ith sistemic sclerosis reacted as well 
as patients iwth p r i m a n Rai naud s phenomenon This studi shows that orally admmis 
lered m/edipine does not convex long term ob/eclive benefit to patients wiih Raynaud s 
phenomenon The apparent increase in vasodilolton during acule administration sug 
gesls (hat sublingual nifedipine prophv laciicalh or during a vasospastic aflnck may be 
more vsefui 
As vascular constriction depends on transmem­brane calcium influx into the vascular smooth 
muscle cell calcium influx inhibitors are expected 
to inhibit vasospasm ' Indeed recently nifedipine 
was found to improve the Raynaud's phenomenon 
as reported in several independent prospective dou­
ble blind placebo-controlled (rials reviewed by 
Smith and Rodeheffer 2 
However 30% of patients did not experience sub­
jective improvement whereas complete relief was 
exceptional and most studies failed to demonstrate 
an increased digital blood flow Therapeutic results 
were disappointing in patients who had underlying 
vascular disease because of decreased vasodilating 
properties of the damaged vessel wall In sclero­
derma nifedipine may even decrease digital blood 
flow perhaps because of a steal mechanism I 
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The aim of this study was to examine the predic­
tive value of one sublingual dose of nifedipine fonts 
long-term efficacy and to determine the response in 
scleroderma patients Therefore a single dose con­
trolled study was performed followed by an open 
assessment of nifedipine in 16 carefully selected pa­
tients either with primary Raynaud's phenomenon 
or with secondary Raynaud s phenomenon caused 
bv systemic sclerosis 
MATERIALS AND METHODS 
Sixteen normolensive adult untreated outpatients 
with at least one Raynaud's attack a day and without 
other known cardiovascular disease, were studied 
All gave informed consent They were classified as 
having Raynaud's disease if they fulfilled the crite­
ria of Allen and Brown4 and if after two years of 
extensive clinical biochemical and immunologic 
follow-up no underlying disease could be identified, 
or as having secondary Raynaud's phenomenon due 
to systemic sclerosis according to the American 
Rheumatism Association (ARA) entena 5 
The study started with a single, blind-adminis­
tered sublingual capsule of placebo followed in four 
weeks by nifedipine 10 mg administered sublm­
gually Subsequently, an open study started that 
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consisted ol two periods of four weeks each In the 
first period no medication was given m Ihe second 
period nifedipine 10 mg qid was administered or­
ally Each dav Ihe patients recorded in a standard­
ized diarv their daily number of attacks they noted 
the mean duration in minutes and the seventy on a 
ten-poinl scale At the end of the study the patients 
were asked whether they preferred to continue ni­
fedipine and to compare its therapeutic effective­
ness with no treatment In addition spontaneously 
mentioned side effects were noted and a preassigned 
checklist with 40 Hems on adverse effects was rom-
pleled From this we calculated the algebraic prod­
uct of (he frequency (seldom = 1 point more often 
= 2 points and very often = 3 points) and Ihe se\er-
it\ (mild = 1 point moderate = 2 points and severe 
= 3 points} of Ihe quoted side effects which was 
summed for all items resulting in the adverse-effect 
score 
During the visits at zero four and eight weeks a 
number of measurements was performed respec­
ts elv after the sublingual dose of 10 mg and after 
the four weeks of nifedipine 10 mg qid oralK Prior 
to the \ isits (he patients had lo abstain from smoking 
for 24 hours to abstain from caffeine- and alcohol-
containing beverages for 12 hours to ingest their last 
tablet two hours before the visit and to take no meal 
within this lime period Body weight (kg) blood 
pressure (mm Hg) and heart rale (bpm) were mea­
sured both after five minutes of rest in the supine 
position and after one minute in the standing posi­
tion After at least 20 minutes of equilibration to a 
constant room temperature of 24 7 ± 0 2 (SD)0C 
(mean ± SD) and a constant humidity of 52 ± 5% a 
standardized finger-cooling lest was performed ac 
cording to (he method described by Cleophas el al * 
The three precooling values were averaged and des­
ignated as the basic value Subsequenllv Ihe gloved 
right hand was immersed into a water bath of 160C 
for five minutes while measurements of cold-in­
duced vasoconstriction were continued everv mm 
ute After cold challenge the vasodilation during 
recovery was determined every two minutes for 20 
minutes 
The measurements on the distal volar surface of 
Ihe second, the third, and the fourth fingertip of the 
right hand included respectively finger skin tem­
perature (FST) (celsius) by Thermocouple (Ellab In 
strumenls Copenhagen Denmark) laser Doppler 
estimated finger skin blood flow (LDF) expressed in 
arbitrary units (AU) by Penflux (Penmed Stock 
holm, Sweden) and transcutaneous oxvgen tension 
(TcPOj) with the skin below the electrode heated to 
45eC, in mm Hg by a Tacometlc (Novamclnx Medi­
cal Systems Ine Connecticut) In addition we mea­
sured heart rale (HR] in bpm (ECG) and at the left 
arm blood pressure (BP) in mm Hg by Artenosonde 
(Roche Medical Electronics Ine Cranburv NJ) and 
forearm muscular blood (low (FBF) in mL*100 
mL l mm-1 by a strain gauge venous occlusion 
Plethysmograph (Loosco BVP 96 Hoekloos Amster­
dam Holland) with a wrist cuff We calculated mean 
arterial pressure (MAP) in mm Hg by the formula 
SBP + 2XDBP
 w
.
n J f 
= MAP and forearm vascular resis-3 
lance (FVR) in AU by the formula FVR - — — 
FBF 
Laser Doppler (low was displayed conlmuoush on a 
pen recorder We ruled out the cyclical variations of 
flux bv determining the mean value during 30 sec­
onds around each time point we measured Besides 
calculating all absolute changes in hemodvnamic 
values during the FCT we corrected for differences 
in basic values and expressed all measurements in 
percentage changes 
The data collected on the sublingual nifedipine 
capsule administration were compared with (he re­
sults of Ihe sublingual placebo administration The 
data of (he no-lreatmenl period were compared with 
(hose obtained after the four-week oral nifedipine 
administration The significance of means of differ­
ences was tested b\ Students paired t lest and in 
case of irregular distribution of the variables bv 
Wilcoxon s signed rank test Ρ values lower than 05 
were considered to be significant Results are given 
as mean ± standard error of the mean (SEM) unless 
stated others ise Tooblain a measure for the overall 
level of FST LDF and TcP02 during the cooling test 
the area under the curve during Ihe experiment was 
divided bv 30 (being Ihe length of thai period) The 
resulting quotient is a weighted average of the pe­
riods for which each value is representative This 
overall level is called 'mean level during lest 
RESULTS 
The relevant clinical characteristics of the 16 pa-
licnls are given in Table 1 The mean age was 45 6 
± 15 (SD) vears The mean Quelelet Index was 22 4 
± 3 0 (SD) kg x m 2 Pnmarv Rav naud s phenome­
non and secondarv Rav naud s phenomenon due to 
svstemic sclerosis were each present in eight pa­
tients The mean duration of the Rav naud s phe­
nomenon was 8 4 ± В 6 (SD) jears with a mean daih 
attack rale of 6 1 ± 2 3 (SD) Nutritional skin lesions 
were seen in seven patients Eleven palientb had 
previouslv been treated bv vasoactive agents with­
out a sadsfactorv response The Figure shows the 
results of (he sublingual stud) There was a slatisti-
callv significant increase in LDF and ТсРОг from (en 
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and 15 minutes on after ihe sublingual gift of nifedi 
pine This improvemeni was mainlamed bolh im 
mediateli, after the cooling and during the reco\ e n 
period The FST v\as sigmficanlK increased b\ ni 
fedi pi ne after three minutes of cold challenge until 
the end of Ihe reco\er\ 
Table II summarizes ihis impro\emenl b\ show 
mg the mean level of the FST (P = 008) I DF (P 
= 013) and TcPO; (P = 006) during the K T Sub-
linguallv administered nifedipine did not influence 
the svslolic BP whereas (he diaslolir BP fell sigmfi-
cantlv from 76 8 ± 0 7 lo 70 Я ± 1 9 mm Hg (P 
= 0 01SJ The maximal rises in FBF (from 3 3 ± 0 2 lo 
4 6 ± 0 4) and HR (from 72 4 ± 1 8 to 84 4 ± 2 1) were 
significant with a decrease in ihe FVR (from 30 0 
± 2 5 to 21 6 ± 2 3) from ten minutes after sublingual 
administration of nifedipine until Ihe end of the ex 
périment Al l different es remained significant if we 
corrected for different basic values and used per 
ccntage changes 
The results of the diary analysis in the chronic 
stud\ are shown in Table III The daih number of 
vasospastic attacks and their severity were reduced 
(bolh P = 006) whereas their duration was nol sig 
niRcantl> influenced (P = 12) The daih number of 
attacks and their duration differed significantly in 
the basic period between padenls with pnmarv Ray-
naud s phenomenon and patients with scleroderma 
(P = 003 and Ρ = 02 respectivelv) however the 
percent improvement in daily number of attacks 
(23% in primary and 14% in scleroderma patients) 
did not differ significantly bul ihe percent improve· 
menls in uuralion of attacks ( 1 % in primary and 
16% in scleroderma patients) (ended to be belter in 
the Idlter group The mean daily ambient tempera­
ture was not sigmficanllv different (P - 96) between 
bolh periods Despite Ihe fad lhat there was a fair 
sub|ective overall effectivenesi» (P = 01) len pa­
tients preferred lo discontinue nifedipine mainly 
because of (he side effects 
The results of the chronic nifedipine treatment on 
the ob|crlive variables determined during the FCT 
are shown in Table И Only LDF improved although 
not significantly (P = 07) The amelioration ob­
served after nifedipine taken sublmguallv did not 
occur for both the FST [P - 19) and the TcPOa (P 
= 48) No significant effects on BP and body weight 
were observed d u r i n g the chronic oral sludv 
whereas HR increased sigmficanllv in the upright 
position from 80 + 2 bpm up to 85 ± 2 bpm (P = 004) 
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Figure The peripheral circulalon changes o/ laser Doppler de 
m e d finger skin blood flou ILDF] transcutaneous!! measured ox 
igen tension (TcPOiJand /mgerskm temperature [FbT before and 
after 10 mg nifedipine or placebo both sublmgualU od m mistered 
(SL) before and during a fingercoohng test IFCTJ 
A comparison of the therapeutic results during 
oral administration of nifedipine between the pa­
tients with primary Raynaud s phenomenon and 
those with secondary Raynaud's phenomenon due 
to systemic sclerosis is presented in Tables III and IV 
There were no major differences especially not if 
we corrected for the lower baseline blood flow 
values and the higher attack rate observed in the 
"secondary" Raynaud group The increase in mean 
level during the FCT after nifedipine taken sublm 
gually and after nifedipine taken orally m compari­
son to placebo did not significantly correlate for the 
FST (correlation coeffiuenl r = 01) LDF (r = 45) or 
ТсРО
г
(г = 31) 
Side effects during nifedipine were mentioned 
sponlaneouslv bv 11 patients Most often lhe\ com­
plained of headache (eight) palpitations (six) dizzi­
ness on standing (five) and transient flushing (four) 
hdema was seen in two patients Headache and 
flushing were most pronounced during the first 
week The palpitations preferenliallv occurred dur­
ing the first hour after nifedipine ingestion In the 
chprkhst on adverse effects there was a high number 
of side pffpeis tmean 2 5) with a high adverse-effects 
score (mean 7 2) that was due mainly to patients 
with the priman Ravnaud's phenomenon in which 
the number of side effects averaged four with a 
mean adverso-effecls score of 10 3 
DISCUSSION 
This sludv shows thai nifedipine administered sub­
lmgualU causes marked vasodilation in fìnger skin 
and forearm muscle vessels The results of chrome 
therap\ were far less pronounced and could not be 
prodirled b\ the reaction during the acute interven-
tion blu(]\ as was shown bv the low and not signifi 
cant correlations between the peripheral circulatory 
assessments during the acute and the chronic studv 
Acute single dose studies were also performed bv 
kahan el al β Winston et a l 4 and U isc el a l , u The 
first studv was a randomized placebo controlled 
double-blind trial of an oral dose of nifedipine 20 
mg which gave significant protection against vaso­
spasm during a fingrr-cooling test in 16 patients The 
btud\ bv Winston et al was not placebo controlled 
and Ihe number of seven evaluated patients was too 
small for statistical analysis However (hey stated 
that lhe\ found no improvement b\ finger venous 
occlusion plethysmography after sublingual inges­
tion of nifedipine 10 mg Wise et al 1ϋ performed a 
double-blind placebo controlled trial and found that 
acutely administered oral nifedipine 20 mg low­
ered both digital perfusion pressure and Plethysmo­
graphie blood flow in Ravnauds patients All three 
studies did not correlate these findings with a sub­
sequent chronic oral studv Boccalon et al " suggest 
the performance of a therapeutic sublingual test 
with nifedipine to determine which patient will 
show' a favorable reaction to chronic oral therapy 
but Ihev show no results that justib such a conclu­
sion 
Kallenberg et al >2 performed such a double-blind 
placebo controlled studv of sublmguallv adminis­
tered nifedipine followed b\ a chronic oral studv of 
slow release nifedipine in 16 Ravnauds patients 
They found a significantly improved digital circula­
tion during acute and chronic dosing However the 
response to sublingual nifedipine did not predict the 
long term results 
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TABLE II 
The Results of the Finger Cooling Test on the Peripheral Circulation In 16 Patients 
with Raynaud's Phenomenon (Mean ± SEM) 
Slnfl· Dow 
Nifedipin· 
IO mg. Sublin|ually Ρ Velu· 
Slngl« Dot· Chronic Oral 
Placebo NireHipln· 10 mj, 
10 mf. Subllneually PValu« qld lor Four Waokt 
Finger skin temperature (SC)' 
Laser Doppler (low (AU)* 
Transcutaneous oxygen Tension (mm Hg)" 
24 7 - 0 8 0 001 22 8 ± 0 6 
1 5 8 ± 2 9 0 0 1 9 6 ± 2 1 
2 1 1 * 2 7 0 0 1 1 3 6 ± 2 0 
0 2 23 2 ± 0 6 
0 07 1 1 4 ± 1 9 
0 5 1 2 9 ± 2 1 
* Wean 1е*е dur ng tesi 
During chronic oral nifedipine mos I controlled 
studies report suhjeclne amelioration However 
objectne variables did nol for the most part im­
prove especidlh if the finger s\stoli( pressureras 
used Moreover in most of these trials no correlation 
ot subjectue alle\lation with ohjoctivr digital blood 
flow improvement was found Ihis mav be due ei 
ther to msensiliuh of the melhodb used or to the 
magnitude of I he stimulus thai should initialed digi 
lal vasospastic attack such as the often painful ice 
water challenge or prolonged bodv cooling which 
are in excess of the mild stimuli that initiate an at­
tack in daih life and cannot be pharmacologicalK 
reversed We use a standard finger cooling lest with 
measurements of the appearance and disappearance 
of cold-induced vasoconstriction b\ a mild cold 
challenge of 160C as a model for a Kavnaud s attack 
Previoush we demonstrated lhal finger skin (em 
perature recovery in this test is reproducible if room 
temperature and smoking are controlled Recover\ 
is significantlv slower in Ravnaud s patients thar m 
hfdllhv subjects and this was ( unsidered to confirm 
ils vdhdilv asa modelh However one ma\ wonder if 
it accurateK represents a Ravnaud s attack because 
onk two digital vdsospaslK attacks were observed 
during the 48 tests and the quantitative measure 
menls onlv wcdklv correlate with the diarv results 
Because bodv temperature regulation dominates ar 
tenovenous shunt blood flow in (he fingertips the 
constant room temperature of 250C ma ν prevent the 
occurrence of digital vasospasm b> a decrease in 
svmpalhetic activity n In addition to FbT we mea 
sured 1 Dt and ТсРО
г
 before during, and after finger 
cooling 
I D F was the onlv finding thai improved during 
chronic nifedipine treatment It is supposed to repre 
sent total skin blond flow by measuring the fre 
quencv shift of back scattered laser light bj moving 
TABLE III 
Diary Results In 16 Raynaud's Patients and Comparison o( the Eight Patients with Primary Raynaud's 
Phenomenon with the Eight Patients with Scleroderma (Mean ± SEM) 
•Пасы 
Daily number 
All patients 
Palients with primary Raynaud s phenomenon 
Patients with scleroderma 
Duration (minutes) 
All patients 
Patients with primary Raynaud s phenomenon 
Patients with scleroderma 
Severity ( 0 - 1 0 point scale) 
All patients 
Patients with Raynaud s phenomenon 
Patients with scleroderma 
Ambient daily temperature (eC) 
Basic Period 
5 8 * 0 6 
4 4 ± 0 5 
7 2 i 0 8 
30 5 ± 3 8 
26 0 ± 4 3 
35 0 » 4 9 
5 6 ± 0 4 
5 8 ± 0 5 
5 4 ± 0 4 
2 3 i 0 4 
Ρ Value 
0 0 0 6 
0 05 
0 07 
0 12 
0 9 1 
0 0 4 
0 0 0 6 
0 02 
0 14 
0 96 
Nlftdlpme Parlixl 
4 8 і . 0 в 
3 4 ± 0 6 
6 2 t 0 6 
27 8 ± 3 1 
26 3 - 5 2 
29 3 i 3 5 
4 6 ± 0 4 
4 6 ± 0 7 
4 6 i 0 2 
2 3 ± 0 4 
16Θ 
TABLE IV 
Percentage Changes in Finger-Cooling Test Variables After Nifedipine Subllngually and After Chronic Oral 
Administration in Comparison to Placebo Values in Patients with Primary Raynaud's Phenomenon and 
in Patients with Secondary Raynaud's Phenomenon Due to Systemic Sclerosis (Mean ± SEM) 
Primary Raynaud s Phtnoinenon Syttwnk Scbrmli 
Finger skin temperature ("C)" 
Nifedipine sublmguallyt 
Nifedipine orallyt 
Laser Doppler flow (AU)* 
Nifedipine sublmguallyt 
Niledipine orallyt 
Transcutanous oxygen tension (mm Hg)* 
Nifedipine sublmguallyt 
Nifedipine orallyt 
+2 2 ± 0 8 
+09 ± 0 3 
+ 7 0 ± 3 7 
+2 9± 1 3 
+ 9 7 + 4 1 
-0 8 ± 1 Э 
060 
019 
0 51 
0 26 
071 
0 92 
+17 ± 0 4 
-0 1 ± 0 4 
+4 1 ± 1 7 
+ 1 6 ± 0 5 
+76 + 38 
- 0 6 ± 14 
* Mean levels during whcle test 1 М ы л level tfurtng niletíipine m comparison to mean level during placebo 
red cells in the outermost laver of the skin u LDF 
values correlate well with other methods of skin 
blood flow such as the Xenon washout technique in 
skin devoid of shunts ,s the heat clearance lech 
nique16 and plethvsmographv l' It proved to be an 
excellent noninvasive method with good reproduc-
ibility to estimate skin digital blood flow during 
pharmacologic and physiologic intervention stud 
íes tfl ,9 There are sufficient studies to show that LDF 
measures total skin blood flow ι e shunt as uell as 
capillary loop blood flow 20 " 
TcPCV* is used as an indicator of rapii la r\ perfu­
sion" that correlates well with capillaroscopt11 and 
with isotope clearance techniques1 and in part 
represents the nulnlumal skin blood flow J* which is 
(he major affected system in scleroderma patientsJ4 
Capillary perfusion was not influenced by chronic 
nifedipine, which may together with the seventy of 
vasospasm the exteni of fixed anatomic arterial 
narrowing, and the presence of active vasculitis or 
thrombosis, contribute to the lack of effect ι vit y ob­
served in scleroderma Thus the increase in total 
finger skin blood flow determined by LDF musi be 
caused by the improved ateno venous shunt flow 
The differences between the positive acute and 
the disappointing long-term results as far as objec­
tive parameters are concerned may be explained b\ 
an insufficient daily dose or altered pharmacoki­
netics during long-term treatment 3D Furthermore 
vasodilators induce counterregulatory mechanisms 
by activation of the sympathetic and the renin an 
giotensin system resulting in limited long-term effi­
cacy and frequent side effects Indeed heart rate in­
creased significantly for the whole group and edema 
was noted in two patients In a rece η I study Sarkozi 
et al " found a trend toward diminished effective­
ness oi. er lime in a long term controlled trial of oral 
nifedipine in patients with primary Raynaud s phe­
nomenon 
In general the side effects were similar to those 
reporlrd in the literature3 and they were not severe 
ï el the lolal number was striking and some patients 
found them so disabling that it was the major reason 
to discontinue treatment after (he study period 
Most side effects were reported bv primary Ray-
naud s patients perhaps because of their increased 
emotional or vasomotor instabilitv31 or because of 
pre existing sympathetic nervous s>slem hvper-
reaclmU м 
Important limitations must be acknowledged in 
this stud} One ma> question if an open studv with­
out placebo controlled treatment is appropriate in 
the therapeutic evaluation of a disease that has 
major emotional implications However doclor and 
patient bias moslh favor positive results " and dur­
ing the FCT onlv obiective measurements were 
used Moreover in view of the pronounced increase 
in HR after sublingual administration of nifedipine 
a double blind studv in a strict sense cannot be 
carried out 
Another limitation of this studv is the fixed oral 
dosage of 40 mgdaih We cannot rule oui whether a 
higher dose would have given better results How 
ever it is known that the number and seventv of 
side effects increase with the dose 31 and m most 
studies concerning the effectiveness of nifedipine in 
Ra>naud s phenomenon a dose of 40 to 60 mg dailv 
was used 3 
To summarize subllngually administered nifedi 
pine improves capillary perfusion and opens art e no 
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\enous anastomoses The increase of rapillar\ flow 
does not persist during chronic treatment Because 
the subjective improvement was not impressive 
with a considerable number of side effects in most 
perhaps sublingual administration of nifedipine in a 
preventive wd\ or during an attack mav be more 
successful A comparative study between sublingual 
and oral long term treatmenl with nifedipine is 
warranted 
The aulhots thank Лп л Verweilen (or secTelanal assisiance 
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CHAPTER 17. 
TREATICNT OF RAYNAID'S PtCNOHENON. AN EPILOGUE. 
Every physician who deals with patients suffering from peripheral vas-
cular diseases knows that effective treatment of Raynaud's phenomenon 
is difficult to obtain. Because the number of therapeutic possibili-
ties are so inexhaustible, we tried to quantify some of our current 
experiences regarding therapy, although we realise that this epilogue 
doea not satisfy the scientific requirements concerning drug evalua-
tion we pleaded in the preceding chapters. 
In primary Raynaud's phenomenon reassurance, an explanation of the 
underlying mechanism and a delineation of aggravating factors are 
usually sufficient. 
Giving up smoking is advisable for all Raynaud patients, although the 
immediate effects of stopping are disappointing (see table 1). Drugs 
known to aggravate symptoms should not be prescribed, although there 
is no unanimity whether for example the widely used G-adrenoceptor 
blocking drugs affect Raynaud's phenomenon. 
The situation at home and at work is important. The environment should 
be warm (above 22 °C) and dry, which is best achieved by central 
heating. Working with vibrating hand tools, cold water or frozen food 
and work that may cause finger injuries should be avoided by patients 
with severe ischaemia. Warm clothed and a pair of fur-lined gloves are 
important. Commercially available pocket warmers, originally intended 
for fishermen, are suitable to be carried in coat pockets. General 
physical exercise, preferably walking, and regular manual activities 
both may improve the peripheral circulation. At night an electric 
blanket is the best way to get and to remain warm. 
To test some of the currently used therapeutic regimens, we asked 
Raynaud's patients to judge the clinical improvement or side effects 
they noticed during treatment by filling in: no (=0), minor (=1), or 
major (=2) improvement or side effects. Furthermore the patients were 
asked whether they preferred to continue the type of treatment they 
used. 
As shown in Table 1 the subjective effectiveness of physiotherapeutic 
therapy by electromodulation according to Trabert was disappointing, 
which was confirmed by means of an uncontrolled study in 13 Raynaud 
TABLE 1 
THERAPY OF RAYNAUD'S PHENOMENON 
Number of Raynaud's patients improvement score side-effects score continuât 
(primary : secondary) 0 1 2 0 1 2 absolute 
Cessation of smoking* 23 (17: 6) 
Physiotherapy" 19 (16: 3) 
Vasodilator drugs 122 (81:41) 
Thoracic sympathectomy 28 (21: 7) 
•*- at least for 4 weeks 
" electromodulation according to Tr'ábert 
x
 The patients were asked: "Would you again agree with the same type of operation?" 
14 
10 
67 
6 
5 
6 
43 
20 
4 
3 
12 
2 
-
17 
64 
11 
-
1 
35 
6 
-
1 
23 
11 
13 (57Й 
10 (53Й 
39 (32S 
12х(Эбй 
TABLE 2 
DRUG THERAPYX IN RAYNAUD'S PHENOMENON 
DRUG 
HYDRALAZINE 
PRIZIDILOL 
PINDOLOL 
LABETALOL 
PRAZOSIN 
KETANSERIN 
CAPTOPRIL 
NIFEDIPINE 
PROSTACYCLIN 
dose 
2x25 mg 
2x200 mg 
2x20 mg* 
3x400 mg 
Зх 1 mg 
2x40 mg 
2x25 mg 
4x10 mg 
2x20 mg+ 
10 mg 
В ng/kg/min° 
route of 
admini­
stration 
oral 
oral 
oral 
oral 
oral 
oral 
oral 
oral 
oral 
sublingual 
intravenous 
6 hours once a week for 3 weeks 
x used for 4 weeks in winter period 
+
 slow-release preparation 
number of improvement side-effect continuation 
Raynaud's patients score score absolute(S) 
(primary : secondary) 0 1 2 0 1 2 
5 (4>1) 
4 (3:1) 
В (6:2) 
12 (10:2) 
11 (9:2) 
13 (5:8) 
14 (11:3) 
16 (12:4) 
1β (12:6) 
9 (5:4) 
12 (4:θ) 
3 
4 
5 
6 
5 
θ 
10 
5 
10 
3 
8 
2 
0 
3 
5 
5 
4 
2 
9 
5 
4 
4 
0 
0 
0 
1 
1 
1 
2 
2 
3 
2 
0 
1 
4 
5 
7 
1 
9 
12 
4 
10 
2 
9 
2 
0 
2 
5 
5 
3 
1 
6 
5 
4 
2 
2 
0 
1 
0 
5 
1 
1 
6 
3 
3 
1 
1 (20S) 
0 (0Й) 
з (эв») 
6 (50S) 
4 (36S) 
5 (З Я) 
4 (29«) 
5 (31Й) 
5 (28Я) 
4 (44Й) 
2 (17Й) 
-J 
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patients who showed no improvement of fingertip circulation before, 
during and after a standardised cooling test, while electrostimulation 
was performed. This unpublished study also showed that after 14 
sessions of electrostimulation neither subjective nor objective im-
provement was found. 
We have no experience with relaxation therapy or the biofeedback 
method, both reported to have a favourable effect in primary Raynaud's 
phenomenon. 
In a few subjects, the symptoms are sufficiently troublesome to test 
the effectiveness of a vasodilator drug, especially during winter. As 
can be seen in table 2, despite the availability of multiple treatment 
modalities, the clinical response to all used vasodilator drugs is 
disappointing and none of them can be considered as appropriate. Al-
though most provide some symptomatic relief, their use is limited by 
their side effects. 
Table 1 shows that in purely vasospastic disease surgical sympathecto-
my may be useful, but a high relapse rate after one or two years is 
frequently reported. Of course, the disappointing results of sympa-
thectomy in our patients and the many side effects like causalgia of 
the limb, anhydrosis or hyperhydrosis, or pain at the site of the 
operation could principally be due to selection because only patients 
with an unsatisfactory response after the operation come to our atten-
tion. 
If the Raynaud's phenomenon is a symptom of an underlying disease, 
this disorder should be treated. Trophic skin lesions should be treat-
ed conaervatively, unless signs of secondary infection occur. To avoid 
pounding and cold, handgloves should be worn permanently, and the 
hands should be kept warm, dry and clean at all times. Daily bathing 
the hands twice in a désinfectant and careful drying afterwards usual-
ly makes it possible to save the finger. If the skin is excessively 
dry with a tendency to fissure, a lanolin preparation could be applied 
daily. Analgetics, especially during the night, are often necessary. 
The effectiveness of antibiotics, reserpine intra-artenally, anti-
thrombotic or haemorheologic therapy has never been proved and is not 
recommended. 
In conclusion, the results of the many therapies used in Raynaud's 
phenomenon are rather poor. Frequently, the side effects are more dis-
abling than the symptomatic relieve obtained. 
SUHHARY 
Introduction 
In Part 1 the aim of the studies presented in this thesis has been 
described, followed by a clinical overview of Raynaud's phenomenon. 
Patients with complaints of cold extremities or discoloration of the 
hands and feet are frequently encountered in the windy and rainy 
northwest of Europe. In case of at least a biphasic discoloration in­
duced by cold or emotion, it is designated Raynaud's phenomenon. In 
1Θ62 Maurice Raynaud first described the symptomcomplex that now bears 
his name and is unfortunately often referred to as Raynaud's disease. 
This has led to a lot of confusion because the term disease suggests 
characteristic, pathognomonic complaints and findings at physical 
examination with a uniform pathogenesis. Not until the past decade in­
vestigators in pathophysiologic and therapeutic studies discriminated 
between primary and secondary types of Raynaud's phenomenon and the 
several subtypes of the latter. 
The questions we tried to answer in this thesis are: 
1. What is the diagnostic value of various clinical, immunological and 
noninvasive vascular tests to identify the several subtypes of 
Raynaud's phenomenon7 
2. Which role does the sympathetic nervous system play in the patho­
physiology of primary Raynaud's phenomenon'' 
3. Are vasodilating agents beneficial in the treatment of Raynaud's 
phenomenon'' 
Classification of Raynaud's patients: 
In Part 2 and in Part 3, we tried to classify our patients properly. 
In most patients who present with a Raynaud's phenomenon a complete 
history and physical examination are usually sufficient for a correct 
diagnosis. As shown in chapter 3, complaints that started before the 
age of 20, reactive hyperaemia at the end of an attack and discolora-
tions of the earlobes and the nose have a high predictive value for 
primary Raynaud's phenomenon. Trophic skin disturbances are rare in 
the latter but are rather specific for connective tissue diseases. In 
case of arterial obstructive disease, the feet are always involved, 
risk factors associated with atherosclerosis are often present, where­
as this type is specifically encountered in men in whom the complaints 
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started before the age of 50 and in whom signs of atherosclerotic 
vessel wall disease elsewhere were seen. Supplementation with 
determination of antinuclear antibodies, and, as others have shown, 
measurements of the capillary perfusion of the skin and the finger 
systolic pressure makes the diagnostic classification complete. The 
type of underlying disease that is going to evolve can be predicted by 
antinuclear antibody determination by means of imminoblotting, as 
shown in chapter 4. Especially the development towards scleroderma, 
the CREST-vanant (calcinosis, Raynaud's phenomenon, esophageal 
motility disturbances, sclerodactyly, teleangiectasia) and mixed 
connective tissue disease is predictable. In doubtful cases, the 
clinical course will ultimately solve the problem. 
The sympathetic nervous system and its relation to the pathophysiology 
of Raynaud's phenomenon 
In Part 3, chapter 5, 6, 7 and 8 investigations about the pathophysio-
logy of primary Raynaud's phenomenon are presented. Clinical, patho-
physiological and therapeutical studies have shown evidence for a 
defect within the sympathetic system. 
In chapter 5, we reviewed the physiologic role of the sympathetic 
nervous system in body temperature homoiostaais. The peripheral vaso-
constriction to decrease heat loss to the surroundings during cold ex-
posure is increased in patients with the primary Raynaud's phenome-
non. Together with the finding that suppression of the sympathetic 
nervous system alleviates vasospastic complaints, this supports the 
theory of a pathophysiologic abnormality in the autonomic nervous 
system. 
In chapter 6, we showed that the laser Doppler technique measures part 
of the skin blood flow that serves thermoregulation, i.e. the arterio-
venous shunt vessels that are richly supplied by sympathetic nerve 
endings. 
In chapter 7 and 8, the effects of various tests that stimulate the 
sympathetic nervous system on the circulation of patients with the 
primary Raynaud's phenomenon are evaluated. Previous to these tests we 
measured an elevated baseline sympathetic nervous system activity in 
these patients by venous catecholamine determinations. The vasocon-
strictive response in them was not different in comparison to normal 
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controls, except for the reaction to mental strain in the Raynaud 
patients who showed, to our surprise, vasodilation. Supplemental 
studies not included in this thesis show that the vasodilation is 
caused by an increased sympathetic sudomotor reflex that liberates 
vasodilating kinines. Finally, we found that vascular reactivity 
depends on baseline skin perfusion, because the amount of baseline 
blood flow and the vasoconstrictive reaction are positively correlat­
ed. 
The following problems were encountered during the studies regarding 
the pathophysiologic role of the sympathetic nervous system in digital 
vasospasms: 
1) Already under resting conditions, a decreased finger skin blood 
flow together with an enhanced sympathetic nervous system activity was 
present in patients with primary Raynaud's phenomenon. 
2) The reactivity of the sympathetic nervous system is not uniform. 
Vasomotor and sudomotor outflow to the hands are just like skin and 
muscle blood flow regulation under different control. Furthermore 
there ie a great diversity in sympathetic reflex pathways that control 
the circulation. 
3) We are only able to measure the sympathetic nervous system activity 
indirectly by means of, for example, venous norepinephrine concentra­
tions. 
Because of these important limitations, only limited conclusions can 
be drawn from these chapters: in patients with primary Raynaud's phe­
nomenon baseline sympathetic activity is increased and baseline skin 
blood flow is decreased. Vascular and sympathetic reactivity seem 
normal. 
The studies concerning vascular reactivity in Raynaud's phenomenon, as 
described in Part 3, chapter 8-12, present two new methods to quantify 
skin perfusion: Laser Doppler flux measurements and determination of 
the transcutaneous oxygen tension. 
The laser Doppler technique measures the erythrocyte flux in the 
outermost layer (a depth of 1 to 2 mm) of the skin. Going from the 
outside to the inside, the nutritive capillaries (depth: 0 - 0.4 mm), 
the arteriovenous anastomoses (depth: 0.Θ - 2.0 mm) and the venules 
are located within this measurement volume. Nearly 90% of the blood 
volume flows through the anastomoses under room temperature condi­
tions. 
During heating of the skin up to 40 centigrades, the sympathetic out-
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flow to the skin is completely abolished. If the vasospasm in patients 
with the primary Raynaud's phenomenon is due to hyperactivity of the 
sympathetic nervous system, one may expect that during heating up to 
40 centigrades skin circulation will become normal. Although this was 
not found in the study described in chapter 9, we have indications 
that the heating time of 5 minutes was too short for complete vaso­
dilation. Now we are investigating whether a heating period of 20 
minutes is able to induce the supposed maximal vasodilation. In case 
of secondary Raynaud's phenomenon due to atherosclerotic obliterative 
vascular disease or due to connective tissue diseases, blood vessel 
wall alterations that lead to increased stiffness might decrease heat 
induced vasodilation. Indeed, a major decrease in vasodilation was 
found. However, this heating test was unable to differentiate between 
individual patients with primary and secondary Raynaud's phenomenon, 
and in the latter group between several subtypes. 
In a subsequent study, described in chapter 10, the same extent of 
overlap between subgroups was found during a post-occlusive reactive 
hyperaemia test which measures the degree of metabolic vasodilation 
after 5 minutes occlusion at the fingerbase. A major problem during 
these experiments, and in general during all studies in which the skin 
perfusion is quantitatively determined, is the large inter- en intra-
individual variability of the measurements which is largely due to the 
enormous physiological fluctuations in skin blood flow with a variabi­
lity up to a two-hundred fold. 
Being able to quantify capillary nutritional skin perfusion would be 
an important progress. Up to now only the dynamic capillaroscopy and 
the 133 Xenon wash-out technique have been used, both with disadvan­
tages too. It would be worthwhile developing a simple and cheap alter­
native. The measurement of the transcutaneous oxygen tension by a 
Clark electrode could be such a method. However, as described in 
chapter 12, the discriminative value between groups with a normal and 
groups with an abnormal capillary perfusion, like in scleroderma-
patients for instance, was disappointing. Especially in cases of a low 
oxygen tension, the reproducibility of the method was moderate. Two 
other disadvantages are: the heating of the electrode up to 45 centi­
grades, which blunts vascular reactivity and the influences of other 
factors beside the circulation such as skin properties, the hemoglobin 
concentration and the arterial oxygen tension of blood. Some of these 
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problems could be solved by using an unhealed electrode and calculat­
ing an index using a reference value elsewhere. Unfortunately, 
measurements with an unhealed electrode give unreliable results, 
whereas the calculated index is not better reproducible than the 
measurements performed on the distal volar surface of the fingertip. 
Therapeutic investigations in Raynaud's phenomenon 
The first treatment modality we investigated in Part 4, chapter 13 and 
14, was prazosin. Selective alpha-1 adrenoceptor blockade was selected 
because of the postulated pathogenetic role of the sympathetic nervous 
system in the provocation of vasospasms, the proven effectiveness of 
non-selective alpha-adrenoceptor blockade and the favourable side-
effect profile of alpha-1 selective blockade. Although prazosin caused 
impressive subjective and objective improvements, with an optimal 
balance between effectiveness and side effects at a dose of 3 mg 
daily, the complaints only improved in 60% of the patients, whereas 
only ΙΟΧ became completely free of attacks. Half of the patients ex­
perienced troublesome side-effects. After the trial period, 75% of the 
patients discontinued prazosin. 
We also investigated some derivatives of the dihydropyndine compounds 
in the treatment of Raynaud's phenomenon (chapters 15 and 16) for 
several reasons. The intracellular calciumconcentration is the final 
common pathway that causes vascular smooth muscle wall contraction. 
Several controlled trials in literature report a favourable effect of 
slow calciumin flux blocking agents out of the dihydropyndine com­
pounds in several types of vasospastic disease. Intravenous nicardi­
pine was indeed, as shown in chapter 15, effective in primary, but not 
in secondary Raynaud's phenomenon. However, during a long-term oral 
trial of nicardipine in Raynaud's phenomenon, which has just been 
finished and has not been included in this thesis, the therapeutic 
efficacy was disappointing. Also nifedipine was found (chapter 16) to 
be more effective during acute, sublingual administration, in contrast 
to oral long-term dosing. However, the use of calcium entry blocking 
agents in Raynaud's phenomenon was also hampered by numerous side-
effects which makes the therapeutic use as doubtful as for example 
selective alpha-1 adrenoceptor blockade. It seems useful to study the 
prophylactic use of sublingual nifedipine in Raynaud's patients with 
predictable attacks. 
Finally, chapter 17 summarises our experiences with different types of 
treatment: none of them seems appropriate. 
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General conclusions 
In conclusion, clinical examination, supplemented by antinuclear anti-
body determination,is of value in the proper classification of 
Raynaud's patients, whereas the additional diagnostic help of vascular 
functional tests is limited. Although we have indications of a defect-
ive function within the sympathetic nervous system in patients with 
primary Raynaud's phenomenon, no definite proof was found. Further-
more, the precise localisation of the defect remains unclear. 
For the time being, the therapeutic efficacy of selective alpha-adre-
noceptor blockade or calciuminflux blockade does not counterbalance 
the disadvantages attached to these treatment modalities. 
From our studies, no single drug emerges as the treatment of choice 
and a causal therapy is not available. Finally, the words written by 
Maurice Raynaud 126 years ago are still true: "On comprendra sans 
peine, je l'espère, qu'en présence d'une maladie dont tant de points 
sont encore obscurs, je ne sois pas en mesure de formuler un traite-
ment complet è lui opposer". 
SAMENVATTING 
Inleiding 
In Deel 1 wordt een algemeen overzicht gegeven van het fenomeen van 
Raynaud en worden de vragen geformuleerd die dit proefschrift tracht 
te beantwoorden. 
Klachten over koude extremiteiten of verkleuringen van vingers en 
tenen komen in het winderige en regenachtige noord-west Europa veel 
voor. Indien er sprake is van een tenminste bi-fasiache verkleuring 
van handen of voeten onder invloed van koude of emoties spreekt men 
van het fenomeen van Raynaud. In 1862 beschreef Maurice Raynaud het 
naar hem genoemde syndroom, later, ten onrechte, vaak de ziekte van 
Raynaud genoemd. Dit heeft geleid tot veel verwarring aangezien de be-
naming ziekte suggereert dat er sprake is van karakteristieke klachten 
en fysisch diagnostische afwijkingen met een uniforme pathofysiolo-
gie. Pas in de laatste decade wordt consequenter bij pathofysiologisch 
en therapeutisch onderzoek gebruik gemaakt van een classificatie in 
primair en secundair Raynaud-fenomeen en tracht men laatstgenoemde 
groep in te delen naar oorzakelijk ziektebeeld. 
De vragen die in dit proefschrift gesteld worden zijn: 
1. Wat is de diagnostische waarde van klinisch en immunologisch onder-
zoek en het testen van de vasculaire reactiviteit bij het 
classificeren van patiënten met het fenomeen van Raynaud? 
2. Welke rol speelt het sympatisch zenuwstelsel bij de pathofysiologie 
van het primaire fenomeen van Raynaud? 
3. Welke zijn de therapeutische effecten van vaatverwijdende genees-
middelen bij het fenomeen van Raynaud? 
Classificatie van Raynaudpatienten 
In Deel 2, en gedeeltelijk in Deel 3, is getracht om de patientenpopu-
latie zo zuiver mogelijk te classificeren. Hoofdstuk 3 laat zien dat 
bij de meeste patiënten die zich presenteren met klachten van een 
Raynaud-fenomeen een gedegen anamnese en lichamelijk onderzoek vol-
doende zijn voor een juiste indeling. Klachten die zijn begonnen voor 
het 20e levensjaar, de aanwezigheid van reactieve hyperaemie op het 
einde van een aanval en verkleuringen die ook voorkomen in het gelaat 
hebben alle een hoge voorspellende waarde voor het primaire fenomeen 
van Raynaud terwijl trofische stoornissen aan de huid hierbij uiterst 
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zelden voorkomen. Trofische stoornissen zijn wel vrij specifiek voor 
collageenziekten. Bij obstructief vaatlijden zijn de voeten altijd 
mede aangedaan, er zijn vaak risicofactoren aanwezig voor de ontwikke-
ling van athérosclérose terwijl deze vorm specifiek voorkomt bij man-
nen met klachten die zijn begonnen boven het 50e jaar en bij mannen 
met atherosclerotisch vaatlijden op andere plaatsen. Indien men daar-
naast nog antinucléaire antistoffen bepaalt en, zoals onderzoek van 
anderen heeft aangetoond, de capillaire perfusie van de huid en de 
systolische bloeddruk aan de vinger meet, lijkt de diagnostische clas-
sificatie compleet. In twijfelgevallen zal het klinisch beloop op 
termijn de oplossing bieden. 
In hoofdstuk 4 wordt aangetoond dat bepaling van antinucléaire anti-
stoffen met behulp van de immunoblot-techniek van voorspellende waar-
de is voor het exact benoemen van de collageenziekte die bij een aan-
tal patiënten ontstaat. Vooral de ontwikkeling naar sclerodermie, het 
CREST-syndroom (calcinosis, Raynaud-fenomeen, stoornissen in de oeso-
phagus motiliteit, sclerodactylie en teleangiëctasieën) en mixed con-
nective tissue disease blijkt goed voorspelbaar. 
De betekenis van het sympatisch zenuwstelsel in de pathofysioloqie van 
het Raynaud-fenomeen 
In Deel 3, hoofdstuk 5, 6, 7 en θ wordt de pathofysiologische beteke­
nis van het sympatisch zenuwstelsel bij het primaire fenomeen van 
Raynaud onderzocht, omdat klinisch, (patho)fysiologisch en therapeu­
tisch onderzoek aanwijzingen geeft dat dit systeem afwijkend functio­
neert. 
In hoofdstuk 5 wordt een overzicht gegeven van de fysiologische bete­
kenis van het sympatisch zenuwstelsel bij de temperatuurregulatie van 
het lichaam. De perifere vasoconstrictie, die optreedt onder invloed 
van koude-expositie en die de bescherming van de centrale lichaamstem­
peratuur als functie heeft, vindt bij patiënten met het Raynaud-feno-
meen versterkt plaats. Dit, gevoegd bij het gegeven dat remming van 
het sympatisch zenuwstelsel de klachten van het Raynaud-fenomeen ver-
mindert, doet een afwijkende functie van het sympatisch zenuwstelsel 
vermoeden. 
In hoofdstuk 6 wordt aangetoond dat met behulp van de laser Doppler 
techniek mede de doorbloeding van de huidvaten die ten dienste staan 
aan de bovengenoemde temperatuurregulatie, de rijkelijk sympatisch ge-
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innerveerde artenoveneuze shunts, niet-invaaief gemeten kan worden. 
In hoofdstuk 7 en θ worden de effecten van sympatische stimulatie door 
middel van, respectievelijk, mentale stress opgewekt door een rekenop­
dracht, een diepe ademteug, persen (de Valsalva-manoeuvre) en actief 
gaan staan op de circulatie van patiënten met het primaire Raynaud-fe-
nomeen bestudeerd. Voorafgaande aan deze tests werd de sympatische 
activiteit indirect door middel van catecholaminebepalingen gemeten, 
en deze bleek bij patiënten met een primair Raynaud-fenomeen ver-
hoogd. Opvallend was verder dat de vasculaire reacties niet verschil-
den van die bij een gezonde controlegroep. Zowel de patiënten met een 
primair fenomeen van Raynaud als de controlepersonen reageerden op 
sympatische stimulatie met een even sterke vaaoconstnctie. Een uit-
zondering vormde de reactie van Raynaud-patiénten op de rekenopdracht 
waarbij, tegengesteld aan onze verwachting, vasodilatatie optrad. 
Blijkens aanvullende studies berust dit op een tevens sterk toegenomen 
zweetsecretie, onder invloed van sympatische sudomotor impulsen. De 
zweetsecretie lijkt mede de waargenomen vasodilatatie te kunnen ver-
klaren (bradykimne). Tenslotte bleek dat in beide groepen de vascu-
laire reactiviteit sterk afhangt van de uitgangssituatie: bij een hoge 
doorbloeding van de huid in rust is de vaaoconstnctie veel sterker 
dan bij een lage doorbloeding in rust. 
Het onderzoek naar de relatie tussen de vasculaire reactiviteit en het 
sympatisch zenuwstelsel werd bemoeilijkt door de volgende punten: 
1) Wij vonden al onder baaiscondities in rust een afgenomen vinger-
huiddoorbloeding en een verhoogde sympatische activiteit bij patiënten 
met een primair Raynaud-fenomeen. 
2) Het sympatisch zenuwstelsel is geen uniform reagerend systeem: 
Vasomotonek en sudomotonek in de handen worden verschillend ge-
stuurd, evenals spier- en huiddoorbloeding. Een complicerende factor 
is daarnaast dat er een groot aantal verschillende sympatische reflex-
bogen is dat de circulatie bestuurt zoals de baroreceptorreflexboog, 
de temperatuur-regulerende reflexboog en locale veno-artenële reflex-
en. 
3) De activiteit van het sympatisch zenuwstelsel is slechts indirect 
te meten. Een van de mogelijkheden, die door ons wordt toegepast, is 
de veneuze noradrenaline-bepaling. 
Door deze beperkingen kunnen uit dit onderzoek alleen voorlopige con-
clusies getrokken worden: bij patiënten met een primair fenomeen van 
Raynaud zijn er aanwijzingen voor een basaal verhoogde sympatische ac-
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liviteit, de sympatische reactiviteit is normaal en de huiddoorbloe-
ding is in rust al afgenomen terwijl de vasculaire reactiviteit af-
hangt van het type prikkel en van de doorbloeding in rust. 
De vasculaire reactiviteit bij het Raynaud-fenomeen werd bestudeerd 
met 2 nieuwe technieken die zijn beschreven in Deel 3, hoofdstuk 6 t/m 
12: de laser Doppler flux-metingen en de meting van de transcutane 
zuurstofspanning. 
Met de laser Doppler wordt de erythrocytenflux in de buitenste laag 
(tot ongeveer 1 ë 2 mm diepte) van de huid gemeten. In dit meetbereik 
bevinden zich van buiten naar binnen: de voedingscapillairen (0-0,4 mm 
diep), de artenoveneuze shunts (0,8-2,0 mm diep) en venulen, waarbij 
bij normale kamertemperatuur de shunts het grootste deel van de huid-
doorbloeding voor hun rekening nemen (90%). 
Tijdens verwarming van de huid tot 40°C valt de sympatische innervatie 
van de huid uit. Indien de vasospasmen bij het primaire Raynaud-feno-
meen door hyperactiviteit van het sympatisch zenuwstelsel veroorzaakt 
zou worden kan men verwachten dat tijdens dit verwarmen tot 40°C de 
circulatie geheel normaal zou worden. Dit gebeurde niet, maar er zijn 
aanwijzingen dat de verwarmingstijd van 5 minuten te kort was voor een 
volledige vasodilatatie, zodat wij momenteel onderzoeken of een lang-
durige verwarming (20 minuten) wel de veronderstelde volledige vasodi-
latatie geeft. 
Indien bij het secundair Raynaud-fenomeen ten gevolge van atheroscle-
rotisch vaatlijden of ten gevolge van vormen van collageenziekten de 
bloedvatwand is aangetast, verwacht men dat de vasodilatatie tijdens 
bovengenoemde verwarming beperkt is. Dit bleek bij de onderzoeken be-
schreven in hoofdstuk 9 ook zo te zijn. Indien we echter de verwar-
mingsproef als diagnostische test gebruikten om een individuele 
Raynaud-patiênt op de juiste wijze in te delen, viel het scheldend 
vermogen tussen primaire en secundaire vormen, en binnen deze laatste 
categorie tussen verschillende typen bindweefselziekten en atheroscle-
rotisch vaatlijden, tegen. 
Dezelfde sterke overlap tussen deze subgroepen werd ook gevonden in 
hoofdstuk 10 bij de post-occlusieve reactieve hyperaemietest waarbij 
de mate van metabole vasodilatatie gemeten wordt na 5 minuten occlusie 
aan de vingerbasis. 
Een groot probleem bij deze proeven, zoals ook bij andere methoden die 
de huidcirculatie trachten te kwantificeren, was de sterke inter- en 
intraindividuele variabiliteit van de meting, die grotendeels inherent 
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is aan de sterke fysiologische fluctuaties in de huidcirculatie. De 
maximale huiddoorbloeding kan wel 200 maal zo hoog zijn als de minima-
le. 
Het meten van de capillaire voedingsperfusie van de huid met behulp 
van de transcutane 02-spanningsmeter zoals beschreven in hoofdstuk 11 
en 12, is een uitdaging. Aangezien dit tot voor kort alleen mogelijk 
was met de dynamische capillairmicroscoop, een kostbare maar nauwkeu-
rige methode, en de minder betrouwbare en moeilijk te interpreteren 
133 Xenon wash-out techniek, zou het van grote waarde kunnen zijn een 
eenvoudig en goedkoop alternatief te ontwikkelen. De transcutane zuur-
stof spanningsmet ing van de huid leek zulk een methode te kunnen zijn. 
Het scheldend vermogen tussen groepen met een ernstig gestoorde capil-
laire per fusie, zoals met name gevonden wordt bij sclerodermie, en 
personen met een normale capillaire doorbloeding was echter matig en 
ook was, vooral bij lage meetwaarden, de reproduceerbaarheid matig. 
Bijkomende nadelen zijn: de noodzakelijke verwarming van de huid tot 
tlb'C, waardoor de vasculaire reactiviteit uitgeschakeld wordt en het 
feit dat de meting behalve door de circulatie beïnvloed wordt door een 
groot aantal andere factoren, zoals huideigenschappen, hemoglobine ge-
halte en arteriale zuuratofspanmng. De laatsgenoemde problemen kunnen 
opgelost worden door onverwarmd de zuurstofspanning in de huid te 
meten en door een index te berekenen op grond van een referentiewaarde 
elders op de huid. Helaas bleek tijdens experimenten die momenteel nog 
gaande zijn onverwarmd meten geen betrouwbare resultaten op te leveren 
terwijl ook de reproduceerbaarheid van de index te wensen overliet. 
Behandeling van het Raynaud fenomeen 
Voor wat betreft de behandeling, zoals beschreven in Deel 4, leek se-
lectieve alpha-1 adrenoceptorblokkade zinvol gezien de veronderstelde 
pathofysiologische rol van het aympatisch zenuwstelsel bij de genese 
van vasospasmen, de bewezen therapeutische effectiviteit van niet se-
lectieve alpha-adrenoceptorblokkerende geneesmiddelen en het ginstiger 
bijwerkingsprofiel van selectieve alpha-1 adrenoceptorblokkers. Hoewel 
prazosine, zoals beschreven in hoofdstuk 13, zeker effectief was, met 
de meest gunstige verhouding tussen effectiviteit en bijwerkingen bij 
een dosering van 3 mg per dag (zie hoofdstuk 14), verbeterden de 
klachten slechts bij 60% van de patiënten terwijl maar 10% klachten-
vnj werd. De helft van de behandelde patiënten vond de bijwerkingen 
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bezwaarlijk. Na het onderzoek verkoos slechts een kwart van de patiën-
ten de behandeling voort te zetten. 
Aangezien er voor de contractie van gladde spiercellen in de vaatwand 
uiteindelijk een toename van de intracellulaire calciumconcentratie 
noodzakelijk is, leek een behandeling met middelen die de instroom van 
calcium in de cel blokkeren, aangewezen. Tevens verschenen er berich-
ten over gunstige effecten van dihydropyridine-derivaten bij de behan-
deling van Raynaud-patiënten. Een van deze stoffen, nicardipine (zie 
hoofdstuk 15), was effectief bij primaire maar niet bij secundaire 
Raynaud-patiënten als het kortdurend intraveneus werd gegeven. Tijdens 
een daaropvolgende chronische behandeling met tabletten, bleek de 
effectiviteit echter gering.* Een andere calciuminstroomremmer uit de 
dihydropyridinegroep, het nifedipine, verbeterde zoals beschreven in 
hoofdstuk 16 de huiddoorbloeding na een eenmalige sublinguale toedie-
ning. Ook in deze studies met calciuminstroomremmers traden bijwerkin-
gen frequent op en het effectiviteitsprofiel was ook niet beter dan 
dat van selectieve alpha-1 adrenoceptorblokkade. Het is wellicht 
interessant om het profylactisch gebruik van deze geneesmiddelen te 
bestuderen bij patiënten waarbij de aanvallen voorspelbaar zijn. 
Tenslotte wordt in het laatste hoofdstuk een overzicht gegeven van 
onze ervaring met de diverse vormen van behandeling. Hieruit komt niet 
een bepaald therapeutisch advies voor een middel van eerste keuze naar 
voren. 
Algemene conclusie : 
Concluderend kan men stellen dat de kliniek, aangevuld met immunologi-
sche bepalingen, grote betekenis heeft voor het juist claasificeren 
van Raynaud-patiënten en dat het testen van de vasculaire reactiviteit 
hierbij vooralsnog van beperkte waarde is. 
Bij het primaire Raynaud-fenomeen levert dit onderzoek aanwijzingen 
maar geen bewijzen voor een afwijkende functie van het sympatisch 
zenuwstelsel, waarvan de precieze oorsprong nog onbekend is. 
Tenslotte wegen de therapeutische resultaten van de behandeling van 
patiënten met het Raynaud-fenomeen met bf selectieve alpha-1 adreno-
ceptorblokkade bf calciuminstroomblokkers in het algemeen niet op 
tegen de nadelen die aan deze behandelingen kunnen kleven. Dat wil 
zeggen dat de arts bij de individuele patiënten alleen door "trial and 
error" kan proberen tot de beste therapeutische maatregelen te komen. 
»De resultaten van deze studie zijn nog in bewerking. 
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bij de klinische en immunologische typering van patiënten, hetgeen een 
niet te onderschatten bijdrage heeft geleverd bij een zo zuiver moge-
lijke classificatie van patiënten. Het Praeventiefonds (subsidie nr. 
28-1217) ondersteunde dit onderdeel middels de financiering van een 
plaats voor een analist (Margot Hoet). 
Sjaak Willemsen (Laboratorium voor Experimentele en Chemische Endocri-
nologie; Hoofd: Prof.Dr Th.J. Benraad) voor de vele deskundig uitge-
voerde catecholaminebepalingen. 
Philip van Eiteren (Medisch Statistische Adviesafdeling) voor de hulp 
bij de interpretatie van de vele meetgegevens. 
1ΘΘ 
José Benneker (afdeling Klinische Farmacie) voor de randomisât ie van 
patiënten bij de verschillende onderzoeken met geneesmiddelen. 
Anky Verweyen, Ineke ten Have en vooral Ans Ruesen voor het toegewijd 
typen van de achtereenvolgende versies van ieder hoofdstuk. Cees 
Nicolasen (afdeling Medische Illustratie) en de afdeling Medische 
Fotografie voor de vervaardiging en het fotografische weergeven van de 
tekeningen in dit proefschrift. 
Ilse Jetten voor het ontwerpen van de omslag. 
Marga Jetten voor het helpen persklaar maken van het manuscript en 
andere ondersteunende werkzaamheden. 
Tenslotte wilde ik alle medewerkers van de Kliniek voor Inwendige 
Ziekten, alle vrienden en kennissen bedanken voor de collegiale sfeer 
en de vriendschappelijke steun die het werken aan een proefschrift tot 
een genoegen kan maken. 
Hub Wollersheim, 
23 juni 1988. 
Curriculum 
Hub Wollersheim werd geboren op 19 augustus 1953 te Brunssum. In 1971 
behaalde hij het Atheneum-B diploma aan het St. Bernardinuscollege te 
Heerlen. In datzelfde jaar begon hij met de studie Geneeskunde aan de 
Katholieke Universiteit van Nijmegen (Kandidaatsexamen: 1974; Docto-
raalexamen: 1976) die hij in januari 1980 met het artsexamen beëindig-
de. Tot juni 19B1 vervulde hij de militaire dienstplicht (Keunngs- en 
Indelingsraad, Knoopkazere te Utrecht). In deze periode werkte hij ge-
durende 9 maanden voor halve dagen als arts-assistent op de afdeling 
Radiotherapie van het Gemeenteziekenhuis Arnhem (Hoofd destijds: Drs 
P. van der Maden). Van 1 juli 1981 tot en met 1 juli 1986 was hij in 
opleiding tot internist in de Kliniek voor Inwendige Ziekten van het 
St. Radboudziekenhuis te Nijmegen (opleider: Prof.Dr A. van 't Laar). 
Van 1 juli 1985 tot 1 juli 1988 bezette hij een onderzoeksplaats van 
de Nederlandse Hartstichting in het kader van een subsidieproject ge-
titeld: "Algemene en vasculaire reactiviteit bij het Raynaud feno-
meen". (NHS projectnr. 84.086). Op 1 juli 1986 werd hij ingeschreven 
als internist in het Specialisten Register. Sedertdien is hij werkzaam 
op de onderafdeling Algemene Inwendige Geneeskunde van de Kliniek voor 
Inwendige Ziekten (Hoofd: Prof.Dr A. van 't Laar). 
Hij IS getrouwd met Marge Jetten. Zij hebben een zoon, Laurens. 



STELLINGEN 
1. Er is geen test die betrouwbaar onderscheid kan maken tussen gezonde 
mensen en patiënten met het fenomeen van Raynaud. Evenzo ontbreekt een 
test die de verschillende oorzaken van het secundaire fenomeen van 
Raynaud van elkaar kan onderscheiden. 
2. Bij het onderzoek van de reproduceerbaarheid van tests waarbij de 
huiddoorbloeding als parameter wordt gebruikt, dient men zich te rea-
liseren dat de fysiologische variatie hierin zo groot is dat zelfs 
onder de meest optimale standaardisatie de reproduceerbaarheid slechts 
matig kan zijn. 
3. De meerderheid van de patiënten met een Raynaud-fenomeen is meer ge-
diend met geruststelling, duidelijke uitleg van hun symptomen en een 
paar warme handschoenen dan met een medicamenteuze behandeling. 
4. De gestandaardiseerde afkoelingstest van de hand, zoals wij die ge-
bruiken, is een methode om een verminderd vasodilaterend vermogen 
tijdens langdurig gebruik van beta-adrenoceptor blokkers vaat te stel-
len bij hypertensiepatiénten met klachten over koude extremiteiten. 
Wollersheim H, Lenders J, Peters H, Thien Th. Influence of cold 
challenge on finger skin temperature during long-term use of beta-
adrenoceptor blocking drugs in hypertensive patients. Inter Angio 
1987; 6: 307-311. 
5. Prostacycline geeft verschillende effecten in verschillende vaatgebie-
den: terwijl arterioveneuze shunts in de huid dilateren, verandert de 
doorbloeding in voedingscapillairen van de huid en in het vaatbed van 
onderarmspieren niet. 
Wollersheim H, Thien Th. Hemodynamic effects of prostacyclin infusions 
in healthy volunteers. Angiology 1988;39:227-233. 
6. Omdat migraine kan worden verergerd door ergotaminepreparaten en het 
onderbreken van de behandeling "rebound-migraine" kan veroorzaken, 
gebruiken sommige patiënten toenemende hoeveelheden, hetgeen 
uiteindelijk kan leiden tot een ergotamine-intoxicatie. Daarom dienen 
ergotamine alkaloïden alleen voor de behandeling en nooit voor de 
profylaxe van migraine te worden gebruikt. 
Wollersheim H, Pijls N, Thien Th, van der Werf T. Multiple vasospastic 
manifestations during ergot therapy. Neth 3 Med 1987; 30: 75-79. 
7. Hypothermie kan een bijwerking zijn van vaatverwijdende geneesmidde­
len. 
Wollersheim H, Berden J, Thien Th. Decreased rectal body temperature 
induced by different vasodilatory drugs. 
Neth J Med; in press. 
Θ. Patienten met een solitair plasmacytoom hebben een veel betere progno­
se dan patiënten met een stadium I multipel myeloom en dienen in het 
stadiermgssysteem van Dune en Salmon als een aparte benigne subgroep 
te worden beschouwd. 
Wollersheim H, Holdnnet RSG, Haanen C. Clinical course and survival 
in 16 patients with localized plasmacytoma. 
Scand J Haematol 1984; 32: 423-428. 
9. De tro fische stoornissen aan de warme voeten met goed kloppende arte-
rien bij een patient met diabetes mellitus kunnen worden verklaard 
door sympathische denervatie hetgeen leidt tot een competitief anta-
gonisme tussen de thermoregulatoire artenoveneuze shunts en de capil-
laire voedingsper fusie van de huid. 
In deze situatie kan een alpha-sympathicomimeticum therapeutisch wor-
den gebruikt terwijl sympathectomie onjuist is. 
10. De door de Voedingsraad gegeven aanbevelingen over gewichtsreductie 
terwille van de atherosclerose-preventie zijn in tegenspraak met de 
adviezen geformuleerd in de consensus osteoporose (Ned Tijdschr 
Geneeskd 1986; 130: 584-590). 
11. De consumptie van tabak eist zoveel meer levens dan verkeersongeval-
len, criminaliteit, drugs en AIDS bij elkaar, dat een accijnsverhoging 
ter betaling van de kosten die hieruit vloeien niet meer dan redelijk 
lijkt. 
12. Het gegeven dat naast 94Й van de vrouwelijke assistenten in opleiding 
tot internist nu ook 64% van de mannelijke assistenten in opleiding 
tot internist na hun opleiding liever part-time dan full-time zou wil­
len werken zal in de toekomst ongetwijfeld leiden tot een grotere 
deelname van vrouwen aan de specialistische geneeskunde. 
(Gegevens ontleend aan een enquête onder assistenten in de regio 
Nijmegen, 1988). 
13. De mening, dat instellingen op Christelijke grondslag een bijzondere 
taak zouden hebben ten aanzien van de bewaking van het ethische niveau 
van de geneeskunde, doet onrecht aan het feit dat alle grondslagen van 
de medische ethiek afkomstig zijn uit de voor-Christelijke periode. 
14. Het feit dat nu ook al veel Limburgers denken dat vlaai vla is en vla 
pudding, toont aan dat integratie van etnische minderheden altijd ten 
koste gaat van het eigen culturele erfgoed. 
Nijmegen, 23 juni 19ΘΒ. 



